var docs;if (!docs) docs =[]; docs["31"]={"3100":"<p><b>Title</b> Calcium Channel Blockers / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated/dose increased, or decreased effects if a macrolide is discontinued/dose decreased. Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, DilTIAZem, Efonidipine, Felodipine*, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil*<br><b>Exception</b> Clevidipine</p>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin*, Erythromycin (Systemic), Telithromycin<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concurrent use of clarithromycin with calcium-channel blockers increased patients' odds of being hospitalized for acute kidney injury (OR=1.98) in a population-based retrospective cohort study of older adults (average age = 76 years) who were newly prescribed clarithromycin (n=96,226) or azithromycin (n=94,083) while receiving a calcium channel blocker (amlodipine, felodipine, nifedipine, diltiazem, or verapamil).<sup>1</sup> Secondary outcomes supported an association with a greater odds for hospitalization due to hypotension (0.12% vs 0.07%, OR=1.6), as well as with a greater odds for all-cause mortality (1.02% vs 0.59%, OR=1.74), in patients who were co-prescribed clarithromycin and calcium channel blockers. These results were consistent with another case-control study also involving older adults (n=7100) hospitalized for hypotension who had been co-prescribed a macrolide antibiotic while on a calcium channel blocker.<sup>2</sup> Erythromycin and clarithromycin were both strongly associated with hypotension (OR=5.8 and OR=3.7, respectively), while azithromycin was not associated with increased odds for hypotension in this population.<sup>2</sup> That these studies were restricted to older patients make it unclear how significant this interaction is in younger patients receiving such combinations.<br><br>The AUC of felodipine (10 mg x1) was increased approximately 200% in 12 healthy subjects when administered following a 24-hour course of erythromycin (250 mg QID); erythromycin half-life and maximum serum concentration (Cmax) were also increased.<sup>3</sup> According to clarithromycin prescribing information, concurrent use with verapamil has been associated with reports of hypotension, bradyarrhythmias, and lactic acidosis.<sup>4</sup> Several published case reports also support that concurrent therapy involving calcium channel blockers and certain macrolide antibiotics can increase drug concentrations and associated symptoms of toxicity.<sup>5,6,7,8</sup><br><br>The mechanism of this interaction appears to be most likely inhibition of the CYP3A4-mediated metabolism of calcium channel blockers by the macrolide antibiotics. Most macrolides are moderate-to-strong CYP3A4 inhibitors (azithromycin reportedly lacks significant CYP3A4 inhibition), and most calcium channel blockers are CYP3A4 substrates. Inhibition of p-glycoprotein by the macrolide antiobiotic may also be involved for selected calcium channel blockers. Of note, verapamil and diltiazem are CYP3A4 and p-glycoprotein inhibitors, and may interact with at least some macrolides, possibly increasing macrolide concentrations/effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. <i>JAMA</i>. 2013;Nov 9 (Epub ahead of print).</p>\n<p>2. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following coprescription of macrolide antibiotics and calcium-channel blockers. <i>CMAJ</i>. 2011;183(3):303-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21242274\">[PubMed 21242274]</a></p>\n<p>3. Bailey DG, Bend JR, Arnold JM, et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. <i>Clin Pharmacol Ther</i>. 1996;60(1):25-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8689808\">[PubMed 8689808]</a></p>\n<p>4. Prescribing information. Biaxin (clarithromycin). North Chicago, IL: Abbott Laboratories, 05/2011.</p>\n<p>5. Liedholm H, Nordin G. Erythromycin-felodipine interaction. <i>DICP</i>. 1991;25(9):1007-1008. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1949959\">[PubMed 1949959]</a></p>\n<p>6. Goldschmidt N, Azaz-Livshits T, Gotsman I, et al. Compound cardiac toxicity of oral erythromycin and verapamil. <i>Ann Pharmacother</i>. 2001;35:1396-1399. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11724091\">[PubMed 11724091]</a></p>\n<p>7. Geronimo-Pardo M, Cuartero-del-Pozo AB, Jimenez-Vizuete JM, et al. Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock. <i>Ann Pharmacother</i>. 2005;39(3):538-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15703161\">[PubMed 15703161]</a></p>\n<p>8. Takeuchi S, Kotani Y, Tsujimoto T. Hypotension induced by the concomitant use of a calcium-channel blocker and clarithromycin [published online January 9, 2017]. <i>BMJ Case Rep</i>. doi: 10.1136/bcr-2016-218388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28069789\">[PubMed 28069789]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3104":"<p><b>Title</b> Vitamin K Antagonists / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects (i.e., INR, signs/symptoms of bleeding) of vitamin K antagonists such as warfarin if an interacting macrolide antibiotic is initiated/dose increased, or decreased effects if an interacting macrolide antibiotic is discontinued/dose decreased.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Azithromycin (Systemic)*, Clarithromycin, Erythromycin (Systemic), Telithromycin*<br><b>Exceptions</b> Fidaxomicin, Roxithromycin, Spiramycin</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Warfarin clearance was decreased approximately 14% in healthy subjects when administered following an 8-day course of erythromycin (1 g/day).<sup>1</sup> Other studies confirm this relatively modest impact of erythromycin on warfarin pharmacokinetics.<sup>2,3,4</sup> Case reports, however, describe significant episodes of bleeding (hematuria, bruising) and increased prothrombin times in association with erythromycin therapy.<sup>5,6,7,8,9</sup> A proposed mechanism for this interaction is the inhibition of CYP3A4 by erythromycin, resulting in reduced metabolism of the (less potent) R-warfarin enantiomer. Acenocoumarol is not metabolized by CYP3A4 enzymes.<br><br>Azithromycin has also been reported to increase the anticoagulant effect of warfarin in several warfarin-stable patients.<sup>10,11,12,13</sup> Increased INR and/or bleeding was noted in each case shortly after (1-3 days) the completion of a short course of azithromycin. A multi-patient study did not demonstrate any effect of multiple azithromycin doses on single doses of warfarin.<sup>14</sup> A 5-day course of azithromycin also did not alter the anticoagulant response to a single dose of warfarin in a study of 22 healthy volunteers.<sup>15</sup> Similarly, two retrospective reviews (26 and 17 patients, respectively) of warfarin-treated patients showed no effect of short courses of azithromycin on INR.<sup>16,17</sup> It is possible that the retrospective data missed the interaction by not measuring the INR (i.e., the effects of azithromycin) until after the effects would have likely dissipated. Azithromycin reportedly has a substantially lower ability to inhibit CYP3A4 than most other macrolides, making the specific mechanism of this apparent interaction unclear.<br><br>The manufacturer of telithromycin, a ketolide antibiotic, reports that the drug does not appear to interact with warfarin.<sup>18</sup> However, at least 6 case reports of a potential interaction (primarily an increased INR requiring a change in the dose of either warfarin or telithromycin) have been reported to Health Canada.<sup>19</sup> A mechanism of this possible interaction is unclear, but may be related to CYP3A4 inhibition of the R-isomer of warfarin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bachmann K, Schwartz JI, Forney R Jr, et al, “The Effect of Erythromycin on the Disposition Kinetics of Warfarin,” <i>Pharmacology</i>, 1984, 28(3):171-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6718483\">[PubMed 6718483]</a></p>\n<p>2. Ellsworth A, Horn JR, Wilkinson W, et al, “An Evaluation of the Effect of Dirithromycin (D) and Erythromycin (E) on the Pharmacokinetics and Pharmacodynamics of Warfarin (W),” <i>Intersci Conf Antimicrob Ag Chemother</i>, 1995, 35:9.</p>\n<p>3. Weibert RT, Lorentz SM, Townsend RJ, et al, “Effect of Erythromycin Patients Receiving Long-Term Warfarin Therapy,” <i>Clin Pharmacol Ther</i>, 1987, 41:224.</p>\n<p>4. Weibert RT, Lorentz SM, Townsend RJ, et al, “Effect of Erythromycin in Patients Receiving Long-Term Warfarin Therapy,” <i>Clin Pharm</i>, 1989, 8:210-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706893\">[PubMed 2706893]</a></p>\n<p>5. Bartle WR, “Possible Warfarin-Erythromycin Interaction,” <i>Arch Intern Med</i>, 1980, 140(7):985-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7387311\">[PubMed 7387311]</a></p>\n<p>6. Schwartz JI and Bachmann KA, “Erythromycin-Warfarin Interaction,” <i>Arch Intern Med</i>, 1984, 144(10):2094. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6486966\">[PubMed 6486966]</a></p>\n<p>7. Husserl FE, “Erythromycin-Warfarin Interaction,” <i>Arch Intern Med</i>, 1983, 143(9):1831,1836. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6615113\">[PubMed 6615113]</a></p>\n<p>8. Sato RI, Gray DR, and Brown SE, “Warfarin Interaction With Erythromycin,” <i>Arch Intern Med</i>, 1984, 144(12):2413-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6508448\">[PubMed 6508448]</a></p>\n<p>9. Hassell D and Utt JK, “Suspected Interaction: Warfarin and Erythromycin,” <i>South Med J</i>, 1985, 78(8):1015-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4023774\">[PubMed 4023774]</a></p>\n<p>10. Lane G, “Increased Hypoprothrombinemic Effect of Warfarin Possibly Induced by Azithromycin,” <i>Ann Pharmacother</i>, 1996, 30(7-8):884-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8826581\">[PubMed 8826581]</a></p>\n<p>11. Woldtvedt BR, Cahoon CL, Bradley LA, et al, “Possible Increased Anticoagulant Effect of Warfarin Induced by Azithromycin,” <i>Ann Pharmacother</i>, 1998, 32(2):269-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9496419\">[PubMed 9496419]</a></p>\n<p>12. Foster DR and Milan NL, “Potential Interaction Between Azithromcyin and Warfarin,” <i>Pharmacotherapy</i>, 1999, 19(7):902-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10417043\">[PubMed 10417043]</a></p>\n<p>13. Rao KB, Pallaki M, Tolbert SR, et al, “Enhanced Hypoprothrombinemia with Warfarin Due to Azithromycin,” <i>Ann Pharmacother</i>, 38(6):982-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15084685\">[PubMed 15084685]</a></p>\n<p>14. Hopkins S, “Clinical Tolerance and Safety of Azithromycin,” <i>Am J Med</i>, 1991, 91(Suppl 3A):40S-45S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1656742\">[PubMed 1656742]</a></p>\n<p>15. Prescribing information. Zithromax (azithromycin). New York, NY: Pfizer Inc, January 2009. </p>\n<p>16. Beckey N, Parra D, and Colon A, “Retrospective Evaluation of a Potential Interaction Between Azithromycin and Warfarin in Patients Stabilized on Warfarin,” <i>Pharmacotherapy</i>, 2000, 20(9):1055-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10999497\">[PubMed 10999497]</a></p>\n<p>17. McCall KL, Anderson HG, and Jones AD, “Determination of the Lack of a Drug Interaction Between Azithromycin and Warfarin,” <i>Pharmacotherapy</i>, 2004, 24(2):188-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14998219\">[PubMed 14998219]</a></p>\n<p>18. Product monograph. Ketek (telithromycin). Laval, Quebec, Canada: Sanofi-Aventis Canada Inc., January 2009.</p>\n<p>19. Djelouah I, “Telithromycin (Ketek) and Warfarin: Suspected Interaction,” Canadian Adverse Reaction Newsletter, 2005, 15(1):1-2.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3106":"<p><b>Title</b> Felbamate / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Felbamate may increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Felbamate. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased concentrations/toxic effects of barbiturates if felbamate is initiated/dose increased, or decreased concentrations/effects if felbamate is discontinued/dose decreased. In patients receiving phenobarbital, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing phenobarbital dose by 20%. No specific dosing guidelines for other barbiturates are available.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of phenobarbital (100 mg/day) was increased by approximately 25% in 24 healthy volunteers within 10 days of initiating felbamate (1200 mg twice daily).<sup>1</sup> A 30% increase in phenobarbital concentrations was noted in 19 patients (taking either phenobarbital or primidone, which is metabolized to phenobarbital) following the addition of felbamate.<sup>2</sup> A case report describes a man who was hospitalized due to lethargy, ataxia, and anorexia 5 weeks after addition of felbamate to his regimen of phenobarbital and valproic acid.<sup>3</sup> The man's phenobarbital concentrations had increased by roughly 50% since felbamate initiation.<br><br>According to a study cited in felbamate prescribing information, steady-state plasma felbamate concentrations were 29% lower in patients receiving felbamate with phenobarbital than in patients receiving felbamate only.<sup>4</sup><br><br>The mechanisms of these interactions have not been investigated. Increases in phenobarbital concentrations likely occur due to felbamate inhibition of CYP2C19 mediated phenobarbital metabolism. Felbamate concentrations may be reduced due to phenobarbital induction of CYP3A4 mediated felbamate metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reidenberg P, Glue P, Banfield C, et al, “Effects of Felbamate on the Pharmacokinetics of Phenobarbital,” <i>Clin Pharmacol Ther</i>, 1995, 58:279-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7554701\">[PubMed 7554701]</a></p>\n<p>2. Kerrick JM, Wolff DL, Risinger MW, et al, “Increased Phenobarbital Plasma Concentrations After Felbamate Initiation,” <i>Epilepsia</i>, 1994, 35(Suppl 8):96.</p>\n<p>3. Gidal BE and Zupanc ML, “Potential Pharmacokinetic Interaction Between Felbamate and Phenobarbital,” <i>Ann Pharmacother</i>, 1994, 28:455-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8038465\">[PubMed 8038465]</a></p>\n<p>4. Prescribing information. Felbatol (felbamate). Somerset, NJ: Meda Pharmaceuticals Inc., 6/08.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3107":"<p><b>Title</b> Primidone / Felbamate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Felbamate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations may increase. Primidone may decrease the serum concentration of Felbamate. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> In patients receiving primidone, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing primidone dose by 20%. Monitor for increased concentrations/toxic effects of phenobarbital and decreased concentrations/therapeutic effects of felbamate.</p> \n<p><b>Discussion</b> The AUC of phenobarbital (100 mg/day) was increased by approximately 25% in 24 normal subjects within 10 days of initiating felbamate (1200 mg twice daily).<sup>1</sup> A 30% increase in phenobarbital concentrations was noted in 19 patients (taking either phenobarbital or primidone, which is metabolized to phenobarbital) following the addition of felbamate.<sup>2</sup> A case report describes a man who was hospitalized due to lethargy, ataxia, and anorexia 5 weeks after addition of felbamate to his regimen of phenobarbital and valproic acid.<sup>3</sup> The man's phenobarbital concentrations had increased by roughly 50% since felbamate initiation.<br><br>According to a study cited in felbamate prescribing information, steady-state plasma felbamate concentrations were 29% lower in patients receiving felbamate with phenobarbital than in patients receiving felbamate only.<sup>4</sup><br><br>The mechanisms of these interactions have not been investigated. Increases in phenobarbital concentrations likely occur due to felbamate inhibition of CYP2C19 mediated phenobarbital metabolism. Felbamate concentrations may be reduced due to phenobarbital induction of CYP3A4 mediated felbamate metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reidenberg P, Glue P, Banfield C, et al, “Effects of Felbamate on the Pharmacokinetics of Phenobarbital,” <i>Clin Pharmacol Ther</i>, 1995, 58:279-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7554701\">[PubMed 7554701]</a></p>\n<p>2. Kerrick JM, Wolff DL, Risinger MW, et al, “Increased Phenobarbital Plasma Concentrations After Felbamate Initiation,” <i>Epilepsia</i>, 1994, 35(Suppl 8):96.</p>\n<p>3. Gidal BE and Zupanc ML, “Potential Pharmacokinetic Interaction Between Felbamate and Phenobarbital,” <i>Ann Pharmacother</i>, 1994, 28:455-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8038465\">[PubMed 8038465]</a></p>\n<p>4. Prescribing information. Felbatol (felbamate). Somerset, NJ: Meda Pharmaceuticals Inc., 6/08.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3108":"<p><b>Title</b> Phenytoin / Felbamate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Felbamate may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Felbamate. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> A decrease in phenytoin dose will likely be required when adding concurrent felbamate, with some authors suggesting an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring of phenytoin concentrations and response. Increase monitoring for toxic effects of phenytoin if felbamate is initiated/dose increased, or decreased effects if felbamate is discontinued/dose decreased. Monitor for decreased therapeutic effects of felbamate if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Several reports have described the need to reduce phenytoin dosage by approximately 20% following the addition of felbamate in order to maintain serum phenytoin concentrations at the desired level.<sup>1,2,3,4,5,6</sup> Signs of phenytoin toxicity have been noted. In addition, felbamate clearance has been increased by as much as 40% following the addition of phenytoin.<sup>6,7,8</sup> Clinical effects resulting from such a change are unknown. The mechanisms of these interactions are unknown. Phenytoin likely induces the CYP metabolism of felbamate. Felbamate might inhibit phenytoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Graves NM, Holmes GB, Fuerst RH, et al, “Effects of Felbamate on Phenytoin and Carbamazepine Serum Concentrations,” <i>Epilepsia</i>, 1989, 30:225-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2647472\">[PubMed 2647472]</a></p>\n<p>2. Fuerst RH, Graves NM, Leppik IE, et al, “A Preliminary Report on Alteration of Carbamazepine and Phenytoin Metabolism by Felbamate,” <i>Drug Intell Clin Pharm</i>, 1986, 20:465-6.</p>\n<p>3. Fuerst RH, Graves NM, Leppik IE, et al, “Felbamate Increases Phenytoin but Decreases Carbamazepine Concentrations,” <i>Epilepsia</i>, 1988, 29:488-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3391153\">[PubMed 3391153]</a></p>\n<p>4. Wilensky AJ, Friel PN, Ojemann LM, et al, “Pharmacokinetics of W-544 (ADD 03055) in Epileptic Patients,” <i>Epilepsia</i>, 1985, 26:602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4076064\">[PubMed 4076064]</a></p>\n<p>5. Sheridan PH, Ashworth M, Milne K, et al, “Open Pilot Study of Felbamate (ADD 03055) in Partial Seizures,” <i>Epilepsia</i>, 1986, 27:649.</p>\n<p>6. Sachdeo R, Wagner ML, Sachdeo S, et al, “Coadministration of Phenytoin and Felbamate: Evidence of Additional Phenytoin Dose-Reduction Requirements Based on Pharmacokinetics and Tolerability with Increasing Doses of Felbamate,” <i>Epilepsia</i>, 1999, 40(8):1122-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10448826\">[PubMed 10448826]</a></p>\n<p>7. Kelley MT, Walson PD, Cox S, et al, “Population Pharmacokinetics of Felbamate in Children,” <i>Ther Drug Monit</i>, 1997, 19:29-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9029743\">[PubMed 9029743]</a></p>\n<p>8. Banfield CR, Zhu GR, Jen JF, et al, “The Effect of Age on the Apparent Clearance of Felbamate: A Retrospective Analysis Using Nonlinear Mixed-Effects Modeling,” <i>Ther Drug Monit</i>, 1996, 18:19-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8848816\">[PubMed 8848816]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3110":"<p><b>Title</b> Flecainide / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for toxic effects of flecainide if a carbonic anhydrase inhibitor is initiated/dose increased, or decreased effects if a carbonic anhydrase inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n</div> \n<p><b>Discussion</b> The serum concentrations of flecainide were significantly increased in 6 normal subjects when administered following a 21-hour course of sodium bicarbonate (4 g every 4 hours).<sup>1</sup> Flecainide half-life was increased in this and other reports.<sup>1,2,3</sup> In alkaline urine (pH &gt;7.3), flecainide exists more in a nonionized form and is, therefore, more readily reabsorbed into circulation. Accordingly, the flecainide prescribing information cautions that flecainide elimination is considerably slowed when urinary pH is 8 or higher.<sup>4</sup> In another study, aluminum hydroxide (15 mL, approximately 840 mg) given 1 hour before, with, and 1 hour after administration of flecainide (200 mg x1) did not significantly affect serum flecainide concentrations.<sup>5</sup> However, urine pH was not measured in this study so it cannot be said if the dose of aluminum hydroxide administered was sufficient to increase the urine pH to a point where it would alter serum concentrations of flecainide. Acetazolamide has been shown to be capable of increasing urine pH levels to a point where flecainide serum concentrations could be increased.<sup>6</sup> Based on this information, it is possible that any similarly potent carbonic anhydrase inhibitors may affect flecainide in a similar fashion, and caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khulood A, Muhiddin A, Johnston A, et al, “The Influence of Urinary pH on Flecainide Excretion and its Serum Pharmacokinetics,” <i>Br J Clin Pharmacol</i>, 1984, 17:447-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6326790\">[PubMed 6326790]</a></p>\n<p>2. Hertrampf R, Gundert-Remy U, Beckmann J, et al, “Elimination of Flecainide as a Function of Urinary Flow Rate and pH,” <i>Eur J Clin Pharmacol</i>, 1991, 41:61-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1789279\">[PubMed 1789279]</a></p>\n<p>3. Johnston A, Warrington S, and Turner P, “Flecainide Pharmacokinetics in Healthy Volunteers: The Influence of Urinary pH,” <i>Br J Clin Pharmacol</i>, 1985, 20:333-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4074602\">[PubMed 4074602]</a></p>\n<p>4. Prescribing information. Tambocor (flecainide). Northridge, CA: 3M Pharmaceuticals, June 1998.</p>\n<p>5. Tjandra-Maga TB, Verbesselt R, Van Hecken A, et al, “Flecainide: Single and Multiple Oral Dose Kinetics, Absolute Bioavailability and Effect of Food and Antacid in Man,” Br J Clin Pharmacol, 1986, 22:309-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3094570\">[PubMed 3094570]</a></p>\n<p>6. Sterrett SP, Penniston KL, Wolf JS Jr, et al, “Acetazolamide is an Effective Adjunct for Urinary Alkalization in Patients with Uric Acid and Cystine Stone Formation Recalcitrant to Potassium Citrate,” <i>Urology</i>, 2008, 72(2):278-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18533229\">[PubMed 18533229]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3113":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lithium may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The combination of a seletive serotonin reuptake inhibitor and lithium should be undertaken with great caution. When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome (e.g., confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia).</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram*, Dapoxetine, Escitalopram, FLUoxetine*, FluvoxaMINE*, PARoxetine*, Sertraline*, Vilazodone, Vortioxetine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Although several clinical studies and case reports/series describing the clinical effects of combining lithium with a selective serotonin reuptake inhibitor (SSRI) indicate little to no evidence of clinically significant interactions,<sup>1,2,3,4,5,6,7,8,9,10</sup> a number of case reports describe adverse clinical events in patients receiving these combinations, including difficulties with speech and gait, arm and leg stiffness, dizziness, heat stroke, tremor, somnolence, and serotonin toxicity/serotonin syndrome.<sup>11,12,13,14,15,16,17,18,19,20</sup> The use of lithium with an SSRI, while common in some clinical practice settings, is expected to increase the risk of serotonin related adverse reactions due to the independent serotonergic effects of these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gram LF, Hansen MG, Sindrup SH, et al, “Citalopram: Interaction Studies With Levopromazine, Imipramine, and Lithium,” <i>Ther Drug Monit</i>, 1993, 15(1):18-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8451775\">[PubMed 8451775]</a></p>\n<p>2. Pope HG, McElroy SL, and Nixon RA, “Possible Synergism Between Fluoxetine and Lithium in Refractory Depression,” <i>Am J Psychiatry</i>, 1988, 145(10):1292-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3262313\">[PubMed 3262313]</a></p>\n<p>3. Bauer M, Linden M, Schaaf B, et al, “Adverse Events and Tolerability of the Combination of Fluoxetine-Lithium Compared With Fluoxetine,” <i>J Clin Psychopharmacol</i>, 1996, 16(2):130-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8690828\">[PubMed 8690828]</a></p>\n<p>4. Breuel HP, Muller-Oerlinghausen B, Nickelsen T, et al, “Pharmacokinetic Interactions Between Lithium and Fluoxetine After Single and Repeated Fluoxetine Administration in Young Healthy Volunteers,” <i>Int J Clin Pharmacol Ther</i>, 1995, 33(7):415-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7582400\">[PubMed 7582400]</a></p>\n<p>5. Hendricks B and Floris M, “A Controlled Study of the Combination of Fluvoxamine and Lithium,” <i>Curr Ther Res Clin Exp</i>, 1991, 49:106-10.</p>\n<p>6. Apelsoff G, Wilner KD, von Deutsch DA, et al, “Sertraline Does Not Alter Steady-State Concentrations of Renal Clearance of Lithium in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 1992, 32(7):643-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1640004\">[PubMed 1640004]</a></p>\n<p>7. Hawley CJ, Roberts AG and Walker MH, “Tolerability of Combined Treatment With Lithium and Paroxetine: 19 Cases Treated Under Open Conditions,” <i>J Psychopharmacol</i>, 1994, 8(4):266-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22298635\">[PubMed 22298635]</a></p>\n<p>8. Hopwood SE, Bogle S and Wildgust HJ, “The Combination of Fluoxetine and Lithium in Clinical Practice,” <i>Int Clin Psychopharmacol</i>, 1993, 8(4):325-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8277157\">[PubMed 8277157]</a></p>\n<p>9. Fagiolini A, Buysse DJ, Frank E, et al, “Tolerability of Combined Treatment With Lithium and Paroxetine in Patients With Bipolar Disorder and Depression,” <i>J Clin Psychopharmacol</i>, 2001, 21(5):474-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11593071\">[PubMed 11593071]</a></p>\n<p>10. Miljkovic BR, Pokrajac M, Timotijevic I, et al, “The Influence of Lithium on Fluvoxamine Therapeutic Efficacy and Pharmacokinetics in Depressed Patients on Combined Fluvoxamine-Lithium Therapy,” <i>Int Clin Psychopharmacol</i>, 1997, 12(4):207-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9347381\">[PubMed 9347381]</a></p>\n<p>11. Salama AA and Shafey M, “A Case of Severe Lithium Toxicity Induced by Combined Fluoxetine and Lithium Carbonate,” <i>Am J Psychiatry</i>, 1989, 146(2):278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2492167\">[PubMed 2492167]</a></p>\n<p>12. Noveske FG, Hahn KR, and Flynn RJ, “Possible Toxicity of Combined Fluoxetine and Lithium,” <i>Am J Psychiatry</i>, 1989, 146(11):1515. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2510522\">[PubMed 2510522]</a></p>\n<p>13. Albukrek D, Moran DS, and Epstein Y, “A Depressed Workman With Heatstroke,” <i>Lancet</i>, 1996, 347(9007):1016. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8606565\">[PubMed 8606565]</a></p>\n<p>14. Evans M and Marwick P, “Fluvoxamine and Lithium: An Unusual Interaction,” <i>Br J Psychiatry</i>, 1990, 156:286. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2107954\">[PubMed 2107954]</a></p>\n<p>15. Ohman R and Spigset O, “Serotonin Syndrome Induced by Fluvoxamine-Lithium,” <i>Pharmacopsychiatry</i>, 1993, 26(6):263-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8127934\">[PubMed 8127934]</a></p>\n<p>16. Sobanski T, Bagli M, Laux G, et al, “Serotonin Syndrome After Lithium Add-On Medication to Paroxetine,” <i>Pharmacopsychiatry</i>, 1997, 30(3):106-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9211572\">[PubMed 9211572]</a></p>\n<p>17. Muly EC, McDonald W, Steffens D, et al, “Serotonin Syndrome Produced by a Combination of Fluoxetine and Lithium,” <i>Am J Psychiatry</i>, 1993, 150(10):1565. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8379573\">[PubMed 8379573]</a></p>\n<p>18. Sacristan JA, Iglesias C, Arellano F, et al, “Absence Seizures Induced by Lithium: Possible Interaction With Fluoxetine,” <i>Am J Psychiatry</i>, 1991, 148(1):146-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1898627\">[PubMed 1898627]</a></p>\n<p>19. Austin LS, Arana GW and Melvin JA, “Toxicity Resulting From Lithium Augmentation of Antidepressant Treatment in Elderly Patients,” <i>J Clin Psychiatry</i>, 1990, 51(8):344-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2380160\">[PubMed 2380160]</a></p>\n<p>20. Warrington SJ, “Clinical Implications of the Pharmacology of Sertraline,” <i>Int Clin Psychopharmacol</i>, 1991, 6 Suppl 2:11-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1806626\">[PubMed 1806626]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3115":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Tryptophan</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tryptophan may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to risks of enhanced serotonin activity and/or adverse reactions (e.g., serotonin syndrome), concomitant use of selective serotonin reuptake inhibitors (SSRIs) and tryptophan is not recommended.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine*, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Signs and symptoms of CNS toxicity (central and peripheral) developed within a few days of adding tryptophan (1-4 g/day) to chronic fluoxetine therapy.<sup>1</sup> Signs and symptoms of toxicity included agitation, restlessness, nausea, vomiting, diarrhea, and worsening obsessive-compulsive disorder. The mechanism of this presumed interaction might be related to an additive effect of the two agents on serotonin activity. The selective serotonin reuptake inhibitors (SSRIs) reduce reuptake into the neurons, and tryptophan acts as a serotonin agonist. The prescribing information for SSRIs recommends against concomitant use with tryptophan.<sup>2,3,4,5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner W and Fontaine R, “Toxic Reaction Following the Combined Administration of Fluoxetine and L-Tryptophan: Five Case Reports,” <i>Biol Psychiatry</i>, 1986, 21:1067-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3488767\">[PubMed 3488767]</a></p>\n<p>2. Prescribing information. Prozac (fluoxetine). Indianapolis, IN: Eli Lilly and Company, October 2009.</p>\n<p>3. Prescribing information. Zoloft (sertraline). New York, NY: Pfizer, Inc., January 2009.</p>\n<p>4. Prescribing information. Paxil (paroxetine). Research Triangle Park, NC: GlaxoSmithKline, June 2010.</p>\n<p>5. Prescribing information. Celexa (citalopram). St. Louis, MO: Forest Laboratories Inc., January 2009.</p>\n<p>6. Prescribing information. Lexapro (escitalopram). St. Louis, MO: Forest Laboratories Inc., March 2009.</p>\n<p>7. Prescribing information. Luvox (fluvoxamine). Baltimore, MD: Bay Pharma, Februay 2009.</p>\n<p>8. Prescribing information. Viibryd (vilazodone hydrochloride). New Haven, CT: Trovis Pharmaceuticals LLC, January 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3116":"<p><b>Title</b> Vitamin K Antagonists / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic/toxic effects of oral anticoagulants if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased effects if an SSRI is discontinued/dose decreased.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine*, FluvoxaMINE*, PARoxetine*, Sertraline*, Vilazodone, Vortioxetine</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Varied reports are published regarding the impact of SSRI on oral anticoagulants. Most pharmacokinetic reports describe little to no apparent effect of SSRI on warfarin serum concentrations in both patients and normal subjects.<sup>1,2,3,4,5</sup> One report describes a 65% increase in serum warfarin concentration in normal subjects when coadministered with fluvoxamine.<sup>6</sup> Even so, several cases of increased INR with fluoxetine (four- to sevenfold) and paroxetine with associated bleeding have been reported.<sup>4,6,7,8,9,10</sup> The mechanism of these interactions is unclear. They may be related to inhibition of CYP isoenzymes, but a clear pattern can not be established. Warfarin is metabolized by CYP1A2, CYP2C, and CYP3A4 isoenzymes. Most SSRI will inhibit at least one of these pathways. Escitalopram only appears to weakly inhibit CYP2D6.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lemberger L, Bergstrom RF, Wolen RL, et al, “Fluoxetine: Clinical Pharmacology and Physiologic Disposition,” <i>J Clin Psychiatry</i>, 1985, 46(3 Pt 2):14-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3871765\">[PubMed 3871765]</a></p>\n<p>2. Rowe H, Carmichael R, and Lemberger L, “The Effect of Fluoxetine on Warfarin Metabolism in the Rat and Man,” <i>Life Sci</i>, 1978, 23:807-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=309056\">[PubMed 309056]</a></p>\n<p>3. Ford MA, Anderson ML, Rindone JP, et al, “Lack of Effect of Fluoxetine on the Hypoprothrombinemic Response of Warfarin,” <i>J Clin Psychopharmacol</i>, 1997, 17:110-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10950474\">[PubMed 10950474]</a></p>\n<p>4. Bannister SJ, Houser VP, Hulse JD, et al, “Evaluation of the Potential Interactions of Paroxetine With Diazepam, Cimetidine, Warfarin and Digoxin,” <i>Acta Psychiatr Scand</i>, 1989, 80:102-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=52530759\">[PubMed 52530759]</a></p>\n<p>5. Apseloff G, Wilner KD, Gerber N, et al, “Effect of Sertraline on Protein Binding of Warfarin,” <i>Clin Pharmacokinet</i>, 1997, 32(Suppl 1):38-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9068939\">[PubMed 9068939]</a></p>\n<p>6. Benfield P and Ward A, “Fluvoxamine, A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in Depressive Illness,” <i>Drugs</i>, 1986, 32:313-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3096686\">[PubMed 3096686]</a></p>\n<p>7. Hanger HC and Thomas F, “Fluoxetine and Warfarin Interactions,” <i>NZ Med J</i>, 1995, 108:157. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=77610459\">[PubMed 77610459]</a></p>\n<p>8. Woolfrey S, Gammack NS, Dewar MS, et al, “Fluoxetine-Warfarin Interaction,” <i>Br Med J</i>, 1993, 307:241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8364688\">[PubMed 8364688]</a></p>\n<p>9. Dent LA and Orrock MW, “Warfarin-Fluoxetine and Diazepam-Fluoxetine Interaction,” <i>Pharmacotherapy</i>, 1997, 17:170-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9017779\">[PubMed 9017779]</a></p>\n<p>10. Askinazi C, “SSRI Treatment of Depression With Comorbid Cardiac Disease,” <i>Am J Psychiatry</i>, 1996, 153:135-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8540578\">[PubMed 8540578]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3119":"<p><b>Title</b> Phenytoin / Folic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Folic Acid may decrease the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effectiveness of phenytoin if folic acid is initiated/dose increased. Similarly, monitor for increases in phenytoin concentrations (and possible toxicity) if folic acid is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations decreased 30% to 50% in 50 patients within one month of initiating folic acid therapy.<sup>1</sup> In small case series reports and individual case reports, the addition of folic acid at doses of 1mg have been associated with 20-23% reductions in phenytoin concentrations,<sup>2,3</sup> while addition of 5mg doses have been associated with 40-60% reductions in phenytoin concentrations.<sup>4,5</sup> Similar reductions in serum phenytoin concentrations have been reported elsewhere.<sup>6,7,8</sup> Several reports have also described an apparent lack of effectiveness following the addition of folic acid, with reports of breakthrough seizures and/or an increase in seizure episodes.<sup>1,2,5,9,10</sup><br><br>Though the detailed mechanism of this interaction has yet to be fully described, folic acid appears to function as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentration increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>2,3,9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>2. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>3. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>4. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>5. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>6. Glazko AJ, “Antiepileptic Drugs: Biotransformation, Metabolism, and Serum Half-Life,” <i>Epilepsia</i>, 1975, 16:367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=238831\">[PubMed 238831]</a></p>\n<p>7. Jensen ON and Olesen OV, “Subnormal Serum Folate Due to Anticonvulsive Therapy. A Double-Blind Study of the Effect of Folic Acid Treatment in Patients With Drug-Induced Subnormal Serum Folates,” <i>Arch Neurol</i>, 1970, 22:181-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4902774\">[PubMed 4902774]</a></p>\n<p>8. Furlanut M, Benetello P, Avogaro A, et al, “Effects of Folic Acid on Phenytoin Kinetics in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 1978, 24:294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688723\">[PubMed 688723]</a></p>\n<p>9. Berg MJ, Rivey MP, Vern BA, et al, “Phenytoin and Folic Acid: Individualized Drug-Drug Interaction,” <i>Ther Drug Monit</i>, 1983, 5:395-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659013\">[PubMed 6659013]</a></p>\n<p>10. Seligmann H, Potasman I, Weller B, et al, “Phenytoin-Folic Acid Interaction: A Lesson to be Learned,” <i>Clin Neuropharmacol</i>, 1999, 22(5):268-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10516876\">[PubMed 10516876]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3120":"<p><b>Title</b> Loop Diuretics / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may diminish the diuretic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of loop diuretics if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The absorption of furosemide (20 mg orally) was reduced by approximately 50% in a study of 5 healthy volunteers when administered following a 10-day course of phenytoin (300 mg/day).<sup>1</sup> The associated diuretic response to furosemide was also reduced with phenytoin. Another study (N=17) reported similar findings of diminished (and delayed) diuretic response to furosemide with concurrent anticonvulsant therapy (all subjects were receiving phenytoin and phenobarbital, some were also receiving other anticonvulsants).<sup>2</sup> The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fine A, Henderson JS, Morgan DR, et al, “Malabsorption of Frusemide Caused by Phenytoin,” <i>Br Med J</i>, 1977, 2:1061-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=922420\">[PubMed 922420]</a></p>\n<p>2. Ahmad S, “Renal Insensitivity to Frusemide Caused by Chronic Anticonvulsant Therapy,” <i>Br Med J</i>, 1974, 3:657-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4609534\">[PubMed 4609534]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3121":"<p><b>Title</b> Loop Diuretics / Beta2-Agonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased risk of hypokalemia, and the associated effects (eg, cardiac conduction problems) in patients receiving concomitant therapy with beta<sub>2</sub>-agonists and loop diuretics. Patients with low baseline serum potassium concentrations are likely at increased risk of negative effects.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The serum potassium concentration was decreased more by the concomitant administration of terbutaline and furosemide than by either agent alone in a study of 15 healthy volunteers.<sup>1</sup> From a baseline serum potassium concentration of 3.88 mmol/L, serum potassium decreased to 3.58 with furosemide alone, 3.35 with terbutaline alone, and 3.13 with the combination. Adding triamterene to the combination attenuated the decrease, but the concentration still dropped to 3.29. Some changes in T-wave amplitude were noted.<br><br>The likely mechanism for this interaction is additive or synergistic effects of these medications on serum potassium concentrations. Both medication classes are known to reduce serum potassium concentrations, with each even listed among potential treatments of hyperkalemia.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Newnham DM, McDevitt DG, and Lipworth BJ, “The Effects of Frusemide and Triamterene on the Hypokalaemic and Electrocardiographic Responses to Inhaled Terbutaline,” <i>Br J Clin Pharmacol</i>, 1991, 32:630-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1954079\">[PubMed 1954079]</a></p>\n<p>2. Kim HJ, Han SW, “Therapeutic Approach to Hyperkalemia,” <i>Nephron</i>, 2002, 92 Suppl 1:33-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12401936\">[PubMed 12401936]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3122":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Beta2-Agonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased risk of hypokalemia, and the associated effects (eg, cardiac conduction problems) in patients receiving concomitant therapy with beta<sub>2</sub>-agonists and thiazide diuretics. Patients with low baseline serum potassium concentrations are likely at increased risk of negative effects.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> The serum potassium concentration was decreased from 3.78 mmol/L to 3.07 mmol/L in 10 normal subjects within 7 days of therapy with bendroflumethiazide.<sup>1</sup> The potassium concentration was decreased even further (to 2.72 mmol/L) following the addition of albuterol inhalation therapy. EKG changes were noted. The mechanism of this interaction would appear related to the combined hypokalemic effects of the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lipworth BJ, McDevitt DG, and Struthers AD, “Prior Treatment With Diuretic Augments the Hypokalemic and Electrocardiographic Effects of Inhaled Albuterol,” <i>Am J Med</i>, 1989, 86:653-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2729315\">[PubMed 2729315]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3123":"<p><b>Title</b> Neuromuscular-Blocking Agents / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Be aware that the therapeutic effects of neuromuscular blockers may be altered by coadministration of loop diuretics. Low doses of the diuretic appear to enhance blockade, whereas higher doses may diminish blockade.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine*, Vecuronium</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The neuromuscular-blocking effect of tubocurarine was prolonged (decreased twitch tension) in 3 kidney transplant patients who also received intravenous furosemide (40 mg or 80 mg) and mannitol (12.5 g).<sup>1</sup> The effects were reversed by administration of an acetylcholinesterase inhibitor and atropine. In contrast, the recovery time from pancuronium was apparently shortened by about one-third in 10 patients who also received furosemide (1 mg/kg).<sup>2</sup> The mechanism of this apparent and mixed interaction is unclear. An animal study demonstrated that furosemide doses of 0.1-10 mcg/kg increased the blocking effects of tubocurarine and succinylcholine; whereas 1-4 mg/kg decreased the blocking effects.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Miller RD, Sohn YJ, and Matteo RS, “Enhancement of D-Tubocurarine Neuromuscular Blockade by Diuretics in Man,” <i>Anesthesiology</i>, 1976, 45:442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=184722\">[PubMed 184722]</a></p>\n<p>2. Azar I, Cottbell J, Gupta B, et al, “Furosemide Facilitates Recovery of Evoked Twitch Response After Pancuronium,” <i>Anesth Analg</i>, 1980, 59:55-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7188666\">[PubMed 7188666]</a></p>\n<p>3. Scappaticci K, Ham JA, Sohn YJ, et al, “Effects of Furosemide on the Neuromuscular Junction,” <i>Anesthesiology</i>, 1982, 57:381-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6291433\">[PubMed 6291433]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3124":"<p><b>Title</b> Phenytoin / Immune Globulins</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Immune Globulins may enhance the adverse/toxic effect of Phenytoin. Specifically the development of hypersensitivity myocarditis. <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for evidence of hypersensitivity myocarditis during concomitant administration of an immune globulin and phenytoin.</p>\n<div>\n <p><b>Immune Globulins Interacting Members</b> Anthrax Immune Globulin (Human), Antithymocyte Globulin (Equine), Botulism Immune Globulin (Intravenous-Human), Cytomegalovirus Immune Globulin (Intravenous-Human), Hepatitis B Immune Globulin (Human), Immune Globulin, Rabies Immune Globulin (Human), Respiratory Syncytial Virus Immune Globulin (Intravenous), Rho(D) Immune Globulin, Tetanus Immune Globulin (Human), Vaccinia Immune Globulin (Intravenous), Varicella-Zoster Immune Globulin (Human)</p>\n</div> \n<p><b>Discussion</b> Case report. A phenytoin patient (also receiving nizatidine and acetaminophen) was administered a 5-day course of IV immune globulin (IVIG) for treatment of Guillain-Barre syndrome. He developed aching shoulders and back, abdominal pain, and hypotension, and subsequently died. Autopsy revealed hypersensitivity myocarditis.<sup>1</sup> Phenytoin has been associated with hypersensitivity myocarditis. Whether or not IVIG administration affected its clinical course is unknown. Causal relationship has not been established.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Koehler PJ and Koudstaal J, “Lethal Hypersensitivity Myocarditis Associated With the Use of Intravenous Gamma Globulin for Guillain-Barre Syndrome in Combination With Phenytoin,” <i>J Neurol</i>, 1996, 243:366-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8965113\">[PubMed 8965113]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3125":"<p><b>Title</b> Vitamin K Antagonists / Glucagon</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Glucagon may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of oral anticoagulants if glucagon is administered in high doses (eg, for treatment of beta blocker or calcium channel blocker overdose). Glucagon dosing of at least 50 mg over a 2-day period appears to be a higher risk regimen than 30 mg doses over the same period.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The hypoprothrombinemic response to warfarin was increased significantly in 8 of 9 patients following the administration of at least 50 mg of glucagon administered over a 2-day period, with bleeding occurring in some patients.<sup>1</sup> Glucagon doses of not more than 30 mg administered over a 1- to 2-day period failed to demonstrate this same effect on warfarin. The mechanism of this interaction is unknown. This type of dosing of glucagon does not appear to be common clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Koch-Weser J, “Potentiation by Glucagon of the Hypoprothrombinemic Action of Warfarin,” <i>Ann Intern Med</i>, 1970, 72:331. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5415418\">[PubMed 5415418]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3126":"<p><b>Title</b> Vitamin K Antagonists / Glutethimide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Glutethimide may increase the metabolism of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider using an alternative sedative/hypnotic in place of glutethimide. Monitor for reduced effects of oral anticoagulants if glutethimide is initiated/dose increased, or decreased effects if glutethimide is discontinued/dose decreased. These effects may take several days/weeks to manifest or dissipate.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The half-life of warfarin has been reported to be decreased up to approximately 50% within 2-4 weeks of initiating glutethimide therapy.<sup>1,2</sup> Reductions in the hypoprothrombinemic response to warfarin have been noted in some patients.<sup>3</sup> The mechanism of this interaction appears related to the ability of glutethimide to increase the metabolism of the anticoagulant by inducing CYP isoenzymes. The effect may take several days to weeks to manifest. Likewise, the effects may not fully dissipate for several days to weeks after the discontinuation of glutethimide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Corn M, “Effect of Phenobarbital and Glutethimide on the Biological Half-Life of Warfarin,” <i>Thromb Diath Haemorrh</i>, 1966, 16:606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=59966777\">[PubMed 59966777]</a></p>\n<p>2. MacDonald MG, Robinson DS, Sylwester D, et al, “The Effects of Phenobarbital, Chloral Betaine, and Glutethimide Administration on Warfarin Plasma Levels and Hypoprothrombinemic Response in Man,” <i>Clin Pharmacol Ther</i>, 1969, 10(1):80-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5763659\">[PubMed 5763659]</a></p>\n<p>3. Udall JA, “Clinical Implications of Warfarin Interactions With Five Sedatives,” <i>Am J Cardiol</i>, 1975, 35:67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1109248\">[PubMed 1109248]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3127":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Patients receiving simvastatin or lovastatin should avoid consuming any grapefruit juice. For other patients, increase monitoring for toxic effects of HMG-CoA reductase inhibitors (“statins”) (e.g., rhabdomyolysis, muscle weakness) in patients whose grapefruit juice intake has recently changed (i.e., recently started/stopped regular consumption or increased/decreased amount of grapefruit juice consumed). It is generally recommended to avoid grapefruit juice (and ingestion of quantities in excess of 1-1.2 L (or 32-40 oz.) per day, in particular) while taking one of these statins. If avoidance is not possible, it is advisable to limit consumption to small quantities (e.g., 200-300 mL (or approximately 7-10 oz.) per day) in order to minimize the risk for a significant interaction. Fluvastatin, pitavastatin, pravastatin, and rosuvastatin all appear to be at particularly low risk for any clinically significant interaction with even larger amounts of grapefruit juice and may be suitable alternatives for patients who consume large amounts of grapefruit juice or for patients whose grapefruit juice consumption is highly variable.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin*, Lovastatin*, Red Yeast Rice, Simvastatin*<br><b>Exceptions</b> Fluvastatin, Pitavastatin, Pravastatin, Rosuvastatin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of atorvastatin was increased 1.4- to 2.5-fold in subjects who consumed double-strength grapefruit juice (GFJ) and then a single dose of atorvastatin.<sup>1,2</sup> The AUC was increased 83% in eight volunteers who consumed 250 mL of single-strength GFJ three times a day for four days prior to a single dose of 20 mg atorvastatin.<sup>3</sup> AUC and Cmax increases of 37% and 16%, respectively, are also reported when 240 mL of GFJ was ingested daily with a single dose of 40 mg atorvastatin.<sup>4</sup> Given these increases in AUC and Cmax with greater GFJ consumption (in volume and/or strength), the atorvastatin prescribing information states that patients taking atorvastatin are likely to experience significantly increased plasma concentrations, particularly with excessive GFJ consumption (i.e., more than 1.2 L (or 40 oz.) per day).<sup>4</sup><br><br>The lovastatin AUC and Cmax increased an average of 12- and 15-fold, respectively, when 10 volunteers consumed 200 mL of double-strength GFJ three times a day for three days with a single dose of 80 mg lovastatin taken on day three.<sup>5</sup> Another study reported a 1.3-fold increase in the plasma concentration of active and total HMG-CoA reductase inhibitory activity after 15 subjects had 8 oz. of single-strength GFJ for three days with a single dose of 40 mg lovastatin on day three.<sup>6</sup> Lovastatin prescribing information recommends avoiding use with GFJ.<sup>6</sup> <br><br>The simvastatin AUC and Cmax increased an average of 16- and 9-fold, respectively, in 10 healthy volunteers who ingested 200 mL of double-strength GFJ three times a day for three days and received a single dose of 60 mg simvastatin on day three.<sup>7</sup> Further, the AUC and Cmax increased 3.6- and 3.9-fold, respectively, when 10 volunteers were administered 200 mL of single-strength GFJ for three days and received a single 40 mg dose of simvastatin on day three.<sup>8</sup> Animal models also confirm an increase in simvastatin concentration with concurrent administration of GFJ.<sup>9</sup> Of note, the interaction between GFJ and simvastatin persisted for 3-7 days after intake of 40 mg of simvastatin and 200 mL of double-strength GFJ three times a day for three days.<sup>10</sup> Simvastatin prescribing information recommends that patients receiving simvastatin avoid any consumption of GFJ.<sup>11</sup><br><br>Though there are no specific data with red yeast rice, given the similarity between its active compounds and lovastatin, it would be expected to interact with GFJ in a manner similar to lovastatin.<br><br>The mechanism of this interaction appears to be predominately related to the ability of some GFJ constituents to inhibit CYP3A4.<sup>12,13,14,15</sup> Some GFJ-mediated alteration in HMG-CoA reductase inhibitor transport (e.g., via p-glycoprotein and/or other efflux or uptake transporters) is also possible.<sup>16</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. <i>Clin Pharmacol Ther</i>. 1999;66(2):118-127. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10460065\">[PubMed 10460065]</a></p>\n<p>2. Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. <i>Br J Clin Pharmacol</i>. 2004;57(4):448-455. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15025743\">[PubMed 15025743]</a></p>\n<p>3. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. <i>Br J Clin Pharmacol</i>. 2005;60(5):494-497. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16236039\">[PubMed 16236039]</a></p>\n<p>4. <i>Lipitor</i> (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; June 2009.</p>\n<p>5. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. <i>Clin Pharmacol Ther</i>. 1998;63(4):397-402. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9585793\">[PubMed 9585793]</a></p>\n<p>6. <i>Mevacor</i> (lovastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; CO., Inc.; February 2014.</p>\n<p>7. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. <i>Clin Pharmacol Ther</i>. 1998;64(5):477-483. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9834039\">[PubMed 9834039]</a></p>\n<p>8. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. <i>Br J Clin Pharmacol</i>. 2004;58(1):56-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15206993\">[PubMed 15206993]</a></p>\n<p>9. Butterweck V, Zdrojewski I, Galloway C, Frye R, Derendorf H. Toxicological and pharmacokinetic evaluation of concomitant intake of grapefruit juice and simvastatin in rats after repeated treatment over 28 days. <i>Planta Med</i>. 2009;75(11):1196-1202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19350484\">[PubMed 19350484]</a></p>\n<p>10. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. <i>Clin Pharmacol Ther</i>. 2000;68(4):384-390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11061578\">[PubMed 11061578]</a></p>\n<p>11. <i>Zocor</i> (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; February 2015.</p>\n<p>12. Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. <i>J Pharmacol Exp Ther</i>. 2005;312(3):1151-1160. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15485894\">[PubMed 15485894]</a></p>\n<p>13. Edwards DJ, Bellevue FH 3rd, Woster PM. Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. <i>Drug Metab Dispos</i>. 1996;24(12):1287-1290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8971132\">[PubMed 8971132]</a></p>\n<p>14. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. <i>Drug Metab Dispos</i>. 1997;25(11):1228-1233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9351897\">[PubMed 9351897]</a></p>\n<p>15. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. <i>J Clin Invest</i>. 1997;99(10):2545-2553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9153299\">[PubMed 9153299]</a></p>\n<p>16. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. <i>Pharmacotherapy</i>. 2006;26(11):1601-1607. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17064205\">[PubMed 17064205]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3128":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Griseofulvin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Griseofulvin may increase the metabolism of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. This interaction should be avoided, if possible. Patients should be instructed to use alternative, nonhormonal forms of contraception during griseofulvin therapy. Alternative therapy to griseofulvin could also be considered. If agents are used concomitantly, monitor for signs of menstrual irregularities, including breakthrough bleeding (which may indicate reduced hormone concentrations) noting that the absence of such signs does not indicate therapeutic success.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Menstrual irregularities (including both breakthrough bleeding and amenorrhea) were noted in 15 of 22 women on estrogen/progestin oral contraceptives following the addition of griseofulvin (500-1000 mg/day).<sup>1</sup> Rechallenge produced the recurrence of symptoms in 4 of these patients. A case report describes a patient taking a combination oral contraceptive who developed oligomenorrhea and irregular menses following the initiation of griseofulvin (250-500 mg/day).<sup>2</sup> The symptoms dissipated following an increase in the estrogen content of the oral contraceptive. The mechanism of these interactions is possibly related to the ability of griseofulvin to induce the CYP metabolism of the contraceptive hormones (probably estrogen). The effect on progestin-only contraceptives is unknown, and therefore caution is warranted. The American College of Obstetricians and Gynecologists recommend the use of nonhormonal contraception during concomitant therapy.<sup>3</sup> Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Van Dijke CP and Weber JC, “Interaction Between Oral Contraceptives and Griseofulvin,” <i>Br Med J,</i> 1984, 288:1125-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6424759\">[PubMed 6424759]</a></p>\n<p>2. McDaniel PA and Caldroney RD, “Oral Contraceptives and Griseofulvin Interaction,” <i>Drug Intell Clin Pharm</i>, 1986, 20:384. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3709350\">[PubMed 3709350]</a></p>\n<p>3. ACOG Practice Bulletin, “The Use of Hormonal Contraception in Women With Coexisting Medical Conditions,” July, 2000, The American College of Obstetricians and Gynecologists, Washington, DC. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16738183\">[PubMed 16738183]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3129":"<p><b>Title</b> Progestins (Contraceptive) / Griseofulvin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Griseofulvin may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. These agents should probably not be used together. Patients must be instructed to use alternative, nonhormonal forms of contraception during griseofulvin therapy. Alternative therapy for griseofulvin could also be selected. If agents are used concomitantly, monitor for signs of menstrual irregularities, including breakthrough bleeding (which may indicate reduced hormone concentrations) noting that the absence of such signs do not indicate therapeutic success. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Menstrual irregularities (including both breakthrough bleeding and amenorrhea) were noted in 15 of 22 women on estrogen/progestin oral contraceptives following the addition of griseofulvin (500-1000 mg/day).<sup>2</sup> Rechallenge produced the recurrence of symptoms in 4 of these patients. A case report describes a patient taking a combination oral contraceptive who developed oligomenorrhea and irregular menses following the initiation of griseofulvin (250-500 mg/day).<sup>3</sup> The symptoms dissipated following an increase in the estrogen content of the oral contraceptive. The mechanism of these interactions is possibly related to the ability of griseofulvin to induce the CYP metabolism of the contraceptive hormones (probably estrogen). The effect on progestin-only contraceptives is unknown, and therefore caution is warranted. The American College of Obstetricians and Gynecologists recommend the use of nonhormonal contraception during concomitant therapy of griseofulvin and hormonal contraceptives.<sup>4</sup> Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Van Dijke CP and Weber JC, “Interaction Between Oral Contraceptives and Griseofulvin,” <i>Br Med J</i>, 1984, 288:1125-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6424754\">[PubMed 6424754]</a></p>\n<p>3. McDaniel PA and Caldroney RD, “Oral Contraceptives and Griseofulvin Interaction,” <i>Drug Intell Clin Pharm</i>, 1986, 20:384. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3709350\">[PubMed 3709350]</a></p>\n<p>4. ACOG Practice Bulletin, “The Use of Hormonal Contraception in Women With Coexisting Medical Conditions,” July, 2000, The American College of Obstetricians and Gynecologists, Washington DC. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11732484\">[PubMed 11732484]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3130":"<p><b>Title</b> Griseofulvin / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Barbiturates may decrease the serum concentration of Griseofulvin. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of griseofulvin if used concomitant with an oral barbiturate. Higher-than-usual doses of griseofulvin may be needed to achieve therapeutic success. Monitor for increased effect/toxicity if an oral barbiturate is discontinued/dose decreased.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital<br><b>Exceptions</b> Methohexital, Thiopental</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The oral absorption of griseofulvin was decreased 33% to 45% in 14 normal subjects while also receiving phenobarbital (90 mg/day oral).<sup>1,2</sup> Therapeutic failures have been reported due to this interaction.<sup>3</sup> <br><br>The mechanism of this interaction is unknown. Phenobarbital does not appear to increase griseofulvin metabolism, but somehow impair its absorption.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Busfield D, Child KJ, Atkinson RM, et al, “An Effect of Phenobarbitone on Blood Levels of Griseofulvin in Man,” <i>Lancet</i>, 1963, ii:1042. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14062729\">[PubMed 14062729]</a></p>\n<p>2. Riegelman S, Rowland M, and Epstein WL, “Griseofulvin-Phenobarbital Interaction in Man,” <i>JAMA</i>, 1970, 213:426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5468016\">[PubMed 5468016]</a></p>\n<p>3. Lorenc E, “A New Factor in Griseofulvin Treatment Failures,” <i>Mo Med</i>, 1967, 64:32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6036155\">[PubMed 6036155]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3131":"<p><b>Title</b> Vitamin K Antagonists / Griseofulvin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Griseofulvin may decrease the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of vitamin K antagonists if griseofulvin is initiated/dose increased, or increased effects if griseofulvin is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The hypoprothrombinemic response to warfarin was decreased in a man over the course of 12 weeks following the initiation of griseofulvin.<sup>1</sup> The patient was restabilized on a dose that was 41% higher than his pregriseofulvin dose. Two other reports showed decreased responses to warfarin within a couple of weeks of initiating griseofulvin in some, but not all, patients.<sup>2,3</sup> <br><br>The mechanism of this interaction is most likely enhancement of warfarin metabolism (R, S, or both enantiomers) via griseofulvin induction of CYP1A2 and/or 2C9.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Okino K and Weibert RT, “Warfarin-Griseofulvin Interaction,” <i>Drug Intell Clin Pharm</i>, 1986, 20:291-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3698827\">[PubMed 3698827]</a></p>\n<p>2. Cullen SI and Catalano PM, “Griseofulvin-Warfarin Antagonism,” <i>JAMA</i>, 1967, 199:582. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6071326\">[PubMed 6071326]</a></p>\n<p>3. Udall JA, “Drug Interference With Warfarin Therapy,” <i>Clin Med</i>, 1970, 77:20.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3132":"<p><b>Title</b> Haloperidol / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of excessive drowsiness or confusion if haloperidol and a nonsteroidal anti-inflammatory agent (NSAID) are used concomitantly. Indomethacin may be more prone to cause this problem than other NSAIDs, however caution with all agents may be warranted.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Marked drowsiness, tiredness, and confusion developed in 6 of 11 patients in a study evaluating the effectiveness of concomitant haloperidol (5 mg/day) and indomethacin (75 mg/day) for the treatment of osteoarthritis-related pain.<sup>1</sup> Due to the significant difference in the incidence of such effects compared to placebo, the study was interrupted. The mechanism of this apparent interaction is unknown, as is the ability of other similar agents to cause it to occur. Indomethacin, compared with other nonsteroidal anti-inflammatory agents, has a higher incidence of CNS-related side effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bird HA, Le Gallez P, and Wright V, “Drowsiness Due to Haloperidol/Indomethacin Combination,” <i>Lancet</i>, 1983, i:830-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6132175\">[PubMed 6132175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3133":"<p><b>Title</b> QuiNIDine / Haloperidol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Haloperidol may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Due to the potential for both increased haloperidol exposure and enhanced QTc interval prolongation, avoid concomitant use of haloperidol and quinidine.</p> \n<p><b>Discussion</b> Pretreatment with quinidine (250 mg bisulfate single oral dose, equivalent to 200 mg quinidine sulfate) 1 hour prior to haloperidol (5 mg single oral dose) approximately doubled the haloperidol AUC in a clinical study of 13 healthy volunteers.<sup>1</sup><br><br>The likely primary mechanism of pharmacokinetic interaction between these agents is quinidine inhibition of CYP2D6 mediated haloperidol metabolism. Additionally, both agents are known to prolong QTc interval, so their concomitant use may increase the risk of arrhythmia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Young D, Midha KK, Fossler MJ, et al, “Effect of Quinidine on the Interconversion Kinetics Between Haloperidol and Reduced Haloperidol in Humans: Implications for the Involvement of Cytochrome P450IID6,” <i>Eur J Clin Pharmacol</i>, 1993, 44:433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8359179\">[PubMed 8359179]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3134":"<p><b>Title</b> Barbiturates / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifamycin Derivatives may increase the metabolism of Barbiturates. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of barbiturates if a rifamycin derivative (especially rifampin) is initiated/dose increased, or increased effects if a rifamycin derivative is discontinued/dose decreased. Monitor barbiturate concentrations if used as an antiseizure therapy. In order of potency/risk: rifampin &gt; rifapentine &gt; rifabutin.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of hexobarbital was decreased approximately threefold in 6 normal subjects following 8 days of rifampin administration (1200 mg/day).<sup>1</sup> More significant changes have been identified in other studies.<sup>2,3,4</sup> The mechanism of these changes is likely related to the ability of rifampin to induce CYP isoenzymes involved in barbiturate metabolism. Rifabutin and rifapentine appear to affect CYP3A4, and rifapentine also induces CYP2C8/9. Their impact on barbiturate metabolism may be less than rifampin. Caution is still advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Breimer DD, Zilly W, and Richter E, “Influence of Rifampicin on Drug Metabolism: Differences Between Hexobarbital and Antipyrine,” <i>Clin Pharmacol Ther</i>, 1977, 21:470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=849678\">[PubMed 849678]</a></p>\n<p>2. Smith DA, Chandler MH, Shedlofsky SI, et al, “Age-Dependent Stereoselective Increase in the Oral Clearance of Hexobarbitone Isomers Caused by Rifampicin,” <i>Br J Clin Pharmacol</i>, 1991, 32:735-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1768567\">[PubMed 1768567]</a></p>\n<p>3. Zilly W, Breimer DD, and Richter E, “Induction of Drug Metabolism in Man After Rifampicin Treatment Measured by Increased Hexobarbital and Tolbutamide Clearance,” <i>Eur J Clin Pharmacol</i>, 1975, 9:219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1233266\">[PubMed 1233266]</a></p>\n<p>4. Zilly W, Breimer DD, and Richter E, “Stimulation of Drug Metabolism by Rifampicin in Patients With Cirrhosis or Cholestasis Measured by Increased Hexobarbital and Tolbutamide Clearance,” <i>Eur J Clin Pharmacol</i>, 1977, 11:287. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=862650\">[PubMed 862650]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3135":"<p><b>Title</b> HydrALAZINE / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of hydralazine if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or increased effects if NSAID is discontinued/dose decreased</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 9 healthy volunteers, coadministration of indomethacin (200 mg, taken as a series of 4 50 mg oral doses between 6 h - 90 min prior to hydralazine) abolished the blood pressure lowering effects of a single dose of hydralazine (0.15 mg/kg intravenously) and significantly diminished the blood pressure lowering effects of a second hydralazine dose given 30 minutes later.<sup>1</sup> An earlier study did not demonstrate this effect in healthy volunteers given lower doses of indomethacin (25 mg every 6 hours for 10 doses) prior to hydralazine.<sup>2</sup><br><br>The mechanism of this interaction has not been specifically investigated in humans. Animal studies have found similar effects of indomethacin and meclofenamate in reducing vasodilatory effects of hydralazine, and suggest that these effects may be the result of inhibition of cyclooxygenase mediated prostaglandin synthesis.<sup>3,4,5</sup> A similar interaction has been seen between the closely related vasodilator dihydralazine and diclofenac in humans.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cinquegrani MP and Liang CS, “Indomethacin Attenuates the Hypotensive Action of Hydralazine,” <i>Clin Pharmacol Ther</i>, 1986, 39(5):564-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3698464\">[PubMed 3698464]</a></p>\n<p>2. Jackson SH and Pickles H, “Indomethacin Does Not Attenuate the Effects of Hydralazine in Normal Subjects,” <i>Eur J Clin Pharmacol</i>, 1983, 25(3):303-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6414822\">[PubMed 6414822]</a></p>\n<p>3. Chelly JE, Doursout MF, Begaud B, et al, “Effects of Hydralazine on Regional Blood Flow in Conscious Dogs,” <i>J Pharmacol Exp Ther</i>, 1986, 238(2):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3735136\">[PubMed 3735136]</a></p>\n<p>4. Panzenbeck M, Baez A and Kaley G, “Prostaglandins Participate in the Renal Vasodilation due to Hydralazine in Dogs,” <i>J Pharmacol Exp Ther</i>, 1986, 237(2):525-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3084759\">[PubMed 3084759]</a></p>\n<p>5. Rubin LJ and Lazar JD, “Influence of Prostaglandin Synthesis Inhibitors on Pulmonary Vasodilatory Effects of Hydralazine in Dogs With Hypoxic Pulmonary Vasoconstriction,” <i>J Clin Invest</i>, 1981, 67(1):193-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7451649\">[PubMed 7451649]</a></p>\n<p>6. Reimann IW, Ratge D, Wisser H, et al, “Are Prostaglandins Involved in the Antihypertensive Effect of Dihydralazine?” <i>Clin Sci (Lond)</i>, 1981, 61 Suppl 7:319s-321s. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7318332\">[PubMed 7318332]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3136":"<p><b>Title</b> QuiNIDine / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Lower tricyclic antidepressant doses may be required when used with quinidine. Monitor patients closely for signs/symptoms of adverse effects of the tricyclic antidepressant when used with quinidine. In addition, both agents can prolong QTc intervals, and thus extra caution should be used if these agents are coadministered. Also note that when quinidine is discontinued in a patient who had been receiving this combination, the tricyclic antidepressant dose may need to be increased.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine*, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline*, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of nortriptyline (50 mg x1) was increased 4-fold in 5 healthy subjects when administered 1 hour after a single dose of quinidine (50 mg).<sup>1</sup> Similarly, the clearance of single doses of imipramine (100 mg) and desipramine (25 mg) were reduced by 30% and 85%, respectively, in healthy subjects when administered following a 12-day course of quinidine (200 mg/day).<sup>2</sup> Clinical effects are likely, although documentation is limited. Enhanced EEG effects of trimipramine were described in one pilot study of 2 healthy subjects, along with increased trimipramine half-life and decreased clearance, when trimipramine was given after 2 doses of quinidine (50 mg).<sup>3</sup><br><br>The mechanism of these interactions is likely inhibition of the CYP2D6-mediated hydroxylation of the tricyclic antidepressants by quinidine. Several in vitro studies have shown that the hydroxylation of amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, and trimipramine is mediated by CYP2D6 and/or that this reaction is potently inhibited by quinidine.<sup>3,4,5,6,7,8,9,10,11,12,13,14,15,16</sup> Individuals with higher baseline CYP2D6 activity are likely at higher risk of toxicity should quinidine be added to their regimen. In addition to the above interaction data, both quinidine and individual tricyclic antidepressants possess the potential to prolong QTc intervals, and thus cause serious cardiac arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ayesh R, Dawling S, Widdop B, et al, “Influence of Quinidine on the Pharmacokinetics of Nortriptyline and Desipramine,” <i>Br J Clin Pharmacol</i>, 1988, 25:140-1P.</p>\n<p>2. Brosen K, Gram LF, “Quinidine Inhibits the 2-Hydroxylation of Imipramine and Desipramine but not the Demethylation of Imipramine,” <i>Eur J Clin Pharmacol</i>, 1989, 37(2):155-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2792169\">[PubMed 2792169]</a></p>\n<p>3. Eap CB, Laurian S, Souche A, et al, “Influence of Quinidine on the Pharmacokinetics of Trimipramine and on Its Effect on the Waking EEG of Healthy Volunteers. A Pilot Study on Two Subjects,” <i>Neuropsychobiology</i>, 1992, 25(4):214-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1454163\">[PubMed 1454163]</a></p>\n<p>4. Haritos VS, Ghabrial H, Ahokas JT, et al, “Role of Cytochrome P450 2D6 (CYP2D6) in the Stereospecific Metabolism of E- and Z-Doxepin,” <i>Pharmacogenetics</i>, 2000, 10(7):591-603. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11037801\">[PubMed 11037801]</a></p>\n<p>5. Venkatakrishnan K, von Moltke LL, Greenblatt DJ, “Nortriptyline E-10-Hydroxylation In Vitro is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme-Inducing Drugs,” <i>J Clin Pharmacol</i>, 1999, 39(6):567-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10354960\">[PubMed 10354960]</a></p>\n<p>6. von Moltke LL, Greenblatt DJ, Duan SX, et al, “Inhibition of Desipramine Hydroxylation (Cytochrome P450-2D6) In Vitro by Quinidine and by Viral Protease Inhibitors: Relation to Drug Interactions In Vivo,” <i>J Pharm Sci</i>, 1998, 87(10):1184-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9758674\">[PubMed 9758674]</a></p>\n<p>7. Koyama E, Chiba K, Tani M, et al, “Reappraisal of Human CYP Isoforms Involved in Imipramine N-Demethylation and 2-Hydroxylation: A Study Using Microsomes Obtained from Putative Extensive and Poor Metabolizers of S-Mephenytoin and Eleven Recombinant Human CYPs,” <i>J Pharmacol Exp Ther</i>, 1997, 281(3):1199-210. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9190854\">[PubMed 9190854]</a></p>\n<p>8. Coutts RT, Bach MV, Baker GB, “Metabolism of Amitriptyline with CYP2D6 Expressed in a Human Cell Line,” <i>Xenobiotica</i>, 1997, 27(1):33-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9041677\">[PubMed 9041677]</a></p>\n<p>9. Nielsen KK, Flinois JP, Beaune P, et al, “The Biotransformation of Clomipramine In Vitro, Identification of the Cytochrome P450s Responsible for the Separate Metabolic Pathways,” <i>J Pharmacol Exp Ther</i>, 1996, 277(3):1659-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8667235\">[PubMed 8667235]</a></p>\n<p>10. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al, “Inhibition of Desipramine Hydroxylation In Vitro by Serotonin-Reuptake-Inhibitor Antidepressants, and by Quinidine and Ketoconazole: A Model System to Predict Drug Interactions In Vivo,” <i>J Pharmacol Exp Ther</i>, 1994, 268(3):1278-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8138941\">[PubMed 8138941]</a></p>\n<p>11. Bolaji OO, Coutts RT, Baker GB, “Metabolism of Trimipramine In Vitro by Human CYP2D6 Isozyme,” <i>Res Commun Chem Pathol Pharmacol</i>, 1993, 82(1):111-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8272570\">[PubMed 8272570]</a></p>\n<p>12. Skjelbo E, Brosen K, “Inhibitors of Imipramine Metabolism by Human Liver Microsomes,” <i>Br J Clin Pharmacol</i>, 1992, 34(3):256-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1389950\">[PubMed 1389950]</a></p>\n<p>13. Pfandl B, Morike K, Winne D, et al, “Stereoselective Inhibition of Nortriptyline Hydroxylation in Man by Quinidine,” <i>Xenobiotica</i>, 1992, 22(6):721-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1441595\">[PubMed 1441595]</a></p>\n<p>14. Brosen K, Zeugin T, Meyer UA, “Role of P450IID6, the Target of the Sparteine-Debrisoquin Oxidation Polymorphism, in the Metabolism of Imipramine,” <i>Clin Pharmacol Ther</i>, 1991, 49(6):609-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2060250\">[PubMed 2060250]</a></p>\n<p>15. Dahl ML, Nordin C, Bertilsson L, “Enantioselective Hydroxylation of Nortriptyline in Human Liver Microsomes, Intestinal Homogenate, and Patients Treated with Nortriptyline,” <i>Ther Drug Monit</i>, 1991, 13(3):189-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1926270\">[PubMed 1926270]</a></p>\n<p>16. Steiner E, Dumont E, Spina E, et al, “Inhibition of Desipramine 2-Hydroxylation by Quinidine and Quinine,” <i>Clin Pharmacol Ther</i>, 1988, 43(5):577-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3365919\">[PubMed 3365919]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3138":"<p><b>Title</b> Protease Inhibitors / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may increase the metabolism of Protease Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Considering the risk of protease inhibitor failure and the benefits of St Johns wort, this combination should probably be avoided.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir*, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of indinavir (800 mg every 8 hours x 4 doses) was decreased by 57% (and the 8-hour serum trough concentration was decreased by 81%) in 8 healthy subjects when administered following a 14-day course of hypericum extract (300 mg 3 times/day).<sup>1</sup> Antiretroviral efficacy would clearly be jeopardized.<br><br>The mechanism of this interaction is likely related to the ability of St Johns wort to induce CYP3A4 isoenzymes and p-glycoprotein, thus increasing the metabolism of indinavir. Other protease inhibitors would likely be affected in a similar fashion, with the prescribing information for all protease inhibitors recommending caution with,<sup>2</sup> not recommending,<sup>3</sup> or contraindicating<sup>4,5,6,7,8,9</sup> concurrent St Johns wort.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Piscitelli SC, Burstein AH, Chaitt D, et al, “Indinavir Concentrations and St John’s Wort,” <i>Lancet</i>, 2000, 355(9203):547-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10683007\">[PubMed 10683007]</a></p>\n<p>2. Prescribing information. Invirase (saquinavir). Nutley, NJ: Roche Laboratories, Inc., January 2010.</p>\n<p>3. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., October 2009. </p>\n<p>4. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol Myers Squibb Co., January 2010.</p>\n<p>5. Prescribing information. Norvir (ritonavir). N. Chicago, IL: Abbott Laboratories, November 2009.</p>\n<p>6. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, September 2009.</p>\n<p>7. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, February 2011.</p>\n<p>8. Prescribing information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, February 2008.</p>\n<p>9. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3139":"<p><b>Title</b> Triamterene / Indomethacin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Indomethacin may enhance the nephrotoxic effect of Triamterene. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to concomitant treatment with triamterene and indomethacin. If the combination cannot be avoided, monitor for development of renal failure.</p> \n<p><b>Discussion</b> Creatinine clearance decreased by 62% or more in 2 of 4 healthy volunteers receiving concomitant indomethacin (150 mg/day) and triamterene (200 mg/day) for 3 days.<sup>1</sup> The agents caused no significant changes in kidney function when used alone, nor did the problem develop in 18 other subjects who received indomethacin with either furosemide, chlorothiazide, or spironolactone. Other supporting case reports have been published, including cases where the combination of indomethacin and triamterene led to acute renal failure.<sup>2,3,4</sup> <br><br>The mechanism for this interaction is unclear. Triamterene-related nephrotoxicity may be mediated via a drug-induced renal ischemia, for which the kidney compensates by increasing production of vasodilating prostaglandins. This compensatory mechanism may be blocked by indomethacin. The effects of other nonsteroidal anti-inflammatory agents are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Favre L, Glasson P, and Vallotton MB, “Reversible Acute Renal Failure From Combined Triamterene and Indomethacin. A Study in Healthy Subjects,” <i>Ann Intern Med</i>, 1982, 96:317-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6949485\">[PubMed 6949485]</a></p>\n<p>2. McCarthy JT, Torres VE, Romero JC, et al, “Acute Intrinsic Renal Failure Induced by Indomethacin: Role of Prostaglandin Synthetase Inhibition,” <i>Mayo Clin Proc</i>, 1982, 57:289-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6952058\">[PubMed 6952058]</a></p>\n<p>3. Weinberg MS, Quigg RJ, Salant DJ, et al, “Anuric Renal Failure Precipitated by Indomethacin and Triamterene,” <i>Nephron</i>, 1985, 40:216-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4000350\">[PubMed 4000350]</a></p>\n<p>4. Mathews A and Bailie GR, “Acute Renal Failure and Hyperkalemia Associated With Triamterene and Indomethacin,” <i>Vet Hum Toxicol</i>, 1986, 28(3):224-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3727353\">[PubMed 3727353]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3140":"<p><b>Title</b> Vancomycin / Nonsteroidal Anti-Inflammatory Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Age</b>: An interaction between these agents has only been demonstrated in infants.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxicity of vancomycin if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreased serum concentrations if a NSAID is discontinued/dose decreased. This interaction has only been demonstrated in infants.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several studies have demonstrated decreases in vancomycin clearance, increases in vancomycin half-life, increases in vancomycin concentrations, or decreased vancomycin dose requirements in infants receiving the nonsteroidal anti-inflammatory drugs (NSAIDs) indomethacin or ibuprofen.<sup>1,2,3,4,5,6</sup> Limited data suggest that these effects may be present after single-day prophylactic NSAID dosing,<sup>5</sup> and that indomethacin may more potently inhibit vancomycin clearance than ibuprofen.<sup>6</sup><br><br>The mechanism of this interaction is unknown. In one epidemiologic analysis, the effect of ibuprofen on vancomycin clearance was explained by changes in renal function during ibuprofen treatment.<sup>2</sup> The impact of NSAIDs on vancomycin pharmacokinetics in non-infant populations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spivey JM and Gal P, “Vancomycin Pharmacokinetics in Neonates,” <i>Am J Dis Child</i>, 1986, 140:859. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3739993\">[PubMed 3739993]</a></p>\n<p>2. Anderson BJ, Allegaert K, Van den Anker JN, et al, “Vancomycin Pharmacokinetics in Preterm Neonates and the Prediction of Adult Clearance,” <i>Br J Clin Pharmacol</i>, 2007, 63(1):75-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16869817\">[PubMed 16869817]</a></p>\n<p>3. Asbury WH, Darsey EH, Rose WB, et al, “Vancomycin Pharmacokinetics in Neonates and Infants: A Retrospective Evaluation,” <i>Ann Pharmacother</i>, 1993, 27(4):490-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8477127\">[PubMed 8477127]</a></p>\n<p>4. Silva R, Reis E, Bispo MA, et al, “The Kinetic Profile of Vancomycin in Neonates,” <i>J Pharm Pharmacol</i>, 1998, 50(11):1255-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9877311\">[PubMed 9877311]</a></p>\n<p>5. Allegaert K, Rayyan M and Anderson BJ, “Impact of Ibuprofen Administration on Renal Drug Clearance in the First Weeks of Life,” <i>Methods Find Exp Clin Pharmacol</i>, 2006, 28(8):519-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136231\">[PubMed 17136231]</a></p>\n<p>6. Allegaert K, “The Impact of Ibuprofen or Indomethacin on Renal Drug Clearance in Neonates,” <i>J Matern Fetal Neonatal Med</i>, 2009, 22 Suppl 3:88-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19701859\">[PubMed 19701859]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3141":"<p><b>Title</b> Levodopa / Iron Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction has only been observed with oral administration of iron salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate*, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Levodopa AUC decreased by 30% in healthy volunteers and 50% in patients with Parkinson disease, when administered with a single oral dose of ferrous sulfate (325 mg, containing 65 mg elemental iron).<sup>1,2</sup> Carbidopa AUC decreased by 75% in one study.<sup>1</sup> Ferric iron, as exists in the acidic pH of the GI tract, forms a poorly absorbed chelate with both levodopa and carbidopa. The exact clinical significance of this interaction is unknown, but the label for the combination carbidopa, levodopa and entacapone combination product does recommend caution with coadministration of iron due to the possibility of chelation that may result in decreased bioavailability.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Campbell NR, Rankine D, Goodridge AE, Hasinoff BB, Kara M. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. <i>Br J Clin Pharmacol</i>. 1990;30(4):599-605. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2291872\">[PubMed 2291872]</a></p>\n<p>2. Campbell NR, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. <i>Clin Pharmacol Ther</i>. 1989;45(3):220-225. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2920496\">[PubMed 2920496]</a></p>\n<p>3. Stalevo (carbidopa, levodopa and entacapone) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3142":"<p><b>Title</b> Methyldopa / Iron Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Only orally administered iron salts are implicated in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the serum concentration of Methyldopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consideration should be given to separating doses of the agents by 2 or more hours to minimize the effects of this interaction, however, the success of this action appears limited. Monitor for decreased therapeutic effects of methyldopa if an oral iron salt is initiated/dose increased, or increased effects if an oral iron salt is discontinued/dose decreased.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate*, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Blood pressures increased by varying amounts in 5 methyldopa-stable hypertension patients within 2 weeks of initiating oral ferrous sulfate therapy (325 mg 3 times/day).<sup>1</sup> The blood pressure increases exceeded 15 mm Hg systolic and 10 mm Hg diastolic. The absorption of methyldopa in 12 normal subjects was decreased from 29% to 8% when administered with a 325 mg dose of ferrous sulfate.<sup>1</sup> The bioavailability of methyldopa was decreased by 42%, 55%, and 83% in normal subjects when taken 2 hours before, 1 hour before, or simultaneous with, an oral dose of ferrous sulfate.<sup>2</sup> Ferric iron likely forms a poorly absorbed chelate with methyldopa in the gastrointestinal tract.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Campbell N, Paddock V, and Sundaram R, “Alteration of Methyldopa Absorption, Metabolism, and Blood Pressure Control Caused by Ferrous Sulphate and Ferrous Gluconate,” <i>Clin Pharmacol Ther</i>, 1988, 43:381-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3356082\">[PubMed 3356082]</a></p>\n<p>2. Campbell NR and Hasinoff BB, “Iron Supplements: A Common Cause of Drug Interactions,” <i>Br J Clin Pharmacol</i>, 1991, 31:251-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2054263\">[PubMed 2054263]</a></p>\n<p>3. Campbell NR, Campbell RR, Hasinoff BB, “Ferrous sulfate reduces methyldopa absorption: methyldopa: iron complex formation as a likely mechanism,” <i>Clin Invest Med</i>, 1990, 13(6):329-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2078911\">[PubMed 2078911]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3143":"<p><b>Title</b> PenicillAMINE / Iron Salts</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of penicillamine if an oral iron salt is initiated/dose increased, or increased effects if an oral iron salt is discontinued/dose decreased. Consideration might be given to separating doses of the agents by 2 or more hours to minimize the effects of this interaction, however, the success of this action is unproven.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate*, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The absorption and clinical effects of penicillamine appear to be reduced by approximately 65% by concomitant administration with oral ferrous salts.<sup>1,2</sup> Similarly, penicillamine toxicity (nephropathy) has been demonstrated following the withdrawal of oral iron therapy.<sup>3</sup> Ferric iron likely forms a poorly absorbed chelate with penicillamine in the gastrointestinal tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lyle WH, “Penicillamine and Iron,” <i>Lancet</i>, 1976, ii:420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=73880\">[PubMed 73880]</a></p>\n<p>2. Osman MA, Patel RB, Schuna A, et al, “Reduction in Oral Penicillamine Absorption by Food, Antacid, and Ferrous Sulphate,” <i>Clin Pharmacol Ther</i>, 1983, 33:465-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6831825\">[PubMed 6831825]</a></p>\n<p>3. Harkness JA and Blake DR, “Penicillamine Nephropathy and Iron,” <i>Lancet</i>, 1982, ii:1368-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6129465\">[PubMed 6129465]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3144":"<p><b>Title</b> Iron Salts / Tetracyclines</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of iron salts and tetracycline antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tetracyclines may decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> In general, the coadministration of oral iron salts and oral tetracycline derivatives should be avoided. Interactions can be minimized by administering oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivatives. Even with dose separation, doxycycline therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate*, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline*, Lymecycline, Minocycline*, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The absorption of tetracycline was decreased by 40% to approximately 75% with concurrent administration of oral tetracycline and ferrous sulfate (100 mg to 300 mg) in several different studies.<sup>1,2,3,4</sup> The absorption of orally-administered doxycycline and minocycline were reduced to a similar or possibly greater extent (i.e., 77% to 90% reductions). Such alterations in absorption and exposure could result in subtherapeutic serum concentrations of the antibiotic. The mechanism of this interaction is most likely related to the formation of tetracycline-iron chelates in the GI tract that are poorly absorbed, resulting in impaired absorption and decreased concentrations. No significant interaction occurred when iron was given at least 3 hours prior to or 2 hours after tetracycline administration.<sup>5</sup> Studies with doxycycline have suggested that oral iron may decrease doxycycline concentrations (by approximately 17% to 45%) even when the iron is administered several hours after doxycycline, and the half-life of intravenously-administered doxycycline was reduced by an average of 34% with concomitant oral iron.<sup>6,7</sup> The reason for the persistence of this interaction despite separation of oral administration and/or the use of intravenous doxycycline is uncertain, but it has been suggested that doxycycline may undergo intestinal secretion and reabsorption, a process that can be altered by chelation of the doxycycline with iron in the intestinal tract.<br><br>An additional consideration with use of this combination is possible impairment of iron absorption. Iron absorption was reduced by an average of 49% to 78% with concurrent tetracycline in human studies.<sup>4,8</sup> Animal studies similarly found a significant impairment of iron absorption when administered with tetracyclines.<sup>9,10</sup> However, other studies in humans have concluded that tetracyclines have only a relatively small impact on iron absorption that is of unclear clinical significance.<sup>11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Leyden JJ. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. <i>J Am Acad Dermatol</i>. 1985;12(2 Pt 1):308-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3838321\">[PubMed 3838321]</a></p>\n<p>2. Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K. Interference of iron with the absorption of tetracyclines in man. <i>Br Med J</i>. 1970;4(5734):532-534. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5483323\">[PubMed 5483323]</a></p>\n<p>3. Neuvonen PJ, Turakka H. Inhibitory effect of various iron salts on the absorption of tetracycline in man. <i>Eur J Clin Pharmacol</i>. 1974;7(5):357-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4213690\">[PubMed 4213690]</a></p>\n<p>4. Neuvonen PJ, Pentikainen PJ, Gothoni G. Inhibition of iron absorption by tetracycline. <i>Br J Clin Pharmacol</i>. 1975;2(1):94-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1234494\">[PubMed 1234494]</a></p>\n<p>5. Gothoni G, Neuvonen PJ, Mattila M, Hackman R. Iron-tetracycline interaction: effect of time interval between the drugs. <i>Acta Med Scand</i>. 1972;191(5):409-411. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5031537\">[PubMed 5031537]</a></p>\n<p>6. Neuvonen PJ, Penttila O. Effect of oral ferrous sulphate on the half-life of doxycycline in man. <i>Eur J Clin Pharmacol</i>. 1974;7(5):361-363. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4607747\">[PubMed 4607747]</a></p>\n<p>7. Venho VM, Salonen RO, Mattila MJ. Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal. <i>Eur J Clin Pharmacol</i>. 1978;14(4):277-280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=729621\">[PubMed 729621]</a></p>\n<p>8. Heinrich HC, Oppitz KH. Tetracycline inhibits iron absorption in man. <i>Naturwissenschaften</i>. 1973;60(11):524-525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4767476\">[PubMed 4767476]</a></p>\n<p>9. Greenberger NJ, Ruppert RD, Cuppage FE. Inhibition of intestinal iron transport induced by tetracycline. <i>Gastroenterology</i>. 1967;53(4):590-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6047919\">[PubMed 6047919]</a></p>\n<p>10. Djaldetti M, Fishman P, Notti I, Bessler H. The effect of tetracycline administration on iron absorption in mice. <i>Biomedicine</i>. 1981;35(5):150-152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7317563\">[PubMed 7317563]</a></p>\n<p>11. Greenberger NJ. Absorption of tetracyclines: interference by iron. <i>Ann Intern Med</i>. 1971;74(5):792-793. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5559446\">[PubMed 5559446]</a></p>\n<p>12. Greenberger NJ. Effects of antibiotics and other agents on the intestinal transport of iron. <i>Am J Clin Nutr</i>. 1973;26(1):104-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4566468\">[PubMed 4566468]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3146":"<p><b>Title</b> Serotonin/Norepinephrine Reuptake Inhibitors / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome. While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of serotonin/norepinephrine reuptake inhibitors (SNRI) and monoamine oxidase inhibitors (MAOI), including both selective and nonselective, should be avoided, and most such combinations are contraindicated. In addition, a significant washout period should be employed when discontinuing one agent and initiating the other (ie, changing from SNRI to MAOI or vice-versa). The washout period should be at least 14 days in most cases. The period should be at least 7 days after discontinuing venlafaxine, desvenlafaxine, or levomilnacipran, and at least 5 days after discontinuing milnacipran or duloxetine. In general, furazolidone, linezolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (eg, more than 10 mg daily of tablet/capsule, or more than 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid*, Moclobemide, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine*<br><b>Exceptions</b> Linezolid, Methylene Blue, Tedizolid</p>\n <p><b>Serotonin/Norepinephrine Reuptake Inhibitors Interacting Members</b> Desvenlafaxine, DULoxetine, Levomilnacipran, Milnacipran, Venlafaxine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The addition of venlafaxine (75 mg/day) to a patient's regimen including isocarboxazid (30 mg/day) resulted in the development of agitation, diaphoresis, dilated pupils, hypomania, and shivering following the second dose of venlafaxine.<sup>1</sup> Symptoms subsided following venlafaxine discontinuation, and recurred in the form of myoclonic jerks and diaphoresis during subsequent coadministration. Similar symptoms developed in a female patient within 45 minutes of taking venlafaxine (37.5 mg). She had discontinued treatment with phenelzine (45 mg/day) 7 days prior.<sup>2</sup> Similar cases have been reported with phenelzine or venlafaxine and tranylcypromine.<sup>3,4,5,6,7</sup> Monoamine oxidase inhibitors reduce serotonin metabolism, and venlafaxine inhibits its uptake into the neuron, thus leaving an abundance of the chemical in the synapse and causing overstimulation of serotonin receptors. The effects can be rapid and serious.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD. Toxic interaction of venlafaxine and isocarboxazide. <i>Lancet</i>. 1995;346(8985):1298-1299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7475741\">[PubMed 7475741]</a></p>\n<p>2. Phillips SD, Ringo P. Phenelzine and venlafaxine interaction. <i>Am J Psychiatry</i>. 1995;152(9):1400-1401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7653704\">[PubMed 7653704]</a></p>\n<p>3. Heisler MA, Guidry JR, Arnecke B. Serotonin syndrome induced by administration of venlafaxine and phenelzine. <i>Ann Pharmacother</i>. 1996;30(1):84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8773172\">[PubMed 8773172]</a></p>\n<p>4. Roxanas MG, Machado JF. Serotonin syndrome in combined moclobemide and venlafaxine ingestion. <i>Med J Aust</i>. 1998;168(10):523-524. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9631680\">[PubMed 9631680]</a></p>\n<p>5. Weiner LA, Smythe M, Cisek J. Serotonin syndrome secondary to phenelzine-venlafaxine interaction. <i>Pharmacotherapy</i>. 1998;18(2):399-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9545162\">[PubMed 9545162]</a></p>\n<p>6. Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK. Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports. <i>Neurology</i>. 1998;51(1):274-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9674820\">[PubMed 9674820]</a></p>\n<p>7. Brubacher JR, Hoffman RS, Lurin MJ. Serotonin syndrome from venlafaxine-tranylcypromine interaction. <i>Vet Hum Toxicol</i>. 1996;38(5):358-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8888541\">[PubMed 8888541]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3147":"<p><b>Title</b> Phenytoin / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Isoniazid may increase the serum concentration of Phenytoin. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to isoniazid in patients receiving phenytoin. If concomitant therapy cannot be avoided, monitor for increased concentrations/toxic effects of phenytoin if isoniazid is initiated/dose increased, or decreased concentrations/effects if isoniazid is discontinued/dose decreased. Heightened monitoring should continue for at least 4 weeks after changes in isoniazid therapy.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations, as well as signs and symptoms of toxicity, have been increased following the initiation of isoniazid therapy in a number of patients and healthy volunteers.<sup>1,2,3,4,5</sup> This interaction has occurred within days of isoniazid initiation in some cases, and up to several weeks after treatment initiation in others.<br> <br>The likely primary mechanism of this interaction is isoniazid inhibition of CYP2C19 mediated phenytoin metabolism. Isoniazid inhibition of CYP2C9 and 3A4 could also contribute. The magnitude of this interaction seems to be greater in individuals with impaired isoniazid metabolism, presumably due to elevated isoniazid concentrations, but determinants of this metabolic impairment are not well understood.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kutt H, Brennan R, Dehejia H, et al, “Diphenylhydantoin Intoxication, A Complication of Isoniazid Therapy,” <i>Am Rev Respir Dis</i>, 1970, 101(3):377-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5414058\">[PubMed 5414058]</a></p>\n<p>2. Brennan RW, Dehejia H, Kutt H, et al, “Diphenylhydantoin Intoxication Attendant to Slow Inactivation of Isoniazid,” <i>Neurology</i>, 1970, 20(7):687-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5463537\">[PubMed 5463537]</a></p>\n<p>3. Murray FJ, “Outbreak of Unexpected Reactions Among Epileptics Taking Isoniazid,” <i>Am Rev Respir Dis</i>, 1962, 86:729-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13936763\">[PubMed 13936763]</a></p>\n<p>4. Miller RR, Porter J and Greenblatt DJ, “Clinical Importance of the Interaction of Phenytoin and Isoniazid: A Report From the Boston Collaborative Drug Surveillance Program,” <i>Chest</i>, 1979, 75(3):356-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=421578\">[PubMed 421578]</a></p>\n<p>5. Witmer DR and Ritschel WA, “Phenytoin-Isoniazid Interaction: A Kinetic Approach to Management,” <i>Drug Intell Clin Pharm</i>, 1984, 18(6):483-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734435\">[PubMed 6734435]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3148":"<p><b>Title</b> Isoniazid / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Though often used together in a safe and efficacious manner, monitor for signs and symptoms of hepatotoxicity if isoniazid and rifamycin derivatives are used concomitantly.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Though the combination of isoniazid and rifampin is successfully used in the treatment of tuberculosis, case reports suggest that the risk of hepatotoxicity may be increased in some patients.<sup>1,2,3,4,5,6,7</sup> The pharmacokinetics of the individual agents do not appear to be affected.<sup>3,7</sup> The mechanism of this interaction is unknown. A suggestion is that rifampin increases the metabolism of isoniazid to form hydrazine, an hepatotoxic metabolite.<sup>1,2</sup> Such a mechanism might place slow acetylators of isoniazid at increased risk of toxicity from this interaction. The effect of other rifamycin derivatives is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gangadharam PR, “Isoniazid, Rifampin and Hepatotoxicity,” <i>Am Rev Respir Dis</i>, 1986, 133:963-5 (review). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3013057\">[PubMed 3013057]</a></p>\n<p>2. Pessayre D, Bentata M, Degott C, et al, “Isoniazid-Rifampicin (Rifampin) Fulminant Hepatitis. A Possible Consequence of the Enhancement of Isoniazid Hepatotoxicity by Enzyme Induction,” <i>Gastroenterology</i>, 1977, 72:284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=830577\">[PubMed 830577]</a></p>\n<p>3. Sarma GR, Kailasam S, Nair NG, et al, “Effect of Prednisolone and Rifampin on Isoniazid Metabolism in Slow and Rapid Inactivators of Isoniazid,” <i>Antimicrob Agents Chemother</i>, 1980, 18:661-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7447424\">[PubMed 7447424]</a></p>\n<p>4. Steele MA, Burk RF, and DesPrez RM, “Toxic Hepatitis With Isoniazid and Rifampin. A Meta-Analysis,” <i>Chest</i>, 1991, 99:465-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1824929\">[PubMed 1824929]</a></p>\n<p>5. Lal S, Singhal SN, Burley DM, et al, “Effect of Rifampicin and Isoniazid on Liver Function,” <i>Br Med J</i>, 1972, 1:148-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5007842\">[PubMed 5007842]</a></p>\n<p>6. Bistritzer T, Barzilay Z, and Jonas A, “Isoniazid-Rifampin-Induced Fulminant Liver Disease in an Infant,” <i>J Pediatr</i>, 1980, 97:480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6967966\">[PubMed 6967966]</a></p>\n<p>7. Boman G, “Serum Concentration and Half-Life of Rifampicin (Rifampin) After Simultaneous Oral Administration of Aminosalicylic Acid or Isoniazid,” <i>Eur J Clin Pharmacol</i>, 1974, 7:217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4854257\">[PubMed 4854257]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3149":"<p><b>Title</b> Theophylline Derivatives / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoniazid may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of theophylline derivatives if isoniazid is initiated/dose increased, or decreased concentrations/effects if isoniazid is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of theophylline was decreased by 16% to 21% in healthy volunteers following the initiation of isoniazid therapy.<sup>1,2</sup> A 31% increase in theophylline AUC was noted in another study.<sup>3</sup> Cases of theophylline toxicity associated with this interaction have been reported.<sup>4,5</sup> <br><br>The likely primary mechanism of this interaction is isoniazid inhibition of CYP3A4 mediated theophylline metabolism. Isoniazid inhibition of CYP1A2 mediated theophylline metabolism may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thompson JR, Burckart GJ, Self TH, et al, “Isoniazid-Induced Alterations in Theophylline Pharmacokinetics,” <i>Curr Ther Res Clin Exp</i>, 1982, 32:921-5.</p>\n<p>2. Samigun, Mulyono and Santoso B, “Lowering of Theophylline Clearance by Isoniazid in Slow and Rapid Acetylators,” <i>Br J Clin Pharmacol</i>, 1990, 29(5):570-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2350534\">[PubMed 2350534]</a></p>\n<p>3. Hoglund P, Nilsson LG, and Paulsen O, “Interaction Between Isoniazid and Theophylline,” <i>Eur J Resp Dis</i>, 1987, 70:110-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3817069\">[PubMed 3817069]</a></p>\n<p>4. Torrent J, Izquierdo I, Cabezas R, et al, “Theophylline-Isoniazid Interaction,” <i>DICP</i>, 1989, 23:143-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2728509\">[PubMed 2728509]</a></p>\n<p>5. Dal Nergo R, et al, “Rifampicin-Isoniazid and Delayed Elimination of Theophylline: A Case Report,” <i>Int J Clin Pharm Res</i>, 1988, 8:275. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3182118\">[PubMed 3182118]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3151":"<p><b>Title</b> QuiNIDine / Kaolin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Only oral preparations of quinidine are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Kaolin may decrease the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider separating doses of kaolin and quinidine by at least 2 hours in order to reduce the risk of interaction. Monitor for decreased therapeutic effects of quinidine if kaolin is simultaneously coadministered.</p> \n<p><b>Discussion</b> The AUC of quinidine (100 mg single oral dose) was decreased by 54% in 4 normal subjects when administered with a 30 mL dose of a kaolin-pectin suspension.<sup>1</sup> <br><br>The mechanism of this interaction is presumed to be related to kaolin and quinidine binding in the GI tract. Although the impact of separating doses has not been investigated, this could theoretically minimize the magnitude of interaction based on the presumed mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Moustafa MA, Al-Shora HI, Gaber M, et al, “Decreased Bioavailability of Quinidine Sulphate Due to Interactions With Adsorbent Antacids and Antidiarrhoeal Mixtures,” <i>Int J Pharm</i>, 1987, 34:207-11.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3152":"<p><b>Title</b> LamoTRIgine / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The manufacturer of lamotrigine has published extensive dosage adjustment guidelines in the approved labeling when the drug is added to an enzyme-inducing antiepileptic drug (EIAED); refer to the labeling for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The half-life of lamotrigine, as monotherapy, is approximately 25 hours (<u>+</u> 10 hours).<sup>1</sup> When combined with metabolic induction agents, such as phenytoin, the half-life is reduced to approximately 14 hours (<u>+</u> 7 hours).<sup>2</sup> Phenytoin likely stimulates hepatic metabolism of lamotrigine, possibly by stimulating uridine glucuronosyl transferase (UGT). Serum lamotrigine concentrations are thus decreased.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cohen AF, Land GS, Breimer DD, et al, “Lamotrigine, A New Anticonvulsant: Pharmacokinetics in Normal Humans,” <i>Clin Pharmacol Ther</i>, 1987, 41:535-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677592\">[PubMed 3677592]</a></p>\n<p>2. Binnie CD, Debets RM, Engelsman M, et al, “Double Blind Crossover Trial of Lamotrigine (Lamictal) as Add-On Therapy in Intractable Epilepsy,” <i>Epilepsy Res</i>, 1989, 4(3):222-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2612495\">[PubMed 2612495]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3154":"<p><b>Title</b> Levodopa / Methionine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Methionine may diminish the therapeutic effect of Levodopa. Probably only with large doses of methionine. Data was generated using 4.5gm daily. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid large daily doses of methionine in patients receiving levodopa (clinical studies showing interaction used 4.5 g methionine daily). More typical doses of methionine (eg, 500 mg) may not cause a problem. Regardless of dose, monitor for decreased therapeutic effects of levodopa if methionine is initiated/dose increased, or increased effects if methionine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The therapeutic effects of levodopa were decreased (ie, gait disturbances, increased tremor, and rigidity) in 14 patients with Parkinson disease when concomitantly administered methionine (4.5 g/day).<sup>1</sup> The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pearce LA and Waterbury LD, “L-Methionine: A Possible Levodopa Antagonist,” <i>Neurology</i> (Minneap), 1974, 24:640.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3155":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Levodopa</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Levodopa may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of nonselective monoamine oxidase (MAO) inhibitors (eg, isocarboxazid, phenelzine, tranylcypromine) and levodopa. This combination is contraindicated in product labeling for levodopa containing products due to the increased risk of a severe hypertensive response. Discontinue the use of any nonselective MAO inhibitor at least two weeks prior to initiating a levodopa containing product. <br><br>Patients receiving concomitant levodopa and a selective or very weak MAO inhibitor should be monitored for the development of adverse events. In general, furazolidone, linezolid, tedizolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide*, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Numerous reports describe significant elevations in blood pressure when levodopa was administered to patients taking nonselective monoamine oxidase inhibitors (MAOIs).<sup>1,2,3,4,5,6</sup> In a few reports, the addition of a dopa decarboxylase inhibitor (eg, carbidopa, benserazide) blunted the hypertensive response.<sup>5,6</sup> The selective monoamine oxidase A inhibitor moclobemide, when combined with levodopa/benserazide in 12 normal subjects, was associated with increased side effects (eg, headache, insomnia, nausea) but did not result in an increase in blood pressure.<sup>7</sup> Due to the variable doses of a dopa decarboxylase inhibitor required to minimize the hypertensive response to the levodopa and nonselective MAOI combination, product labeling for levodopa containing products (even those containing a dopa decarboxylase inhibitor) contraindicates their combined use.<sup>8,9,10</sup> Nonselective MAOIs should be discontinued at least two weeks prior to initiation of levodopa therapy.<br><br>The mechanism of the interaction between nonselective MAOIs and levodopa is likely related to an increased concentration of dopamine and/or norepinephrine. Levodopa is converted to dopamine and subsequently norepinephrine. The use of a MAOI prevents the degradation of dopamine, thus increasing its concentrations and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M. Biochemical and pressor effects of oral D,L-dihydroxyphenylalanine in patients pretreated with antidepressant drugs. <i>Ann N Y Acad Sci</i>. 1963;107:1005-1015. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13991689\">[PubMed 13991689]</a></p>\n<p>2. Friend DG, Bell WR, Kline NS. The action of L-dihydroxyphenylalanine in patients receiving nicalamide. <i>Clin Pharmacol Ther</i>. 1965;6:362-366. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14296035\">[PubMed 14296035]</a></p>\n<p>3. Hunter KR, Boakes AJ, Laurence DR, Stern GM. Monoamine oxidase inhibitors and L-dopa. <i>Br Med J</i>. 1970;3(5719):388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5451592\">[PubMed 5451592]</a></p>\n<p>4. Sharpe J, Marquez-Julio A, Ashby P. Idiopathic orthostatic hypotension treated with levodopa and MAO inhibitor: a preliminary report. <i>Can Med Assoc J</i>. 1972;107(4):296-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5056115\">[PubMed 5056115]</a></p>\n<p>5. Teychenne PF, Calne DB, Lewis PJ, Findley LJ. Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase. <i>Clin Pharmacol Ther</i>. 1975;18(3):273-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1164817\">[PubMed 1164817]</a></p>\n<p>6. Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. <i>Lancet</i>. 1977;1(8009):439-443. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=65560\">[PubMed 65560]</a></p>\n<p>7. Dingemanse J. An update of recent moclobemide interaction data. <i>Int Clin Psychopharmacol</i>. 1993;7(3-4):167-180. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8468439\">[PubMed 8468439]</a></p>\n<p>8. <i>Duopa</i> (carbidopa and levodopa) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>9. <i>Stalevo</i> (carbidopa, levodopa, and entacapone) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2014.</p>\n<p>10. <i>Sinemet</i> (carbidopa and levodopa) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3156":"<p><b>Title</b> Levodopa / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may diminish the therapeutic effect of Levodopa. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of levodopa if phenytoin is initiated/dose increased, or increased effects/toxicity if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The therapeutic (anti-Parkinson) effects of levodopa were essentially abolished in 5 patients within several days of initiating phenytoin (100-500 mg/day) for the treatment of levodopa-induced dyskinesias.<sup>1</sup> Levodopa doses were 630-4600 mg/day (plus carbidopa 150-225 mg/day). The effectiveness of levodopa was evident again within 2 weeks of discontinuing the phenytoin.<br><br>In another study (n=5), concurrent use of phenytoin with levodopa was associated with an increased growth hormone and prolactin response to levodopa.<sup>2</sup> In fact, plasma phenytoin concentrations were correlated with the measured growth hormone response.<br><br>Though the specific mechanism and nature of this potential interaction remains uncertain, available data suggest that phenytoin can alter dopaminergic signalling in the central nervous system in a region-specific manner (i.e., increasing dopamine signalling in some regions and decreasing such activity in other regions).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mendez JS, Cotzias GC, Mena I, et al, “Diphenylhydantoin. Blocking of Levodopa Effects,” <i>Arch Neurol</i>, 1975, 32(1):44-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=123156\">[PubMed 123156]</a></p>\n<p>2. D'Alessandro R, Cortelli P, Gallassi R, et al, “Phenytoin-Induced Increase in Growth Hormone Response to Levodopa in Adult Males,” <i>J Neurol Neurosurg Psychiatry</i>, 1984, 47(7):715-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6431057\">[PubMed 6431057]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3157":"<p><b>Title</b> Levodopa / Pyridoxine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pyridoxine may diminish the therapeutic effect of Levodopa. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction. If pyridoxine and levodopa (without a DDI) are used concomitantly, monitor for decreased/abolished therapeutic effects of the levodopa.</p> \n<p><b>Discussion</b> The therapeutic effects of levodopa have been abolished in patients receiving concomitant pyridoxine in doses from 5-1000 mg/day.<sup>1,2,3,4,5</sup> When levodopa is administered with carbidopa (a dopa-decarboxylase inhibitor), no such interaction with pyridoxine occurs.<sup>6</sup> Pyridoxine enhances the conversion of levodopa to dopamine by increasing the concentration of a necessary cofactor, pyridoxal-5-phosphate. Excess pyridoxine increases the rate of conversion, and thus decreases the amount of levodopa available to cross the blood-brain barrier, and thus exert its therapeutic, anti-Parkinson's effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Carter AB, “Pyridoxine and Parkinsonism,” <i>Br Med J</i>, 1973, 4:236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4758412\">[PubMed 4758412]</a></p>\n<p>2. Cotzias GC and Papavasiliou PS, “Blocking the Negative Effects of Pyridoxine on Patients Receiving Levodopa,” <i>JAMA</i>, 1971, 215:1504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107638\">[PubMed 5107638]</a></p>\n<p>3. Duvoisin RC, Yahr MD, and Cote LD, “Pyridoxine Reversal of L-Dopa Effects in Parkinsonism,” <i>Trans Am Neurol Ass</i>, 1969, 94:81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5374494\">[PubMed 5374494]</a></p>\n<p>4. Hildick-Smith M, “Pyridoxine in Parkinsonism,” <i>Lancet</i>, 1973, ii:1029.</p>\n<p>5. Yahr MD and Duvoisin RC, “Pyridoxine and Levodopa in the Treatment of Parkinsonism,” <i>JAMA</i>, 1972, 220:861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5067358\">[PubMed 5067358]</a></p>\n<p>6. Papavasiliou PS, Cotzias GC, Duby SE, et al, “Levodopa in Parkinsonism: Potentiation of Central Effects With a Peripheral Inhibitor,” <i>N Engl J Med</i>, 1972, 285:8-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4550085\">[PubMed 4550085]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3159":"<p><b>Title</b> Lithium / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may increase the serum concentration of Lithium. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of lithium if an angiotensin-converting enzyme (ACE) inhibitor is initiated /dose increased, or decreased effects if an ACE inhibitor is discontinued/dose decreased. Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor. Switching between individual ACE inhibitors may also result in changes in lithium serum concentrations. Monitor serum lithium concentrations for at least 4-6 weeks after changes in ACE inhibitor treatment. Patients over 50 years of age or those who experience significant increases in serum creatinine after ACE inhibitor initiation may be at greatest risk for lithium toxicity and/or a significant increase in lithium concentrations.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril*, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum lithium concentrations increased nearly 4-fold in a patient within 5 weeks of initiating enalapril therapy.<sup>1</sup> Symptoms of lithium toxicity (e.g., ataxia, confusion, tremor) began to appear within a few weeks of enalapril initiation. Trough serum lithium concentrations increased to as high as 3.8 mmol/L, accompanied by signs and symptoms of intoxication, within a few weeks of initiating lisinopril (20 mg/day).<sup>2</sup> Several similar reports are available.<sup>3,4,5,6</sup> In a retrospective case-control study of 20 hypertensive patients maintained on lithium therapy, the addition of an angiotensin-converting enzyme (ACE) inhibitor was associated with an average 36% increase in serum lithium concentrations, with 4 patients displaying signs/symptoms of clinical lithium toxicity.<sup>7</sup> One finding of note in this study was that the change in lithium concentrations was significantly related to both changes in serum creatinine and age, with greater increases in lithium concentrations associated with increases in serum creatinine and with an age of greater than 50 years. In another study, of 413 elderly patients who had been hospitalized for lithium toxicity at least once during the 10-year study period, initiation of loop diuretics or ACE inhibitors were the main drug-related factors for elevated lithium levels (relative risk for ACE inhibitor initiation = 7.6 (95% CI = 2.6 to 22.0)).<sup>8</sup> Of interest, one case report even describes a 5-fold increase in serum lithium concentrations associated with a change from one ACE inhibitor (fosinopril) to another (lisinopril).<sup>9</sup> As indicated in a prior study, this change in serum lithium was accompanied by a change in serum creatinine.<br><br>In contrast to these reports and study findings, in a study of 9 healthy males, no significant difference in serum lithium concentrations was observed when lithium was administered with enalapril for 10 days.<sup>10</sup> The specific reason for this discrepant finding is uncertain, though the short course of treatment or the lack of comorbidities could be important factors. Of note, one patient did have a 31% increase in serum lithium concentrations after the addition of enalapril.<br><br>The specific mechanism for this apparent interaction is not certain, but several possible mechanisms have been proposed surrounding lowered serum concentrations of angiotensin II. Lowered levels of angiotensin II leads to lower circulating levels of aldosterone. Subsequently, sodium and water excretion increase possibly causing greater renal retention of the lithium ion.<sup>8</sup> Another possible mechanism involves the vasoconstrictive properties of angiotensin II. In patients who require angiotensin II to maintain normal renal perfusion, loss of this hormone could decrease perfusion pressures, thereby lowering glomerular filtration and lithium clearance.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Douste-Blazy PH, Rostin M, Livarek B, et al, “Angiotensin-Converting Enzyme Inhibitors and Lithium Treatment,” <i>Lancet</i>, 1986, i:1448. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2872554\">[PubMed 2872554]</a></p>\n<p>2. Baldwin CM and Safferman AZ, “A Case of Lisinopril-Induced Lithium Toxicity,” <i>DICP</i>, 1990, 24:946-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2173864\">[PubMed 2173864]</a></p>\n<p>3. Navis GJ, de Jong PE, and de Zeeuw D, “Volume Homeostasis, Angiotensin-Converting Enzyme Inhibition, and Lithium Therapy,” <i>Am J Med</i>, 1989, 86:621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2496602\">[PubMed 2496602]</a></p>\n<p>4. Correa FJ and Eiser A, “Angiotensin-Converting Enzyme Inhibitors and Lithium Toxicity,” <i>Am J Med</i>, 1992, 93:108-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1626561\">[PubMed 1626561]</a></p>\n<p>5. Griffin JH and Hahn SM, “Lisinopril-Induced Lithium Toxicity,” <i>DICP</i>, 1991, 25:101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1848957\">[PubMed 1848957]</a></p>\n<p>6. Spinewine A, Schoevaerdts D, Swine C, et al, “Drug-Induced Lithium Intoxication: A Case Report,” <i>J Am Geriatr Soc</i>, 2005, 53(2):360-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15673374\">[PubMed 15673374]</a></p>\n<p>7. Finley P, O'Brien J, Coleman R, “Lithium and Angiotensin-Converting Enzyme Inhibitors: Evaluation of a Potential Interaction,” <i>J Clin Psychopharmacol</i>, 1996, 16(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8834421\">[PubMed 8834421]</a></p>\n<p>8. Juurlink D, Mamdani M, Kopp A, “Drug-Induced Lithium Toxicity in the Elderly: A Population-Based Study,” <i>J Am Geriatr Soc</i>, 2004, 52(5):794-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15086664\">[PubMed 15086664]</a></p>\n<p>9. Meyer J, Dollarhide A, Tuan I, “Lithium Toxicity After Switch from Fosinopril to Lisinopril,” <i>Int Clin Psychopharmacol</i>, 2005, 20(2):115-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15729089\">[PubMed 15729089]</a></p>\n<p>10. DasGupta K, Jefferson J, Kobak K, et al, “The Effect of Enalapril on Serum Lithium Levels in Healthy Men,” <i>J Clin Psychiatry</i>, 1992, 53(11):398-400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1459971\">[PubMed 1459971]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3160":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider alternative anti-inflammatory therapy, especially in CHF patients, to avoid the potential negative consequences of concomitant nonsteroidal anti-inflammatory agent (NSAID) therapy (fluid accumulation/edema). Monitor for decreased therapeutic effects of angiotensin-converting enzyme (ACE) inhibitor with concurrent use of an NSAID. This is likely of most concern with chronic dosing and/or higher doses of the NSAID; however, blood pressure increases have been noted following a single NSAID dose. In addition, concomitant therapy with NSAIDs and ACE inhibitors increases the risk of renal dysfunction, particularly if the patient is also receiving a diuretic.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril*, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril*, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac*, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The addition of a nonselective nonsteroidal anti-inflammatory agent (NSAID) to a hypertension patient's angiotensin-converting enzyme (ACE) inhibitor-containing medication regimen has been shown to reduce the efficacy of the ACE inhibitor.<sup>1,2,3</sup> Blood pressure changes have been noted to occur as soon as 1 hour following initial NSAID dose administration. A recent report also describes a substantial increase in blood pressure in a lisinopril-treated patient following the initiation of the selective COX-2 inhibitor, rofecoxib.<sup>4</sup> Dechallenge and rechallenge with the same dose of both agents in this case confirm the interaction. The mechanism of these interactions would seem to be related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins. This would affect vascular tone and fluid homeostasis. A pharmacokinetic effect is also possible. The manufacturer of oxaprozin reports that the drug caused a significant decrease in the AUC and Cmax of enalapril, and a significant increase in the AUC of enalaprilat (the active metabolite of enalapril).<sup>5</sup><br><br>The findings of several case-control and cohort studies suggest that the risk for acute kidney injury (AKI) may also be increased with concurrent use of an NSAID and an ACE inhibitor, and that the risk may be particularly high with use of the three drug combination of an ACE inhibitor/angiotensin receptor blocker, diuretic, and NSAID,<sup>6,7,8,9</sup> and higher than that observed with any single drug or two drug combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Swartz SL, Williams GH. Angiotensin-converting enzyme inhibition and prostaglandins. <i>Am J Cardiol</i>. 1982;49(6):1405-1409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6280473\">[PubMed 6280473]</a></p>\n<p>2. Ogihara T, Maruyama A, Hata T, et al. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. <i>Clin Pharmacol Ther</i>. 1981;30(3):328-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6268347\">[PubMed 6268347]</a></p>\n<p>3. Goldstone R, Martin K, Zipser R, Horton R. Evidence for a dual action of converting enzyme inhibitor on blood pressure in normal man. <i>Prostaglandins</i>. 1981;22(4):587-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6275456\">[PubMed 6275456]</a></p>\n<p>4. Brown CH. Effect of rofecoxib on the antihypertensive activity of lisinopril. <i>Ann Pharmacother</i>. 2000;34(12):1486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11144708\">[PubMed 11144708]</a></p>\n<p>5. Daypro Alta (oxaprozin) [prescribing information]. Chicago, IL: G.D. Searle LLC; July 2005.</p>\n<p>6. Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: “The Triple Whammy”. <i>Nefrologia</i>. 2015;35(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26300514\">[PubMed 26300514]</a></p>\n<p>7. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. <i>Kidney Int</i>. 2015;88(2):396-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25874600\">[PubMed 25874600]</a></p>\n<p>8. Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centres. More on the “Triple Whammy”: antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database. <i>Ren Fail</i>. 2014;36(7):1166-1168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24826803\">[PubMed 24826803]</a></p>\n<p>9. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23299844\">[PubMed 23299844]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3161":"<p><b>Title</b> Lithium / Methyldopa</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methyldopa may enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of lithium toxicity if used concomitantly with methyldopa. Evidence of toxicity may not be supported/identified by increasing serum lithium concentrations.</p> \n<p><b>Discussion</b> Signs and symptoms of lithium-associated toxicity has been described in several patients and normal subjects following the addition of methyldopa to their medication regimens.<sup>1,2,3,4,5,6</sup> In most cases, the serum lithium concentration remained in the accepted therapeutic range. Problems typically developed within 2 to 3 days of initiating methyldopa. The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Byrd GJ, “Methyldopa and Lithium Carbonate: Suspected Interaction,” <i>JAMA</i>, 1975, 233:320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1173643\">[PubMed 1173643]</a></p>\n<p>2. Byrd GJ, “Lithium Carbonate and Methyldopa: Apparent Interaction in Man,” <i>Clin Toxicol</i>, 1977, 11:1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=872534\">[PubMed 872534]</a></p>\n<p>3. O’Regan JB, “Adverse Interaction of Lithium Carbonate and Methyldopa,” <i>Can Med Ass J</i>, 1976, 115:385. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=953910\">[PubMed 953910]</a></p>\n<p>4. Osanloo E and Deglin JH, “Interaction of Lithium and Methyldopa,” <i>Ann Intern Med</i>, 1980, 92:433. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7356241\">[PubMed 7356241]</a></p>\n<p>5. Walker N, White K, Tornatore F, et al, “Lithium-Methyldopa Interactions in Normal Subjects,” <i>Drug Intell Clin Pharm</i>, 1980, 14:638.</p>\n<p>6. Yassa R, “Lithium-Methyldopa Interaction,” <i>Can Med Ass J</i>, 1986, 134:141-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3080214\">[PubMed 3080214]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3162":"<p><b>Title</b> Lithium / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Lithium. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The combination of a monoamine oxidase inhibitor and lithium should be undertaken with great caution. When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome (e.g., confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia). Such monitoring should occur throughout the course of concomitant therapy. A selective MAOI may pose less risk than the nonselective agents. Note that lithium is sometimes added to MAOI therapy to augment the antidepressant effects of the MAOI. In general, furazolidone, linezolid, tedizolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine*<br><b>Exception</b> Moclobemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The concomitant use of monoamine oxidase inhibitors (MAOI) and lithium has proved to be safe and effective in a number of evaluations.<sup>1,2,3</sup> However, a few case reports describe the development of adverse events associated with concomitant therapy. One report describes two patients receiving both tranylcypromine and lithium for a minimum of 1.5 years who developed a buccolingual masticatory syndrome.<sup>4</sup> The syndrome was attributed to the hypersensitization of dopamine receptors. Two additional reports describe the development of malignant hyperpyrexia that included hepatic failure, and eventually death, within approximately 4-6 weeks of initiating concomitant therapy with lithium and phenelzine.<sup>5,6</sup> Both of the latter patients were also receiving L-tryptophan, a serotonin agonist. A report on the concomitant use of moclobemide and lithium for up to 52 weeks in 50 patients identified no adverse events.<sup>7</sup> The mechanism(s) of these interactions is unknown. Selective MAOI may introduce less risk than nonselective agents. Due to the significance of the outcomes in some cases, caution is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Himmelhoch JM, Detre T, Kupfer DJ, et al, “Treatment of Previously Intractable Depressions With Tranylcypromine and Lithium,” <i>J Nerv Ment Dis</i>, 1972, 155:216-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5053920\">[PubMed 5053920]</a></p>\n<p>2. Price LH, Charney DS, and Heninger GR, “Efficacy of Lithium-Tranylcypromine Treatment in Refractory Depression,” <i>Am J Psychiatry</i>, 1985, 142:619-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3920923\">[PubMed 3920923]</a></p>\n<p>3. Fein S, Paz V, Rao N, et al, “The Combination of Lithium Carbonate and an MAOI in Refractory Depression,” <i>Am J Psychiatry</i>, 1988, 145:249-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3124635\">[PubMed 3124635]</a></p>\n<p>4. Stancer HC, “Tardive Dyskinesia Not Associated With Neuroleptics,” <i>Am J Psychiatry</i>, 1979, 136:727. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=434260\">[PubMed 434260]</a></p>\n<p>5. Brennan D, MacManus M, Howe J, et al, “Neuroleptic Malignant Syndrome Without Neuroleptics,” <i>Br J Psychiatry</i>, 1988, 152:578-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3167427\">[PubMed 3167427]</a></p>\n<p>6. Staufenberg EF and Tantam D, “Malignant Hyperpyrexia Syndrome in Combined Treatment,” <i>Br J Psychiatry</i>, 1989, 154:577-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2590798\">[PubMed 2590798]</a></p>\n<p>7. Amrein R, Guntert TW, Dingemanse J, et al, “Interactions of Moclobemide With Concomitantly Administered Medication: Evidence From Pharmacological and Clinical Studies,” <i>Psychopharmacology</i>, 1992, 106:S24-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1546135\">[PubMed 1546135]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3163":"<p><b>Title</b> Lithium / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may enhance the adverse/toxic effect of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of lithium-associated toxicity if lithium and phenytoin are used concomitantly. Lithium toxicity may occur without any apparent increase in lithium concentrations.</p> \n<p><b>Discussion</b> Three case reports describe the development of typical signs and symptoms of lithium intoxication that developed during concomitant therapy with phenytoin, and without any apparent increase in lithium concentrations.<sup>1,2,3</sup> A cause-effect relationship has not been established, and a specific mechanism for the possible interaction is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. MacCallum WA. Interaction of lithium and phenytoin. <i>Br Med J</i>. 1980;280(6214):610-611. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7370605\">[PubMed 7370605]</a></p>\n<p>2. Speirs J, Hirsch SR. Severe lithium toxicity with “normal” serum concentrations. <i>Br Med J</i>. 1978;1(6116):815-816. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=638462\">[PubMed 638462]</a></p>\n<p>3. Raskin DE. Lithium and phenytoin interaction. <i>J Clin Psychopharmacol</i>. 1984;4(2):120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6423703\">[PubMed 6423703]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3164":"<p><b>Title</b> Lithium / Potassium Iodide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium Iodide may enhance the hypothyroid effect of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of decreased thyroid function during concomitant therapy with lithium and potassium iodide.</p> \n<p><b>Discussion</b> Several case reports describe apparent additive effects of lithium and potassium iodide in reducing thyroid function.<sup>1,2,3,4</sup> Additionally, a study of 10 patients receiving chronic lithium therapy showed a rise in thyroid stimulating hormone and T3 following initiation of potassium iodide (250 mg orally four times daily).<sup>5</sup> Two patients developed hypothyroidism.<br><br>Both lithium and potassium iodide can diminish thyroid function. Lithium appears to block the release of thyroid hormones from the thyroid gland, while potassium iodide interrupts the production of thyroid hormones. Caution is advised when these agents are used concomitantly.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shopsin B, Shenkman L, Blum M, Hollander CS. Iodine and lithium-induced hypothyroidism. Documentation of synergism. <i>Am J Med</i>. 1973;55(5):695-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4749208\">[PubMed 4749208]</a></p>\n<p>2. Luby ED, Schwartz D, Rosenbaum H. Lithium-carbonate-induced myxedema. <i>JAMA</i>. 1971;218(8):1298-1299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5171179\">[PubMed 5171179]</a></p>\n<p>3. Jorgensen JV, Brandrup F, Schroll M. Possible synergism between iodine and lithium carbonate. <i>JAMA</i>. 1973;223(2):192-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4540138\">[PubMed 4540138]</a></p>\n<p>4. Wiener JD. Lithium carbonate-induced myxedema. <i>JAMA</i>. 1972;220(4):587. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4401588\">[PubMed 4401588]</a></p>\n<p>5. Spaulding SW, Burrow GN, Ramey JN, Donabedian RK. Effect of increased iodide intake on thyroid function in subjects on chronic lithium therapy. <i>Acta Endocrinol (Copenh)</i>. 1977;84(2):290-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=576345\">[PubMed 576345]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3165":"<p><b>Title</b> Lithium / Sodium Chloride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sodium Chloride may increase the excretion of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of lithium if sodium chloride is initiated/dose increased, or increased effects if sodium chloride is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Ingestion of sodium bicarbonate (and other sodium-containing substances) has resulted in decreased serum lithium concentrations.<sup>1,2,3,4,5</sup> It appears that the renal proximal tubule treats lithium and sodium ions in a similar fashion, and thus when sodium concentrations are increased, both sodium and lithium ions are excreted. The converse would also be true.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thomsen K and Schou M, “Renal Lithium Excretion in Man,” <i>Am J Physiol</i>, 1968, 215:823. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5676383\">[PubMed 5676383]</a></p>\n<p>2. Bleiweiss H, “Salt Supplements With Lithium,” <i>Lancet</i>, 1970, i:416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4189720\">[PubMed 4189720]</a></p>\n<p>3. Hurtig HI and Dyson WL, “Lithium Toxicity Enhanced by Diuresis,” <i>N Engl J Med</i>, 1974, 290:748. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4813752\">[PubMed 4813752]</a></p>\n<p>4. Corcoran AC, Taylor RD, and Page IH, “Lithium Poisoning From the Use of Salt Substitutes,” <i>JAMA</i>, 1949, 139:685. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18110875\">[PubMed 18110875]</a></p>\n<p>5. Demers R and Heninger G, “Sodium Intake and Lithium Treatment in Mania,” <i>Am J Psychiatry</i>, 1971, 128(1):132-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4949647\">[PubMed 4949647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3166":"<p><b>Title</b> Lithium / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Theophylline Derivatives may decrease the serum concentration of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and/or therapeutic effects of lithium if a theophylline derivative is initiated/dose increased, or increased lithium effects if a theophylline derivative is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline</p>\n</div> \n<p><b>Discussion</b> The clearance of lithium (carbonate: 900 mg/day) was increased an average of 30% with 2 weeks of concomitant theophylline (400-800 mg/day) in a study of 10 healthy volunteers.<sup>1</sup> Similarly, in a study of 10 healthy volunteers who took lithium carbonate (600 mg twice daily) for 3 different 1-week periods, average lithium clearance increased 51% following intravenous theophylline vs. only an average 0.6% increase in clearance after a bicarbonate infusion.<sup>2</sup> Consistent with these experimental findings, a clinical report describes a decreased therapeutic response to lithium following the addition of theophylline to the patient's medication regimen.<sup>3</sup> Lithium dosage changes were necessary with each theophylline dosage change in order to maintain therapeutic efficacy.<br><br>The precise mechanism of this apparent interaction is unknown, but some evidence suggests that this may be related to the diuretic effects of theophylline (and derivatives).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cook BL, Smith RE, Perry PJ, et al, “Theophylline-Lithium Interaction,” <i>J Clin Psychiatry</i>, 1985, 46:278-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4008452\">[PubMed 4008452]</a></p>\n<p>2. Holstad SG, Perry PJ, Kathol RG, et al, “The Effects of Intravenous Theophylline Infusion Versus Intravenous Sodium Bicarbonate Infusion on Lithium Clearance in Normal Subjects,” <i>Psychiatry Res</i>, 1988, 25(2):203-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2845461\">[PubMed 2845461]</a></p>\n<p>3. Sierles FS and Ossowski MG, “Concurrent Use of Theophylline and Lithium in a Patient With Chronic Obstructive Lung Disease and Bipolar Disorder,” <i>Am J Psychiatry</i>, 1982, 139:117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7055254\">[PubMed 7055254]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3168":"<p><b>Title</b> Vitamin K Antagonists / HMG-CoA Reductase Inhibitors (Statins)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> HMG-CoA Reductase Inhibitors (Statins) may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of oral anticoagulants if an HMG-CoA reductase inhibitor (aka, statin) is initiated/dose increased, or decreased effects if a statin is discontinued/dose decreased. Dosage adjustments of the anticoagulant may be needed. Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice).</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> Fluvastatin*, Lovastatin*, Pitavastatin, Pravastatin*, Red Yeast Rice, Rosuvastatin*, Simvastatin*<br><b>Exception</b> AtorvaSTATin</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The prothrombin time (PT) approximately doubled in 2 warfarin-treated patients within 10-21 days of initiating lovastatin (20 mg/day), and they experienced minor bleeding.<sup>1</sup> The INR increased by an average of 17% in 8 other patients when additionally treated with lovastatin 40 mg for 7 days.<sup>2</sup> Similarly, two separate reports describe a total of 6 patients who experienced an approximate 50% increase in INR following the initiation of fluvastatin (20-40 mg/day).<sup>3,4</sup> The manufacturer of fluvastatin reports no changes in the concentration of warfarin (30 mg single dose) when administered following an 8-day course of fluvastatin (40 mg daily).<sup>5</sup> INR values increased approximately 27% in 29 warfarin-stable patients following the initiation of simvastatin.<sup>6</sup> Other reports with simvastatin have demonstrated little to no effect on INR.<sup>7,8</sup> The manufacturer of pravastatin reports no effect of the drug (40 mg) on the INR in warfarin-stable elderly patients.<sup>9</sup> Other reports seem to support this outcome.<sup>10,11</sup> However, a report demonstrating the safety in switching from pravastatin to simvastatin in warfarin-stable patients may indicate that pravastatin has a modest effect on INR, although not greater than simvastatin.<sup>12</sup> Rosuvastatin administration has been reported to increase the INR in warfarin patients from a baseline of 2-3 to a post-rosuvastatin value of &gt; 4.<sup>13</sup> In contrast, reports involving concomitant therapy with warfarin and atorvastatin,<sup>14</sup> have demonstrated no clinical effects on the activity of warfarin. One case report describes an increase in INR when fluvastatin was initiated in place of atorvastatin, and a reversal in this effect when atorvastatin was subsequently re-initiated in place of fluvastatin.<sup>15</sup> The effects of fluvastatin and lovastatin are possibly related to inhibition of CYP2C9 isoenzymes. Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice) and several other mevinic acid compounds.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ahmad S, “Lovastatin. Warfarin Interaction,” <i>Arch Intern Med</i>, 1990, 150:2407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2241455\">[PubMed 2241455]</a></p>\n<p>2. O’Rangers EA, Ford M, and Hershey A, “The Effect of HMG-CoA Reductase Inhibitors on the Anticoagulant Response to Warfarin,” <i>Pharmacotherapy</i>, 1994, 14:349.</p>\n<p>3. Trilli LE, Kelley CL, Aspinall SL, et al, “Potential Interaction Between Warfarin and Fluvastatin,” <i>Ann Pharmacother</i>, 1996, 30:1399-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8968451\">[PubMed 8968451]</a></p>\n<p>4. Kline SS and Harrell C, “Potential Warfarin-Fluvastatin Interaction,” <i>Ann Pharmacother</i>, 1997, 31:790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9184730\">[PubMed 9184730]</a></p>\n<p>5. Lescol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2003.</p>\n<p>6. Hickmott H, Wynne H, and Kamali F, “The Effect of Simvastatin Co-medication on Warfarin Anticoagulation Response and Dose Requirements,” <i>Thromb Haemost</i>, 2003, 89(5):949-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12719797\">[PubMed 12719797]</a></p>\n<p>7. Keech A, Collins R, MacMahon S, et al, “Three-Year Follow-Up of the Oxford Cholesterol Study: Assessment of the Efficacy and Safety of Simvastatin in Preparation for Large Mortality Study,” <i>Eur Heart J</i>, 1994, 15:255-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8005129\">[PubMed 8005129]</a></p>\n<p>8. Gaw A and Wosornu D, “Simvastatin During Warfarin Therapy in Hyperlipoproteinaemia,” <i>Lancet</i>, 1992, 340:979-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1357387\">[PubMed 1357387]</a></p>\n<p>9. Pravachol [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2003.</p>\n<p>10. O’Rangers EA, Ford M, and Hershey A, “The Effect of HMG-CoA Reductase Inhibitors on the Anticoagulant Response to Warfarin,” <i>Pharmacotherapy</i>, 1994, 14:349.</p>\n<p>11. Pan HY, “Clinical Pharmacology of Pravastatin: A Selective Inhibitor of HMC-CoA Reductase,” <i>Eur J Clin Pharmacol</i>, 1991, 40(Suppl 1):S15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1904355\">[PubMed 1904355]</a></p>\n<p>12. Lin JC, Ito MK, Stolley SN, et al, “The Effect of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin,” <i>J Clin Pharmacol</i>, 1999, 39(1):86-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9987704\">[PubMed 9987704]</a></p>\n<p>13. Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2004.</p>\n<p>14. Stern R, Abel R, Gibson GL, et al, “Atorvastatin Does Not Alter the Anticoagulant Activity of Warfarin,” <i>J Clin Pharmacol</i>, 1997, 37:1062-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9506000\">[PubMed 9506000]</a></p>\n<p>15. Andrus MR, “Oral Anticoagulant Drug Interactions With Statins: Case Report of Fluvastatin and Review of the Literature,” <i>Pharmacotherapy</i>, 2004, 24(2):285-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14998226\">[PubMed 14998226]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3169":"<p><b>Title</b> Magnesium Salts / Calcium Channel Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for hypotension or muscle weakness in patients receiving calcium channel blockers with elevated serum magnesium concentrations. High-risk patients include those with impaired renal function and those receiving parenteral magnesium. Rare cases of muscular paralysis have been reported in patients receiving parenteral magnesium (for treatment of pre-eclampsia) and oral nifedipine.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil</p>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate*, Magnesium Trisilicate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Two case reports describe the development of muscular paralysis in pregnant women being treated for pre-eclampsia with concomitant oral nifedipine and parenteral magnesium sulfate.<sup>1,2</sup> In one case, the symptoms dissipated within 25 minutes of stopping the magnesium, and in the other administration of IV calcium gluconate reversed the paralytic state. Two other pregnant patients (receiving methyldopa and IV magnesium) experienced transient hypotension within 1 hour following the administration of oral nifedipine.<sup>3</sup><br><br>In contrast to these case reports, two studies have concluded that the combination of magnesium sulfate and nifedipine can be safe and effective. A prospective study of 91 women with eclampsia reported that the combination of magnesium sulfate and nifedipine exerted synergistic effects that were beneficial, associated with reduced maternal and perinatal morbidity and mortality.<sup>4</sup> A retrospective chart review of women being treated for preeclampsia evaluated neuromuscular and cardiovascular adverse events in women who had received intravenous magnesium sulfate either with nifedipine (cases; n=162) or with another anti-hypertensive or no anti-hypertensive (controls; n=215).<sup>5</sup> There was no significant difference in reports of neuromuscular weakness between cases and controls (53.1% vs. 46.0%, respectively). Episodes of neuromuscular blockade and hypotension were both less common in cases than in controls, further supporting the safety of this combination.<br><br>The mechanism of this possible interaction is probably attributable to the additive effects of the agents in reducing the amount of ionic calcium available to muscle cells.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Snyder SE and Cardwell MS, “Neuromuscular Blockade With Magnesium Sulphate and Nifedipine,” <i>Am J Obst Gynecol</i>, 1989, 161:35-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2750819\">[PubMed 2750819]</a></p>\n<p>2. Ben-Ami M, Giladi Y, and Shalev E, “The Combination of Magnesium Sulphate and Nifedipine: A Cause of Neuromuscular Blockade,” <i>Br J Obst Gyn</i>, 1993, 101:62-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8193107\">[PubMed 8193107]</a></p>\n<p>3. Waisman GD, Mayorga LM, Camera MI, et al, “Magnesium Plus Nifedipine: Potentiation of Hypotensive Effect in Pre-eclampsia?” <i>Am J Obstet Gynecol</i>, 1988, 159:308-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3407684\">[PubMed 3407684]</a></p>\n<p>4. Bhalla AK, Dhall GI, Dhall K, “A Safer and More Effective Treatment Regimen for Eclampsia,” <i>Aust N Z J Obstet Gynaecol</i>, 1994, 34:144-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7980301\">[PubMed 7980301]</a></p>\n<p>5. Magee LA, Miremadi S, Li J, et al, “Therapy with Both Magnesium Sulfate and Nifedipine Does Not Increase the Risk of Serious Magnesium-Related Maternal Side Effects in Women with Preeclampsia,” <i>Am J Obstet Gynecol</i>, 2005, 193:153-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16021073\">[PubMed 16021073]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3170":"<p><b>Title</b> Neuromuscular-Blocking Agents / Magnesium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for enhanced or prolonged effects of neuromuscular blocking agents in patients receiving magnesium supplementation. High-risk patients include those with elevated serum magnesium concentrations or renal impairment and those receiving parenteral magnesium.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate*, Magnesium Trisilicate</p>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium*, Cisatracurium*, Mivacurium, Pancuronium*, Rocuronium*, Succinylcholine*, Vecuronium*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Numerous case reports and clinical studies have demonstrated enhanced neuromuscular blockade in patients receiving magnesium in combination with neuromuscular blocking agents, including atracurium, cisatracurium, succinylcholine, pancuronium, vecuronium, and rocuronium.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24</sup> Enhanced effects have included more rapid onset, greater duration of action, and lower dose requirements of the neuromuscular blocking agent. Two studies have also shown a return of neuromuscular blockade when parenteral magnesium was administered shortly after recovery.<sup>7,18</sup> Enhanced neuromuscular blocking effects have been most often seen in hypermagnesemic patients and those treated with parenteral magnesium. Two studies showed no enhancement of succinylcholine induced neuromuscular blockade with magnesium supplementation.<sup>25,26</sup> <br><br>Magnesium possesses some weak neuromuscular blocking activity. This is likely additive with neuromuscular-blocking agents, and other medications that possess such properties (eg, aminoglycoside antibiotics). Specific dose adjustment guidelines are lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sinatra RS, Philip BK, Naulty JS, et al, “Prolonged Neuromuscular Blockade With Vecuronium in a Patient Treated With Magnesium Sulphate,” <i>Anesth Analg</i>, 1985, 64:1220-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2865911\">[PubMed 2865911]</a></p>\n<p>2. Ghoneim MM and Long JP, “The Interaction between Magnesium and Other Neuromuscular-Blocking Agents,” <i>Anesthesiology</i>, 1970, 32:23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5460601\">[PubMed 5460601]</a></p>\n<p>3. Ip-Yam C and Allsop E, “Abnormal Response to Suxamethonium in a Patient Receiving Magnesium Therapy,” <i>Anaesthesia</i>, 1994, 49:355-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8179157\">[PubMed 8179157]</a></p>\n<p>4. Baraka A and Yazigi A, “Neuromuscular Interaction of Magnesium with Succinylcholine-Vecuronium Sequence in the Eclamptic Parturient,” <i>Anesthesiology</i>, 1987, 67(5):806-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2890318\">[PubMed 2890318]</a></p>\n<p>5. Gaiser RR and Seem EH, “Use of Rocuronium in a Pregnant Patient With an Open Eye Injury, Receiving Magnesium Medication, for Preterm Labour,” <i>Br J Anaesth</i>, 1996, 77:669-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8957990\">[PubMed 8957990]</a></p>\n<p>6. Morris R and Giesecke AH, “Potentiation of Muscle Relaxants by Magnesium Sulfate Therapy in Toxemia of Pregnancy,” <i>South Med J</i>, 1968, 61:25.</p>\n<p>7. Fuchs-Buder T and Tassonyi E, “Magnesium Sulphate Enhances Residual Neuromuscular Block Induced by Vecuronium,” <i>Br J Anaesth</i>, 1996, 76(4):565-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8652332\">[PubMed 8652332]</a></p>\n<p>8. Kussman B, Shorten G, Uppington J, et al, “Administration of Magnesium Sulphate before Rocuronium: Effects on Speed of Onset and Duration of Neuromuscular Block,” <i>Br J Anaesth</i>, 1997, 79(1):122-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9301400\">[PubMed 9301400]</a></p>\n<p>9. Gupta K, Vohra V and Sood J, “The Role of Magnesium as an Adjuvant During General Anaesthesia,” <i>Anaesthesia</i>, 2006, 61(11):1058-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17042843\">[PubMed 17042843]</a></p>\n<p>10. Yoshida A, Itoh Y, Nagaya K, et al, “Prolonged Relaxant Effects of Vecuronium in Patients with Deliberate Hypermagnesemia: Time for Caution in Cesarean Section,” <i>J Anesth</i>, 2006, 20(1):33-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16421674\">[PubMed 16421674]</a></p>\n<p>11. Pinard AM, Donati F, Martineau R, et al, “Magnesium Potentiates Neuromuscular Blockade with Cisatracurium During Cardiac Surgery,” <i>Can J Anaesth</i>, 2003, 50(2):172-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12560310\">[PubMed 12560310]</a></p>\n<p>12. Kwan WF, Lee C and Chen BJ, “A Noninvasive Method in the Differential Diagnosis of Vecuronium-Induced and Magnesium-Induced Protracted Neuromuscular Block in a Severely Preeclamptic Patient,” <i>J Clin Anesth</i>, 1996, 8(5):392-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8832451\">[PubMed 8832451]</a></p>\n<p>13. Ryu JH, Kang MH, Park KS, et al, “Effects of Magnesium Sulphate on Intraoperative Anaesthetic Requirements and Postoperative Analgesia in Gynaecology Patients Receiving Total Intravenous Anaesthesia,” <i>Br J Anaesth</i>, 2008, 100(3):397-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18276652\">[PubMed 18276652]</a></p>\n<p>14. Na HS, Lee JH, Hwang, et al, “Effects of Magnesium Sulphate on Intraoperative Neuromuscular Blocking Agent Requirements and Postoperative Analgesia in Children with Cerebral Palsy,” <i>Br J Anaesth</i>, 2010, 104(3):344-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20042475\">[PubMed 20042475]</a></p>\n<p>15. Telci L, Esen F, Akcora D, et al, “Evaluation of Effects of Magnesium Sulphate in Reducing Intraoperative Anaesthetic Requirements,” <i>Br J Anaesth</i>, 2002, 89(4):591-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12393361\">[PubMed 12393361]</a></p>\n<p>16. Aldrete JA, Zahler A and Aikawa JK, “Prevention of Succinylcholine-Induced Hyperkalaemia by Magnesium Sulfate,” <i>Can Anaesth Soc J</i>, 1970, 17(5):477-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5506078\">[PubMed 5506078]</a></p>\n<p>17. Fuchs-Buder T, Ziegenfuss T, Lysakowski K, et al, “Interaction of Magnesium Sulphate with Vecuronium-Induced Neuromuscular Block,” <i>Br J Anaesth</i>, 1995, 74(4):405-9.<a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7734259\">[PubMed 7734259]</a></p>\n<p>18. Fawcett WJ and Stone JP, “Recurarization in the Recovery Room Following the Use of Magnesium Sulphate,” <i>Br J Anaesth</i>, 2003, 91(3):435-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925489\">[PubMed 12925489]</a></p>\n<p>19. De Vore JS and Asrani R, “Magnesium Sulfate Prevents Succinylcholine-Induced Fasciculations in Toxemic Parturients,” <i>Anesthesiology</i>, 1980, 52(1):76-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7352649\">[PubMed 7352649]</a></p>\n<p>20. Lee DH and Kwon IC, “Magnesium Sulphate has Beneficial Effects as an Adjuvant During General Anaesthesia for Caesarean Section,” <i>Br J Anaesth</i>, 2009, 103(6):861-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19783538\">[PubMed 19783538]</a></p>\n<p>21. Cizmeci P and Ozkose Z, “Magnesium Sulphate as an Adjuvant to Total Intravenous Anesthesia in Septorhinoplasty: A Randomized Controlled Study,” <i>Aesthetic Plast Surg</i>, 2007, 31(2):167-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17437152\">[PubMed 17437152]</a></p>\n<p>22. Olivieri L and Plourde G, “Prolonged (More Than Ten Hours) Neuromuscular Blockade after Cardiac Surgery: Report of Two Cases,” <i>Can J Anaesth</i>, 2005, 52(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15625263\">[PubMed 15625263]</a></p>\n<p>23. Khafagy HF, Osman ES, Naguib AF, “Effects of Different Dose Regimens of Magnesium on Pharmacodynamics and Anesthetic Requirements of Balanced General Anesthesia,” <i>J Egypt Soc Parasitol</i>, 2007, 37(2):469-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17985581\">[PubMed 17985581]</a></p>\n<p>24. James MF, Schenk PA and van der Veen BW, “Priming of Pancuronium with Magnesium,” <i>Br J Anaesth</i>, 1991, 66(2):247-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1817630\">[PubMed 1817630]</a></p>\n<p>25. Stacey MR, Barclay K, Asai T, et al, “Effects of Magnesium Sulphate on Suxamethonium-Induced Complications during Rapid-Sequence Induction of Anaesthesia,” <i>Anaesthesia</i>, 1995, 50(11):933-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8678246\">[PubMed 8678246]</a></p>\n<p>26. James MF, Cork RC and Dennett JE, “Succinylcholine Pretreatment with Magnesium Sulfate,” <i>Anesth Analg</i>, 1986, 65(4):373-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3513667\">[PubMed 3513667]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3171":"<p><b>Title</b> Mebendazole / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Mebendazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of mebendazole if phenytoin is initiated/dose increased, especially if mebendazole is being used to treat infections in tissues affected by serum drug concentrations (versus GI tract infections). Mebendazole dose increases might become necessary.</p> \n<p><b>Discussion</b> A single report describes decreases in serum mebendazole concentrations presumably due to phenytoin therapy.<sup>1</sup> It is suggested that this interaction would likely only be of concern when treating infections within tissues, as opposed to GI infections. Mebendazole dose increases might become necessary. The mechanism of this presumed interaction is thought to be phenytoin-mediated induction of mebendazole metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Luder PJ, Siffert B, Witassek F, et al, “Treatment of Hydatid Disease With High Oral Doses of Mebendazole. Long-Term Follow Up of Plasma Mebendazole Levels and Drug Interactions,” <i>Eur J Clin Pharmacol</i>, 1986, 31:443-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3816925\">[PubMed 3816925]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3172":"<p><b>Title</b> Meperidine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid meperidine use in patients who are receiving, or have received within 14 days, monoamine oxidase inhibitors (MAOIs). Prescribing information for meperidine and many MAOIs states that concomitant use of these agents is contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline*, Syrian Rue, Tedizolid, Tranylcypromine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several reports describe the development of signs and symptoms of apparent serotonin syndrome, sometimes fatal, in patients receiving monoamine oxidase inhibitors (MAOIs) within a short time (1 hour to 2 days) of initiating meperidine.<sup>1,2,3,4,5,6,7,8</sup> In contrast, one small study (N = 25) found no adverse reactions with concomitant use of meperidine and MAOIs,<sup>9</sup> but due to the low incidence of this condition and the small sample size, this analysis was likely underpowered to detect the true risk of serotonin syndrome with these agents. <br><br>Prescribing information for meperidine and many MAOIs state that concomitant use of these agents is contraindicated due to the risk of serotonin syndrome.<sup>10,11,12,13,14,15,16,17</sup><br><br>The mechanism of these interactions is likely related to additive effects on serotonin, with MAOI reducing serotonin metabolism, and meperidine possibly blocking neuronal uptake.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Asch DA, Parker RM. The Libby Zion case. One step forward or two steps backward? <i>N Engl J Med</i>. 1988;318(12):771-775. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3347226\">[PubMed 3347226]</a></p>\n<p>2. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. <i>Lancet</i>. 1991;337(8735):246. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1670882\">[PubMed 1670882]</a></p>\n<p>3. Das PK, Warkentin DI, Hewko R, Forrest DL. Serotonin syndrome after concomitant treatment with linezolid and meperidine. <i>Clin Infect Dis</i>. 2008;46(2):264-265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18171260\">[PubMed 18171260]</a></p>\n<p>4. Altman EM, Manos GH. Serotonin syndrome associated with citalopram and meperidine. <i>Psychosomatics</i>. 2007;48(4):361-363. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17600178\">[PubMed 17600178]</a></p>\n<p>5. Tissot TA. Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use. <i>Anesthesiology</i>. 2003;98(6):1511-1512. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12766667\">[PubMed 12766667]</a></p>\n<p>6. Dougherty JA, Young H, Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine. <i>Ann Pharmacother</i>. 2002;36(10):1647-1648. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12243617\">[PubMed 12243617]</a></p>\n<p>7. Meyer D, Halfin V. Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. <i>J Clin Psychopharmacol</i>. 1981;1(5):319-321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7334144\">[PubMed 7334144]</a></p>\n<p>8. Gillman PK. Possible serotonin syndrome with moclobemide and pethidine. <i>Med J Aust</i>. 1995;162(10):554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7776924\">[PubMed 7776924]</a></p>\n<p>9. Evans-Prosser CD. The use of pethidine and morphine in the presence of monoamine oxidase inhibitors. <i>Br J Anaesth</i>. 1968;40(4):279-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5654977\">[PubMed 5654977]</a></p>\n<p>10. Demerol (meperidine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2011.</p>\n<p>11. Emsam (selegiline) transdermal [prescribing information]. Morgantown, WV: Somerset Pharmaceuticals Inc; March 2015.</p>\n<p>12. Marplan (isocarboxazid) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals Inc; June 2007.</p>\n<p>13. Nardil (phenelzine) [prescribing information]. New York, NY: Pfizer Inc; May 2007.</p>\n<p>14. Azilect (rasagiline) [prescribing information]. North Wales, PA: TEVA Pharmaceuticals USA Inc; May 2014.</p>\n<p>15. Parnate (tranylcypromine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2010.</p>\n<p>16. Manerix (moclobemide) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; November 2014.</p>\n<p>17. Xadago (safinamide) [prescribing information]. Louisville, KY: US WorldMeds, LLC; March 2017.</p>\n<p>18. Rogers KJ. Role of brain monoamines in the interaction between pethidine and tranylcypromine. <i>Eur J Pharmacol</i>. 1971;14(1):86-88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4252179\">[PubMed 4252179]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3174":"<p><b>Title</b> Meperidine / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Meperidine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased analgesic effects of meperidine if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased. Phenytoin may also increase the rate of formation of normeperidine, a neuroexcitatory metabolite of meperidine.</p> \n<p><b>Discussion</b> The clearance of meperidine (50 mg intravenous or 100 mg oral) was increased by 27% in healthy volunteers when administered following a 9-day course of phenytoin (300 mg/day).<sup>1</sup> <br><br>The likely mechanism of this interaction is phenytoin induction of meperidine metabolism. This would increase the rate at which normeperidine (the neuroexcitatory metabolite of meperidine) is formed. A study of human liver microsomes demonstrated a role of CYP2B6, 3A4, and 2C19 in catalyzing this metabolism.<sup>2</sup> Phenytoin likely induces all of these enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pond SM and Kretzschmar KM, “Effect of Phenytoin on Meperidine Clearance and Normeperidine Formation,” <i>Clin Pharmacol Ther</i>, 1981, 30:680. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7297025\">[PubMed 7297025]</a></p>\n<p>2. Ramirez J, Innocenti F, Schuetz EG, et al, “CYP2B6, CYP3A4, and CYP2C19 are Responsible for the In Vitro N-Demethylation of Meperidine in Human Liver Microsomes,” <i>Drug Metab Dispos</i>, 2004, 32(9):930-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15319333\">[PubMed 15319333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3175":"<p><b>Title</b> Alpha1-Agonists / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concomitant use of alpha<sub>1</sub>-agonists and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. In general, furazolidone, linezolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Alpha1-Agonists Interacting Members</b> Midodrine, Naphazoline (Nasal), Naphazoline (Ophthalmic), Oxymetazoline (Nasal), Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic), Phenylephrine (Topical), Propylhexedrine, Xylometazoline</p>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine<br><b>Exceptions</b> Linezolid, Tedizolid</p>\n</div> \n<p><b>Discussion</b> The pressor response to oral phenylephrine was greatly increased (six to 35-fold) in 4 normal subjects when pretreated with phenelzine (45 mg/day) or tranylcypromine (30 mg/day) for 7 days.<sup>1</sup> Blood pressure increases were accompanied by severe headache. A modest twofold increase in effect was noted when IV phenylephrine was used. Other reports have confirmed both the exaggerated response to oral phenylephrine,<sup>2,3</sup> and the milder response to IV phenylephrine.<sup>4,5</sup> <br><br>A pargyline-treated patient experienced a dangerous increase in blood pressure (300 mm Hg systolic) within 10 minutes of receiving a dose of metaraminol.<sup>6</sup> The effect of selective MAOI-B on alpha<sub>1</sub>-agonist toxicity is less likely than with nonselective products, however, one report describes a three- to fourfold increase in the pressor effects of ephedrine in subjects receiving moclobemide.<sup>7,8</sup><br><br>The mechanism of specific interactions depends on both the medication and the route of administration. For oral phenylephrine, the primary route of metabolism is via MAO in the gut, thus the need for oral doses to be significantly larger than I.V. doses. In the face of MAOI therapy, a significant increase in phenylephrine absorption takes place (less metabolism in the gut; less first pass effect). IV phenylephrine would not be appreciably affected by MAOI, however, it may possess a slight indirect effect on the adrenergic system.<br><br>Monoamine oxidase inhibitors (nonselective) cause an accumulation of norepinephrine within adrenergic neurons. Of particular importance are the neurons in the sympathetic system that innervate arterial blood vessels. Under such circumstances, the administration of an indirect-acting alpha<sub>1</sub>-agonist such as metaraminol (or any other indirect acting sympathomimetic) will cause the release of the stored, excess norepinephrine, and a subsequent exaggerated constriction of blood vessels - thus an exaggerated increase in blood pressure.<sup>2,3,5,9,10</sup> The hypertensive reactions can occur within minutes of sympathomimetic administration. Fatalities have occurred.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Boakes AJ, Laurence DR, Teoh PC, et al, “Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,” <i>Br Med J</i>, 1973, 1:311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>2. Jenkins LC and Graves HB, “Potential Hazards of Psychoactive Drugs in Association With Anaesthesia,” <i>Can Anaes Soc J</i>, 1965, 12:121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14311657\">[PubMed 14311657]</a></p>\n<p>3. Harrison WM, McGrath PJ, Stewart JW, et al, “MAOIs and Hypertensive Crises: The Role of OTC Drugs,” <i>J Clin Psychiatry</i>, 1989, 50:64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2464583\">[PubMed 2464583]</a></p>\n<p>4. Elis J, Laurence DR, Mattie H, et al, “Modification by Monoamine Oxidase Inhibitors of the Effect of Some Sympathomimetics on Blood Pressure,” <i>Br Med J</i>, 1967, 2:75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6020852\">[PubMed 6020852]</a></p>\n<p>5. Amrein R, Guntert TW, Dingemanse J, et al, “Interactions of Moclobemide With Concomitantly Administered Medication: Evidence From Pharmacological and Clinical Studies,” <i>Psychopharmacology</i>, 1992, 106:S24-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1546135\">[PubMed 1546135]</a></p>\n<p>6. Horler AR and Wynne NA, “Hypertensive Crisis Due to Pargyline and Metaraminol,” <i>Br Med J</i>, 1965, 2:460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14314914\">[PubMed 14314914]</a></p>\n<p>7. Dingemanse J, “An Update of Recent Moclobemide Interaction Data,” <i>Int Clin Psychopharmacol</i>, 1993, 7:167-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8468439\">[PubMed 8468439]</a></p>\n<p>8. Dingemanse J, Guentert T, Gieschke R, et al, “Modification of the Cardiovascular Effects of Ephedrine by the Reversible Monoamine Oxidase A-Inhibitor Moclobemide,” <i>J Cardiovasc Pharmacol</i>, 1996, 28:856-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8961085\">[PubMed 8961085]</a></p>\n<p>9. Wright SP, “Hazards With Monoamine Oxidase Inhibitors: A Persistent Problem,” <i>Lancet</i>, 1978, i:284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=74715\">[PubMed 74715]</a></p>\n<p>10. Low-Beer GA and Tidmarsh D, “Collapse After Parstelin,” <i>Br Med J</i>, 1963, 2:683. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14056938\">[PubMed 14056938]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3177":"<p><b>Title</b> Methadone / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Methadone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for symptoms of methadone withdrawal upon starting phenytoin. Likewise, monitor for excess sedation upon discontinuation of phenytoin.</p> \n<p><b>Discussion</b> An analysis of 43 patients receiving methadone for treatment of heroin addiction who had withdrawal symptoms found that 10 of these patients had low serum methadone trough (i.e., minimum serum concentration, Cmin) concentrations associated with concurrent use of metabolism-inducing medications, including 4 patients who were receiving concurrent phenytoin therapy.<sup>1</sup> Another 5 patients demonstrated withdrawal symptoms within 3-4 days of initiating phenytoin; methadone serum concentrations were decreased approximately 60%.<sup>2</sup> Another similar case report is also published.<sup>3</sup> The mechanism of this interaction is likely due to the ability of phenytoin to induce the hepatic metabolism of methadone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bell J, Seres V, Bowron P, et al, “The Use of Serum Methadone Levels in Patients Receiving Methadone Maintenance,” <i>Clin Pharmacol Ther</i>, 1988, 43:623-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3378383\">[PubMed 3378383]</a></p>\n<p>2. Tong TG, Pond SM, Kreek MJ, et al, “Phenytoin-Induced Methadone Withdrawal,” <i>Ann Intern Med</i>, 1981, 94:349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7224382\">[PubMed 7224382]</a></p>\n<p>3. Finelli PF, “Phenytoin and Methadone Tolerance,” <i>N Engl J Med</i>, 1976, 294:227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1244546\">[PubMed 1244546]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3178":"<p><b>Title</b> Methadone / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Seek alternatives to rifamyciin derivatives in methadone treated patients. If used concomitantly, monitor closely for symptoms of methadone withdrawal upon rifamycin derivative initiation, and for excess sedation upon rifamycin derivative discontinuation. In order of expected potency/risk: rifampin &gt; rifapentine &gt; rifabutin.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> RifAMPin*, Rifapentine<br><b>Exception</b> Rifabutin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Symptoms of methadone withdrawal developed in 21 of 30 patients within 1-33 days of initiating rifampin (600-900 mg/day).<sup>1</sup> Other similar cases have been reported with patients requiring significant methadone dosage increases to maintain adequate treatment.<sup>2,3,4,5</sup> In contrast, rifabutin had minimal effect on methadone therapy in 24 patients, and therefore appears to be of less clinical concern.<sup>6</sup> <br><br>In a clinical study of 11 healthy volunteers, rifampin pretreatment (600 mg orally daily for 5 days prior to methadone) decreased AUCs of oral and intravenous methadone to roughly 23% and 32%, respectively.<sup>7</sup> <br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP2B6 mediated methadone metbolism.<sup>7,8</sup> Induction of CYP2C19 and 3A4 mediated methadone metabolism may play a role in this interaction as well.<sup>7,8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kreek MJ, Garfield JN, Gutjahr CL, et al, “Rifampin-Induced Methadone Withdrawal,” <i>N Engl J Med</i>, 1976, 294:1104-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1256526\">[PubMed 1256526]</a></p>\n<p>2. Bending MR and Skacel PO, “Rifampin and Methadone Withdrawal,” <i>Lancet</i>, 1977, i:1211. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=68314\">[PubMed 68314]</a></p>\n<p>3. Holmes VF, “Rifampin-Induced Methadone Withdrawal in AIDS,” <i>J Clin Psychopharmacol</i>, 1990, 10:443-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2286719\">[PubMed 2286719]</a></p>\n<p>4. Raistrick D, Hay Al, and Wolff K, “Methadone Maintenance and Tuberculosis Treatment,” <i>BMJ</i>, 1996, 313(7062):925-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8876100\">[PubMed 8876100]</a></p>\n<p>5. Brockmeyer NH, Mertins L and Goos M, “Pharmacokinetic Interaction of Antimicrobial Agents with Levomethadon in Drug-Addicted AIDS Patients,” <i>Klin Wochenschr</i>, 1991, 69(1):16-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2016843\">[PubMed 2016843]</a></p>\n<p>6. Brown LS, Sawyer RC, Li R, et al, “Lack of a Pharmacological Interaction Between Rifabutin and Methadone in HIV-Infected Former Injecting Drug Users,” <i>Drug Alcohol Depend</i>, 1996, 43:71-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8957145\">[PubMed 8957145]</a></p>\n<p>7. Kharasch ED, Hoffer C, Whittington D, et al, “Role of Hepatic and Intestinal Cytochrome P450 3A and 2B6 in the Metabolism, Disposition, and Miotic Effects of Methadone,” <i>Clin Pharmacol Ther</i>, 2004, 76(3):250-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15371986\">[PubMed 15371986]</a></p>\n<p>8. Totah RA, Allen KE, Sheffels P, et al, “Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism,” <i>J Pharmacol Exp Ther</i>, 2007, 321(1):389-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17259447\">[PubMed 17259447]</a></p>\n<p>9. Gerber JG, Rhodes RJ and Gal J, “Stereoselective Metabolism of Methadone N-Demethylation by Cytochrome P4502B6 and 2C19,” <i>Chirality</i>, 2004, 16(1):36-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14628297\">[PubMed 14628297]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3180":"<p><b>Title</b> Methotrexate / Proton Pump Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The clinical significance of this interaction may be lower with the typically lower antirheumatic methotrexate doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may increase the serum concentration of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased methotrexate toxicity (eg, mucositis, myalgias, etc) and/or delayed methotrexate elimination if a proton pump inhibitor (PPI) is used concomitantly. The use of methotrexate in antirheumatic doses likely carries less risk for significant toxicity than its use in larger doses for antineoplastic purposes.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole*, Pantoprazole*, RABEprazole, Revaprazan</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Published case reports describe patients who experienced altered methotrexate pharmacokinetics (ie, increased concentrations and/or delayed elimination) and/or excessive toxicities associated with concurrent methotrexate and the proton pump inhibitors (PPIs) omeprazole, esomeprazole, or pantoprazole.<sup>1,2,3,4,5,6,7</sup> In most of these cases, the abnormal methotrexate concentrations/elimination were not evident with prior or subsequent administration of methotrexate without the concurrent PPI.<sup>1,2,3,4,5</sup><br><br>Concurrent use of a PPI (pantoprazole, lansoprazole, omeprazole, or esomeprazole) was significantly associated with delayed methotrexate elimination in a retrospective cohort study of 79 patients and 197 methotrexate cycles (OR = 6.66).<sup>8</sup> Of the 32 cycles with delayed methotrexate elimination, concurrent PPIs were used in 53%. In comparison, concurrent PPIs were only used in 15% (24/165) of the cycles without delayed methotrexate elimination. Similarly, a study of 74 patients and 171 methotrexate cycles concluded that concurrent use of omeprazole, lansoprazole, rabeprazole, or pantoprazole was a significant risk factor for delayed methotrexate elimination.<sup>9</sup> Finally, a retrospective analysis of impact of PPIs on 73 cycles of high dose methotrexate showed that patients who received a PPI with methotrexate had significantly higher methotrexate levels and were more likely to have a longer methotrexate infusion time compared to patients who did not receive a PPI.<sup>10</sup><br><br>In contrast to the above reports and studies, one published case report describes a patient who experienced elevated methotrexate concentrations with concurrent omeprazole, but in whom the elevated methotrexate concentrations remained apparent during subsequent cycles despite omeprazole discontinuation.<sup>11</sup> Also, methotrexate pharmacokinetics were not significantly changed by concurrent lansoprazole (30 mg/day) and naproxen (500 mg twice/day) in a study of 27 patients with rheumatoid arthritis who were receiving stable methotrexate therapy.<sup>12</sup> In a retrospective review of medical records of 56 patients who received 201 cycles of high intravenous doses of methotrexate (at least 1 g/m<sup>2</sup> over 3-4 hours or 200 mg/m<sup>2</sup> bolus followed by 800 mg/m<sup>2</sup> infusion over 22-24 hours), delayed methotrexate elimination was not associated with PPI use in unadjusted or adjusted analyses (adjusted for repeated measures and numerous other variables).<sup>13</sup> In a retrospective analysis of 73 patients receiving their first high intravenous methotrexate dose (at least 1 g/m<sup>2</sup>), patients identified as having delayed methotrexate elimination were more likely to have been coprescribed a PPI than patients not having delayed methotrexate elimination (48% vs 38%) but this difference was not statistically different.<sup>14</sup> Finally, in a clinical study investigating the use of PPIs as potential chemosensitizing agents in patients receiving methotrexate, cisplatin, and doxorubicin for osteosarcoma treatment, only 3 of 98 patients receiving this combination were identified as having delayed methotrexate elimination.<sup>15</sup> <br><br>The mechanism for this possible interaction is uncertain, but possible mechanisms have been proposed. Methotrexate is actively secreted in the distal renal tubules with hydrogen ions produced via the hydrogen/potassium ATPase pump. Proton pump inhibitors, by inhibiting renal elimination of the hydrogen ion, may inhibit methotrexate elimination. Other data from in vitro and animal studies support at least some role for PPI-mediated inhibition of the breast cancer resistance protein (BCRP, ABCG2) and/or MRP2 transporters.<sup>9,16</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. <i>Cancer Chemother Pharmacol</i>.1993;33(1):82-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8269594\">[PubMed 8269594]</a></p>\n<p>2. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. <i>Ann Pharmacother</i>. 2000;34(9):1024-1027. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10981249\">[PubMed 10981249]</a></p>\n<p>3. Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. <i>BMJ</i>. 2002;324(7352):1497. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12077038\">[PubMed 12077038]</a></p>\n<p>4. Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. <i>Anticancer Res</i>. 2010;30(3):963-965. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20393020\">[PubMed 20393020]</a></p>\n<p>5. McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. <i>J Pharm Pract</i>. 2012;25(4):477-485. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22550162\">[PubMed 22550162]</a></p>\n<p>6. Bauters TG, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. <i>Pharm World Sci</i>. 2008;30(4):316-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18386155\">[PubMed 18386155]</a></p>\n<p>7. Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? <i>Chemotherapy</i>. 2011;57(3):225-229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21597286\">[PubMed 21597286]</a></p>\n<p>8. Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. <i>Anticancer Res</i>. 2010;30(9):3807-3810. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20944174\">[PubMed 20944174]</a></p>\n<p>9. Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. <i>Br J Clin Pharmacol</i>. 2009;67(1):44-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076159\">[PubMed 19076159]</a></p>\n<p>10. Narumi K, Sato Y, Kobayashi M, et al. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug-drug interactions mediated by organic anion transporter 3. <i>Biopharm Drug Dispos</i>. 2017; Aug 12 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28801980\">[PubMed 28801980]</a></p>\n<p>11. Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate clearance. <i>Cancer Chemother Pharmacol</i>. 1999;44(1):88-89. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10367754\">[PubMed 10367754]</a></p>\n<p>12. Vakily M, Amer F, Kukulka MJ, Andhivarothai N. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. <i>J Clin Pharmacol</i>. 2005;45(10):1179-1186. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16172183\">[PubMed 16172183]</a></p>\n<p>13. Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors [published online March 20, 2014]. <i>Br J Clin Pharmacol</i>. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24646036\">[PubMed 24646036]</a></p>\n<p>14. Chan AJ, Rajakumar I. High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity. <i>J Oncol Pharm Pract</i>. 2014;20(2):93-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23698198\">[PubMed 23698198]</a></p>\n<p>15. Ferrari S, Perut F, Fagioli F, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. <i>J Transl Med</i>. 2013;11:268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24156349\">[PubMed 24156349]</a></p>\n<p>16. Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. <i>Cancer Res</i>. 2004;64(16):5804-5811. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15313923\">[PubMed 15313923]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3182":"<p><b>Title</b> Amantadine / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor for signs and symptoms of myoclonus, delirium, or other neurological complications (e.g., abnormal gait) during concomitant administration of amantadine and trimethoprim. If symptoms develop, discontinuation or dose reduction of one or both agents may be necessary. Patients with impaired renal function may be at greater risk for these adverse effects.</p> \n<p><b>Discussion</b> An 84 year old man receiving amantadine (100 mg twice daily for 2 years) for Parkinson’s disease developed mental confusion, cogwheel rigidity, resting tremor, and combativeness 72 hours after the addition of trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg orally twice daily) to treat bronchitis.<sup>1</sup> Within 24 hours of discontinuing both agents, the patient’s mental status returned to normal. Similar adverse events have been reported with use of the related compound memantine in conjunction with TMP/SMX and TMP alone.<sup>2</sup> <br><br>The mechanism(s) for this proposed interaction is (are) unclear, but several possibilities exist. As proposed in the case report, competition for renal transport sites within the proximal tubule, with a subsequent rise in serum concentrations of either agent, may be responsible.<sup>1</sup> Both amantadine and trimethoprim undergo renal clearance via active tubular secretion,<sup>3,4,</sup> and both are substrates for organic cation transporter-2 (OCT2),<sup>5,6,7</sup> resulting in an opportunity for an interaction to occur.<br><br>Another possible mechanism involves a pharmacodynamic explanation, considering that amantadine<sup>8</sup> and memantine<sup>9</sup> both have been reported to cause myoclonus (independent of a known drug-drug interaction) as has TMP/SMX.<sup>10</sup> Additionally, decreased dopamine levels as a result of trimethoprim therapy could possibly contribute to motor function impairment with subsequent adverse events. An additional possible mechanism to consider is a drug-disease interaction, whereby alkalinization of the urine by bacteria (i.e., urinary tract infection, or even asymptomatic bacturia) results in impaired clearance and increased serum concentrations of amantadine, whose clearance is significantly decreased with increased urine pH.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Speeg KV, Leighton JA, and Maldonodo AL, “Case Report: Toxic Delirium in a Patient Taking Amantadine and Trimethoprim-Sulfamethoxazole,” <i>Am J Med Sci</i>, 1989, 298:410-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2596498\">[PubMed 2596498]</a></p>\n<p>2. Moellentin D, Picone C, Leadbetter E, “Memantine-Induced Myoclonus and Delirium Exacerbated by Trimethoprim,” <i>Ann Pharmacother</i>, 2008, 42:443-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18303133\">[PubMed 18303133]</a></p>\n<p>3. Prescribing Information. Amantadine. Chadds Ford, PA: Endo Pharmaceuticals, Inc., March 2003.</p>\n<p>4. Prescribing Information. Proloprim (trimethoprim). Bristol, TN: Monarch Pharmaceuticals, Inc., February 2005.</p>\n<p>5. Drug development and drug interactions: table of substrates, inhibitors, and inducers. Table 11. http://www.fda.gov/CDER/drug/druginteractions/tableSubstrates.htm (accessed 2009, January 16).</p>\n<p>6. Barnedt WM, Wright SH, “The Human Organic Cation Transporter (hOCT2) Recognizes the Degree of Substrate Ionization,” <i>J Biol Chem</i>, 2002, 277(25):22491-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11953440\">[PubMed 11953440]</a></p>\n<p>7. Urakami Y, Kimura N, Okuda M, et al, “Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney,” <i>Pharm Res</i>, 2004, 21(6):976-81. PubMed 15212162]</p>\n<p>8. Nakata M, Shoichi I, Wakako S, et al, “Severe Reversible Neurological Complications following Amantadine Treatment in Three Elderly Patients with Renal Insufficiency,” <i>Euro Neurol</i>, 2006, 56:59-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16921246\">[PubMed 16921246]</a></p>\n<p>9. Papageorgiou SG, Kontaxis T, Antelli A, et al, “Exacerbation of Myoclonus by Memantine in a Patient With Alzheimer Disease,” <i>J Clin Psychopharmacol</i>, 2007, 27(4):407-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17632233\">[PubMed 17632233]</a></p>\n<p>10. Dib EG, Bernstein S, Benesch C, “Multifocal Myoclonus Induced by Trimethoprim-Sulfamethoxazole Therapy in a Patient with Nocardia Infection,” <i>N Engl J Med</i>, 2004, 350(1):88-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14702438\">[PubMed 14702438]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3183":"<p><b>Title</b> Methotrexate / Sulfonamide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sulfonamide Antibiotics may enhance the adverse/toxic effect of Methotrexate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential severity of this interaction, consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).</p>\n<div>\n <p><b>Sulfonamide Antibiotics Interacting Members</b> SulfADIAZINE, Sulfadoxine, Sulfamethoxazole*, SulfiSOXAZOLE</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe the development of severe toxicity (including bone marrow suppression and immunologic reactions, at times fatal) in patients taking as little as 7.5 mg of methotrexate weekly with trimethoprim/sulfamethoxazole.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15</sup> <br><br>The mechanism of this interaction is unknown, and it is not clear whether the interaction may be dependent on trimethoprim, sulfamethoxazole, or the combination. Trimethoprim/sulfamethoxazole appears to increase the concentration of free (unbound) methotrexate by approximately 30%, and reduces its excretion by approximately one-half.<sup>16</sup> However, one study failed to demonstrate any pharmacokinetic interaction.<sup>17</sup> Both trimethoprim/sulfamethoxazole and methotrexate can contribute to folate deficiency (via suppression of dihydrofolate reductase) which could affect bone marrow activity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thomas MH and Gutterman LA, “Methotrexate Toxicity in a Patient Receiving Trimethoprim-Sulfamethoxazole,” <i>J Rheumatol</i>, 1986, 13:440-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3487652\">[PubMed 3487652]</a></p>\n<p>2. Kobrinsky NL and Ramsay NKC, “Acute Megaloblastic Anaemia Induced by High Dose Trimethoprim-Sulfamethoxazole,” <i>Ann Intern Med</i>, 1981, 94:780-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6972183\">[PubMed 6972183]</a></p>\n<p>3. Maricic M, Davis M, and Gall EP, “Megaloblastic Pancytopenia in a Patient Receiving Concurrent Methotrexate and Trimethoprim-Sulphamethoxazole Treatment,” <i>Arthritis Rheum</i>, 1986, 29:133-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3484954\">[PubMed 3484954]</a></p>\n<p>4. Jeurissen ME, Boerbooms AM, and van de Putte LB, “Pancytopenia and Methotrexate with Trimethoprim-Sulfamethoxazole,” <i>Ann Intern Med</i>, 1989, 111:261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2787612\">[PubMed 2787612]</a></p>\n<p>5. Govert JA, Patton S, and Fine RL, “Pancytopenia From Using Trimethoprim and Methotrexate,” <i>Ann Intern Med</i>, 1992, 117:877-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1416570\">[PubMed 1416570]</a></p>\n<p>6. Steuer A and Gumpel JM, “Methotrexate and Trimethoprim: A Fatal Interaction,” <i>Br J Rheumatol</i>, 1998, 37:105-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9487262\">[PubMed 9487262]</a></p>\n<p>7. Chevrel G, Brantus JF, Sainte-Laudy J, et al, “Allergic Pancytopenia to Trimethoprim-Sulphamethoxazole for Pneumocystis Carinii Pneumonia following Methotrexate Treatment for Rheumatoid Arthritis,” <i>Rheumatology (Oxford)</i>, 1999, 38(5):475-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10371291\">[PubMed 10371291]</a></p>\n<p>8. Thomas DR, Dover JS and Camp RD, “Pancytopenia Induced by the Interaction between Methotrexate and Trimethoprim-Sulfamethoxazole,” <i>J Am Acad Dermatol</i>, 1987, 1055-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3501437\">[PubMed 3501437]</a></p>\n<p>9. Yang CH, Yang LJ, Jaing TH, et al, “Toxic Epidermal Necrolysis following Combination of Methotrexate and Trimethoprim-Sulfamethoxazole,” <i>Int J Dermatol</i>, 2000, 39(8):621-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10971734\">[PubMed 10971734]</a></p>\n<p>10. Dan M and Shapira I, “Possible Role of Methotrexate in Trimethoprim-Sulfamethoxazole-Induced Acute Megaloblastic Anemia,” <i>Isr J Med Sci</i>, 1984, 20(3):262-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6724876\">[PubMed 6724876]</a></p>\n<p>11. Frain JB, “Methotrexate Toxicity in a Patient Receiving Trimethoprim-Sulfamethoxazole,” <i>J Rheumatol</i>, 1987, 14(1):176-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3494846\">[PubMed 3494846]</a></p>\n<p>12. Groenendal H and Rampen FH, “Methotrexate and Trimethoprim-Sulphamethoxazole--A Potentially Hazardous Combination,” <i>Clin Exp Dermatol</i>, 1990, 15(5):358-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2225539\">[PubMed 2225539]</a></p>\n<p>13. Ng HW, Macfarlane AW, Graham RM, et al, “Near Fatal Drug Interactions with Methotrexate Given for Psoriasis,” <i>Br Med J (Clin Res Ed)</i>, 1987, 295(6601):752-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3119023\">[PubMed 3119023]</a></p>\n<p>14. Blatt J, Howrie DL, Wollman MR, et al, “Toxicity following Concurrent Intrathecal and Moderate-Dose Intravenous Methotrexate,” <i>Leukemia</i>, 1993, 7(11):1734-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8231243\">[PubMed 8231243]</a></p>\n<p>15. Ferrazzini G, Klein J, Sulh H, et al, “Interaction Between Trimethoprim-Sulfamethoxazole and Methotrexate in Children With Leukaemia,” <i>J Pediatr</i>, 1990, 117:823-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2231218\">[PubMed 2231218]</a></p>\n<p>16. Beach BJ, Woods WG, and Howell SB, “Influence of Co-trimoxazole on Methotrexate Pharmacokinetics in Children With Acute Lymphoblastic Leukaemia,” <i>Am J Pediatr Hematol Oncol</i>, 1981, 3:115-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6975580\">[PubMed 6975580]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3184":"<p><b>Title</b> Methotrexate / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Trimethoprim may enhance the adverse/toxic effect of Methotrexate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential severity of this interaction, consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).</p> \n<p><b>Discussion</b> A number of case reports describe the development of methotrexate-associated toxicity (e.g., bone marrow suppression, at times fatal) in patients taking as little as 10 mg of methotrexate weekly and trimethoprim-sulfamethoxazole (TMP-SMX).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14</sup> Additionally, results of a practitioner survey identified concomitant treatment with TMP-SMX as a possible risk factor for methotrexate-associated pancytopenia.<sup>15</sup><br><br>The mechanism of the interaction is unclear. TMP-SMX may increase the concentration of free (unbound) methotrexate by approximately 30% and reduce its excretion by approximately one-half.<sup>16</sup> However, one study failed to demonstrate any pharmacokinetic interaction.<sup>17</sup> Both TMP-SMX and methotrexate can contribute to folate deficiency (via suppression of dihydrofolate reductase) which might affect bone marrow activity. Whether the presumed interaction is due to a single component of TMP-SMX or the combination is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thomas MH and Gutterman LA, “Methotrexate Toxicity in a Patient Receiving Trimethoprim-Sulfamethoxazole,” <i>J Rheumatol</i>, 1986, 13:440-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3487652\">[PubMed 3487652]</a></p>\n<p>2. Kobrinsky NL and Ramsay NK, “Acute Megaloblastic Anaemia Induced by High Dose Trimethoprim-Sulfamethoxazole,” <i>Ann Intern Med</i>, 1981, 94:780-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6972183\">[PubMed 6972183]</a></p>\n<p>3. Maricic M, Davis M and Gall EP, “Megaloblastic Pancytopenia in a Patient Receiving Concurrent Methotrexate and Trimethoprim-Sulphamethoxazole Treatment,” <i>Arthritis Rheum</i>, 1986, 29:133-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3484954\">[PubMed 3484954]</a></p>\n<p>4. Jeurissen ME, Boerbooms AM and van de Putte LB, “Pancytopenia and Methotrexate With Trimethoprim-Sulfamethoxazole,” <i>Ann Intern Med</i>, 1989, 111:261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2787612\">[PubMed 2787612]</a></p>\n<p>5. Govert JA, Patton S and Fine RL, “Pancytopenia From Using Trimethoprim and Methotrexate,” <i>Ann Intern Med</i>, 1992, 117:877-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1416570\">[PubMed 1416570]</a></p>\n<p>6. Steuer A and Gumpel JM, “Methotrexate and Trimethoprim: A Fatal Interaction,” <i>Br J Rheumatol</i>, 1998, 37:105-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9487262\">[PubMed 9487262]</a></p>\n<p>7. Yang CH, Yang LJ,Jaing TH, et al,“Toxic Epidermal Necrolysis Following Combination of Methotrexate and Trimethoprim-Sulfamethoxazole,”Int J Dermatol. 2000, 39(8):621-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10971734\">[PubMed 10971734]</a></p>\n<p>8. Chevrel G, Brantus JF, Sainte-Laudy J, et al, “Allergic Pancytopenia to Trimethoprim-Sulphamethoxazole for Pneumocystis Carinii Pneumonia Following Methotrexate Treatment for Rheumatoid Arthritis,” <i>Rheumatology (Oxford)</i>, 1999, 38(5):475-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10371291\">[PubMed 10371291]</a></p>\n<p>9. Thomas DR, Dover JS and Camp RD, “Pancytopenia Induced by the Interaction Between Methotrexate and Trimethoprim-Sulfamethoxazole,” <i>J Am Acad Dermatol</i>, 1989, 17(6):1055-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3501437\">[PubMed 3501437]</a></p>\n<p>10. Groenendal H and Rampen FH, “Methotrexate and Trimethoprim-Sulphamethoxazole--A Potentially Hazardous Combination,” <i>Clin Exp Dermatol</i>, 1990, 15(5):358-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2225539\">[PubMed 2225539]</a></p>\n<p>11. Ng HW, Macfarlane AW, Graham RM, et al, “Near Fatal Drug Interactions With Methotrexate Given for Psoriasis,” <i>Br Med J (Clin Res Ed)</i>, 1987, 295(6601):752-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3119023\">[PubMed 3119023]</a></p>\n<p>12. Saravana S and Lalukotta K, “Myelotoxicity due to Methotrexate - An Iatrogenic Cause,” <i>Eur J Haematol</i>, 2003, 71(4):315-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12950246\">[PubMed 12950246]</a></p>\n<p>13. Frain JB, “Methotrexate Toxicity in a Patient Receiving Trimethoprim-Sulfamethoxazole,” <i>J Rheumatol</i>, 1987, 14(1):176-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3494846\">[PubMed 3494846]</a></p>\n<p>14. Dan M and Shapira I, “Possible Role of Methotrexate in Trimethoprim-Sulfamethoxazole-Induced Acute Megaloblastic Anemia,” <i>Isr J Med Sci</i>, 1984, 20(3):262-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6724876\">[PubMed 6724876]</a></p>\n<p>15. al-Awadhi A, Dale P and McKendry RJ, “Pancytopenia Associated With Low Dose Methotrexate Therapy. A Regional Survey,” <i>J Rheumatol</i>, 1993, 20(7):1121-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8371202\">[PubMed 8371202]</a></p>\n<p>16. Ferrazzini G, Klein J, Sulh H, et al, “Interaction Between Trimethoprim-Sulfamethoxazole and Methotrexate in Children With Leukaemia,” <i>J Pediatr</i>, 1990, 117:823-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2231218\">[PubMed 2231218]</a></p>\n<p>17. Beach BJ, Woods WG and Howell SB, “Influence of Co-trimoxazole on Methotrexate Pharmacokinetics in Children With Acute Lymphoblastic Leukaemia,” <i>Am J Pediatr Hematol Oncol</i>, 1981, 3:115-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6975580\">[PubMed 6975580]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3185":"<p><b>Title</b> Beta-Blockers / Propafenone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propafenone may increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic/toxic effects of beta-blockers if propafenone is initiated/dose increased, or decreased effects if propafenone is discontinued/dose decreased. Beta-blockers undergoing limited hepatic metabolism, and those intended for ophthalmic administration, would not likely be of concern. Propafenone also possesses some independent beta-blocking activity.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol*, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Atenolol, Carteolol (Ophthalmic), Levobunolol, Metipranolol, Nadolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Steady state serum metoprolol concentrations (150-200 mg/day) increased two- to fivefold in 4 patients receiving concomitant propafenone (150 mg 3 times/day).<sup>1</sup> Metoprolol side effects were increased. Propafenone pharmacokinetics were unaltered by metoprolol in 4 other patients.<sup>1</sup> The AUC of propranolol (50 mg every 8 hours) was increased approximately twofold in 12 normal subjects receiving concomitant propafenone (225 mg/day).<sup>2</sup> No changes in propafenone pharmacokinetics were observed. It is likely that propafenone decreases the CYP2D6 metabolism of the beta-blockers, thus increasing their serum concentrations. Propafenone possesses some independent beta-blocking activity.<br><br>Manufacturer's labeling reports a 200% increase in propafenone AUC with co-administration of propranolol.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wagner F, Kalusche D, Trenk D, et al, “Drug Interaction Between Propafenone and Metoprolol,” <i>Br J Clin Pharmacol</i>, 1987, 24:213-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3620296\">[PubMed 3620296]</a></p>\n<p>2. Kowey PR, Kirsten EB, Fu CH, et al, “Interaction Between Propranolol and Propafenone in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 1989, 29:512-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2754020\">[PubMed 2754020]</a></p>\n<p>3. Prescribing information. Inderal LA (propranolol). Philadelphia, PA. Wyeth Pharmaceuticals, Inc., 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3188":"<p><b>Title</b> Beta-Blockers / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of beta-blockers if rifampin is initiated/dose increased, or increased effects if rifampin is discontinued/dose decreased. An increased dose of the beta-blocker will likely be needed following rifampin initiation. Beta-blockers undergoing limited hepatic metabolism, and those intended for ophthalmic administration, would not likely be of concern.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol*, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Atenolol, Carteolol (Ophthalmic), Levobunolol, Metipranolol, Nadolol</p>\n <p><b>Rifamycin Derivatives Interacting Members</b> RifAMPin*, Rifapentine<br><b>Exception</b> Rifabutin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of metoprolol (100 mg single dose) was decreased by 40% (and the peak serum concentration by 33%) in 10 normal subjects when administered following a 15-day course of rifampin (600 mg/day).<sup>1</sup> The AUC of bisoprolol were decreased by 34% in normal subjects during concomitant rifampin therapy.<sup>2</sup> The clearance of propranolol has been increased as much as 300% following 3 weeks of concomitant rifampin therapy.<sup>3,4</sup> Pharmacodynamic effects coinciding with the pharmacokinetic changes are unknown. It would seem that the extent of change would be sufficient to cause reductions in beta-blocker effects. Rifampin likely induces the metabolism of the beta blockers, however, specific information regarding this mechanism is not available. Beta-blockers undergoing limited hepatic metabolism would not likely be of concern.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bennett PN, John VA, Witmarsh VB, et al, “Effects of Rifampicin on Metoprolol and Antipyrine Kinetics,” <i>Br J Clin Pharmacol</i>, 1982, 13:387. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7059439\">[PubMed 7059439]</a></p>\n<p>2. Kirch W, Rose I, Klingmann I, et al, “Interaction of Bisoprolol With Cimetidine and Rifampicin,” <i>Eur J Clin Pharmacol</i>, 1986, 31:59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2877885\">[PubMed 2877885]</a></p>\n<p>3. Herman RJ, Nakamura K, Wilkinson GR, et al, “Induction of Propranolol Metabolism by Rifampicin,” <i>Br J Clin Pharmacol</i>, 1983, 16:565-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6639842\">[PubMed 6639842]</a></p>\n<p>4. Shaheen O, Biollaz J, Koshakji RP, et al, “Influence of Debrisoquin Phenotype on the Inducibility of Propranolol Metabolism,” <i>Clin Pharmacol Ther</i>, 1989, 45:439-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2702801\">[PubMed 2702801]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3190":"<p><b>Title</b> MetyraPONE / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of MetyraPONE. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The results of the metyrapone test (using standard dosing) will be unreliable in patients receiving phenytoin. Doubling the dosage of metyrapone (750 mg every 2 hours) has been shown to provide near-normal results.</p> \n<p><b>Discussion</b> Serum metyrapone concentrations (750 mg oral) in 3 phenytoin-treated patients were only 14% of the concentrations achieved in 5 normal subjects.<sup>1</sup> The corticosteroid response was similarly reduced. Another report confirms this interaction.<sup>2</sup> Under such circumstances, the results of the test are unreliable. The initial report demonstrated that doubling the dosage (by administering 750 mg every 2 hours instead of every 4 hours) may give results similar to patients not receiving phenytoin.<sup>1</sup> The likely mechanism of this interaction is related to the ability of phenytoin to induce the metabolism of metyrapone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Meikle AW, Jubiz W, Matsukura S, et al, “Effect of Diphenylhydantoin on the Metabolism of Metyrapone and Release of ACTH in Man,” <i>J Clin Endoncrinol Metab</i>, 1969, 29:1553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4310497\">[PubMed 4310497]</a></p>\n<p>2. Werk EE, Thrasher K, Choi Y, et al, “Failure of Metyrapone to Inhibit 11-Hydroxylation of 11-Deoxycortisol During Drug Therapy,” <i>J Clin Endocrinol</i>, 1967, 27:1358. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4292251\">[PubMed 4292251]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3191":"<p><b>Title</b> Mexiletine / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Mexiletine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of mexiletine if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The mean AUC and half-life of mexiletine (single 400 mg dose) were decreased by 55% and 51%, respectively, in 6 healthy volunteers when administered following seven days of phenytoin (300 mg/daily).<sup>1</sup> The magnitude of this pharmacokinetic effect was judged to be likely to result in clinically important changes in mexiletine response.<br><br>The mechanism of this interaction is uncertain, but given the ability of phenytoin to induce several drug metabolizing enzymes and the fact that mexiletine is extensively metabolized (via CYP2D6 and CYP1A2),<sup>2</sup> phenytoin-mediated induction of mexiletine metabolism is a likely mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Begg EJ, Chinwah PM, Webb C, et al, “Enhanced Metabolism of Mexiletine After Phenytoin Administration,” <i>Br J Clin Pharmacol</i>, 1982, 14:219-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7104173\">[PubMed 7104173]</a></p>\n<p>2. Prescribing information. Mexitil (mexiletine). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 05/30/03.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3192":"<p><b>Title</b> Theophylline Derivatives / Mexiletine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mexiletine may decrease the metabolism of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> The dosage of theophylline will likely have to be reduced (by as much as 50%) within a few days of initiating mexiletine therapy. An empiric reduction may be considered. Monitor for toxic effects of theophylline if mexiletine is initiated/dose increased, and decreased effects if mexiletine is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of an infusion of theophylline (5 mg/kg) was decreased by more than 40% in 15 normal subjects when administered following a 5-day course of mexiletine (600 mg/day).<sup>1,2</sup> Similar reports documenting changes in theophylline clearance and half-life have been published.<sup>3,4,5</sup> A theophylline-stable patient developed symptoms of theophylline toxicity, and an approximate 60% increase in serum theophylline concentrations, within a few days of initiating mexiletine therapy (200 mg 3 times/day).<sup>6</sup> Other similar cases have been published.<sup>7,8,9</sup> Mexiletine is an inhibitor of CYP1A2, the primary metabolizing isoenzyme for theophylline.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Loi CM and Vestal RE, “Effect of Mexiletine on Theophylline Metabolism,” <i>Clin Pharmacol Ther</i>, 1990, 47:130.</p>\n<p>2. Loi CM, Wei X, and Vestal RE, “Inhibition of Theophylline Metabolism by Mexiletine in Young Male and Female Nonsmokers,” <i>Clin Pharmacol Ther</i>, 1991, 49:571-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2029830\">[PubMed 2029830]</a></p>\n<p>3. Gannon JM, Mohiuddin SM, Destache CJ, et al, “Interaction Between Theophylline and Mexiletine,” <i>Clin Pharmacol Ther</i>, 1991, 49:142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1693023\">[PubMed 1693023]</a></p>\n<p>4. Stoysich AM, Mohiuddin SM, Destache CJ, et al, “Influence of Mexiletine on the Pharmacokinetics of Theophylline in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 1991, 31:354-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2037708\">[PubMed 2037708]</a></p>\n<p>5. Hurwitz A, Vacek JL, Botteron GW, et al, “Mexiletine Effects on Theophylline Disposition,” <i>Clin Pharmacol Ther</i>, 1991, 50:299-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1914365\">[PubMed 1914365]</a></p>\n<p>6. Katz A, Buskila D, and Sukenik S, “Oral Mexiletine-Theophylline Interaction,” <i>Int J Cardiol</i>, 1987, 17:227-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3679607\">[PubMed 3679607]</a></p>\n<p>7. Kessler KM, Interian A, Cox M, et al, “Proarrhythmia Related to a Kinetic and Dynamic Interaction of Mexiletine and Theophylline,” <i>Am Heart J</i>, 1989, 117:964-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2929410\">[PubMed 2929410]</a></p>\n<p>8. Stanley R, Comer T, and Taylor JL, “Mexiletine-Theophylline Interaction,” <i>Am J Med</i>, 1989, 86:733-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2729333\">[PubMed 2729333]</a></p>\n<p>9. Kendall JD, Chrymko MM, and Cooper BE, “Theophylline-Mexiletine Interaction: A Case Report,” <i>Pharmacotherapy</i>, 1992, 12:416-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1437703\">[PubMed 1437703]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3193":"<p><b>Title</b> Serotonin 5-HT1D Receptor Agonists / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The use of interacting serotonin 5-HT1D receptor agonists and monoamine oxidase-A inhibitors (and nonselective MAO inhibitors) should be avoided. The manufacturers of rizatriptan, sumatriptan, and zolmitriptan state that concurrent use (or use within 2 weeks of MAO therapy) is contraindicated. If inadvertently used concomitantly, monitor for evidence of serotonin 5-HT1D receptor agonist toxicity. In general, furazolidone, linezolid, tedizolid, and procarbazine might pose less risk than isocarboxazid, phenelzine, or tranylcypromine, but are probably also best avoided. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity and should also be avoided.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide*, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n <p><b>Serotonin 5-HT1D Receptor Agonists Interacting Members</b> Almotriptan, Rizatriptan*, SUMAtriptan*, ZOLMitriptan*<br><b>Exceptions</b> Eletriptan, Frovatriptan, Naratriptan</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC and C<sub>max</sub> of rizatriptan were increased 2.2-fold and 2.4-fold, respectively, in 12 healthy subjects when administered following a 4-day course of moclobemide (an MAO-A inhibitor).<sup>1</sup> The AUC and C<sub>max</sub> of rizatriptan's minor, but active, metabolite, were increased 5.3-fold and 2.6-fold, respectively. The metabolism of rizatriptan is dependent on MAO-A activity. Based on this and similar data regarding the metabolism of other serotonin 5-HT1D agonists, the manufacturers of rizatriptan, sumatriptan, and zolmitriptan have labeled these products as “contraindicated” during concurrent use of, or recent (within 2 weeks) use of, agents that inhibit MAO-A.<sup>2,3,4</sup> The MAO-B inhibitor, selegiline (when administered as an oral tablet in doses &lt;10 mg/day, or as an orally disintegrating tablet in doses &lt;2.5 mg/day), would not usually pose a problem. However, higher oral doses or transdermal administration of selegiline exhibit nonselective MAOI activity and would also be expected to enhance serotonergic activity of these agents. The manufacturer of naratriptan provides no evidence of concern regarding the potential for the agent to be affected by a MAO inhibitor, as the agent is either metabolized by CYP isoenzymes, or is excreted in the urine as unchanged drug.<sup>5</sup> Likewise, neither frovatriptan nor eletriptan appear to be metabolized by MAO.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. van Haarst AD, van Gerven JM, Cohen AF, et al, “The Effects of Moclobemide on the Pharmacokinetics of the 5-HT1D Agonist Rizatriptan in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 1997, 52(Suppl):A142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10417495\">[PubMed 10417495]</a></p>\n<p>2. Maxalt [package insert]. West Point, PA: Merck &amp; Co, Inc, 1999.</p>\n<p>3. Imitrex [package insert]. Research Triangle Park, NC: Glaxo Wellcome, 2000.</p>\n<p>4. Zomig [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2000.</p>\n<p>5. Amerge [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2000.</p>\n<p>6. Frova [package insert]. South San Francisco, CA: Elan Pharmaceuticals, 2001.</p>\n<p>7. Relpax [package insert]. New York, NY: Roerig, 2002.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3195":"<p><b>Title</b> Vitamin K Antagonists / Cephalosporins</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated INR and bleeding if a vitamin K antagonist is used in combination with cephalosporins. Cephalosporins that have an NMTT (1-MTT) side chain in their chemical structure may pose the greatest risk of interaction.</p>\n<div>\n <p><b>Cephalosporins Interacting Members</b> Cefaclor, Cefadroxil, Cefazedone, CeFAZolin*, Cefcapene, Cefdinir, Cefditoren, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime, CefoTEtan*, Cefotiam, CefOXitin*, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone*, Cefuroxime, Cephalexin, Cephalothin, Cephradine, Flomoxef</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Some cephalosporin antibiotics possess anticoagulant properties, and thus can both cause bleeding on their own and enhance the anticoagulant effects of oral anticoagulants.<sup>1,2,3,4</sup> Several case reports and clinical studies have described warfarin treated patients who experienced increases in PT/INR, with or without signs of bleeding, shortly after initiating treatment with a cephalosporin.<sup>5,6,7,8,9,10,11,12,13,14</sup> <br><br>Cephalosporins may act to enhance anticoagulant effects of vitamin K antagonists by one or more of the following mechanisms: 1) chemical structure contains an N-methylthiotetrazole (NMTT) side chain that acts as a vitamin K-antagonist in the production of vitamin K-dependent clotting factors (cefotetan); 2) cephalosporin-associated platelet inhibition; and/or 3) decreasing the population of gastrointestinal tract flora that serve as a minor source of vitamin K2. Prolonged exposure to beta-lactam antibiotics appears to cause irreversible platelet dysfunction by binding to the platelet membrane and inhibiting aggregation.<sup>15</sup> It is unclear to what degree bacterial vitamin K2 synthesis contributes to human nutrition.<sup>16,17</sup> Patients on broad-spectrum antibiotics for extended periods of time that are critically ill and/or have an inadequate diet should be monitored closely for signs/symptoms of bleeding and coagulopathies, and may require vitamin K supplementation.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wood TC, Johnson KL, Naylor S, et al, “Cefazolin Administration and 2-Methyl-1,3,4-Thiadiazole-5-Thiol in Human Tissue: Possible Relationship to Hypoprothrombinemia,” <i>Drug Metab Dispos</i>, 2002, 30(10):1123-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12228189\">[PubMed 12228189]</a></p>\n<p>2. Natelson EA, Brown CH, and Bradshaw MW, “Influence of Cephalosporin Antibiotics on Blood Coagulation and Platelet Function,” <i>Antimicrob Agents Chemother</i>, 1976, 9(1):91-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1259395\">[PubMed 1259395]</a></p>\n<p>3. Haubenstock A, Schmidt P, Zazgomik J, et al, “Hypoprothrombinaemic Bleeding Associated With Ceftriaxone,” <i>Lancet</i>, 1983, 1(8335):1215-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6134007\">[PubMed 6134007]</a></p>\n<p>4. Cazzola M, Santangelo G, Martucci P, et al, “An In Vitro Study of the Possible Interaction between Human Platelets and Cephalosporins,” <i>Int J Clin Pharmacol Res</i>, 1991;11(1):7-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1874581\">[PubMed 1874581]</a></p>\n<p>5. Brown RB, Klar J, Lemeshow S, et al, “Enhanced Bleeding With Cefoxitin or Moxalactam. Statistical Analysis Within a Defined Population of 1493 Patients,” <i>Arch Intern Med</i>, 1986, 146(11):2159-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3778044\">[PubMed 3778044]</a></p>\n<p>6. Angaran DM, Dias VD, Arom KV, et al, “The Comparative Influence of Prophylactic Antibiotics on the Prothrombin Response to Warfarin in the Postoperative Prosthetic Cardiac Valve Patients,” <i>Ann Surg</i>, 1987, 206(2):155-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3300580\">[PubMed 3300580]</a></p>\n<p>7. Chung AH, Watson K, “Cefazolin-Induced Hypoprothrombinemia,” <i>Am J Health Syst Pharm</i>, 2008, 65(9):823-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18436729\">[PubMed 18436729]</a></p>\n<p>8. O'Donnell D, “Hypoprothrombinaemia Associated with Use of Cephamandole,” <i>Aust N Z J Surg</i>, 1991, 61(6):471-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2059184\">[PubMed 2059184]</a></p>\n<p>9. Lerner PI and Lubin A, “Coagulopathy With Cefazolin in Uremia,” <i>N Engl J Med</i>, 1974, 290(23):1324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4827633\">[PubMed 4827633]</a></p>\n<p>10. Dupuis LL, Paton TW, Suttie JW, et al, “Cefazolin-Induced Coagulopathy,” <i>Clin Pharmacol Ther</i>, 1984, 35:237.</p>\n<p>11. Conjura A, Bell W, and Lipsky JJ, “Cefotetan and Hypoprothrombinemia,” <i>Ann Intern Med</i>, 1988, 108(4):643. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3162358\">[PubMed 3162358]</a></p>\n<p>12. Clark TR, Burns S, “Elevated International Normalized Ratio values associated with concomitant use of warfarin and ceftriaxone,” <i>Am J Health Syst Pharm</i>, 2011, 68(17):1603-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21856805\">[PubMed 21856805]</a></p>\n<p>13. Bohm NM, Crosby B, “Hemarthrosis in a Patient on Warfarin Receiving Ceftaroline: A Case Report and Brief Review of Cephalosporin Interactions with Warfarin,” <i>Ann Pharmacother</i>, 2012, 46(7-8):e19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22764328\">[PubMed 22764328]</a></p>\n<p>14. Farhat NM, Hutchinson LS, Peters M. Elevated international normalized ratio values in a patient receiving warfarin and ceftaroline. <i>Am J Health Syst Pharm</i>. 2016;73(2):56-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26721534\">[PubMed 26721534]</a></p>\n<p>15. Burroughs SF, Johnson GJ, “Beta-Lactam Antibiotic-Induced Platelet Dysfunction: Evidence for Irreversible Inhibition of Platelet Activation In Vitro and In Vivo After Prolonged Exposure to Penicillin,” <i>Blood</i>, 1990, 75(7):1473-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2180496\">[PubMed 2180496]</a> </p>\n<p>16. Conly J, Stein K, “Reduction of Vitamin K2 Concentration in Human Liver Associated With the Use of Broad Spectrum Antimicrobials,” <i>Clin Invest Med</i>, 1994, 17(6): 531-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7895417\">[PubMed 7895417]</a></p>\n<p>17. Suttie JW, “The Importance of Menaquinones in Human Nutrition,” <i>Ann Rev Nutr</i>, 1995, 15:399-417 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8527227\">[PubMed 8527227]</a></p>\n<p>18. Bhat RV, Deshmukh CT, “A Study of Vitamin K Status in Children on Prolonged Antibiotic Therapy,” <i>Indian Pediatr</i>, 2003, 40(1):36-40 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12554916\">[PubMed 12554916]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3197":"<p><b>Title</b> Vitamin K Antagonists / Nafcillin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nafcillin may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider choosing an alternative antibiotic. Monitor for decreased therapeutic effects of oral anticoagulants if nafcillin is initiated/dose increased, or increased effects if nafcillin is discontinued/dose decreased. Warfarin dosage adjustments may be necessary. The effects on warfarin dosing may persist long after the nafcillin is discontinued.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe reductions in the anticoagulant effect of warfarin following the addition of nafcillin therapy.<sup>1,2,3,4,5,6,7</sup> Decreases in warfarin half-life and prothrombin time were noted along with a need for warfarin dosage adjustments. In most cases, the reduced anticoagulant effect persisted for 2-4 weeks after nafcillin discontinuation. There are no reports that describe an interaction between acenocoumarol and nafcillin. Although acenocoumarol is not a CYP3A4 substrate, it is unknown if there is no interaction with nafcillin or if it has yet to be explored fully.<br><br>A proposed mechanism for this interaction is nafcillin induction of the CYP isoenzymes responsible for the metabolism of warfarin, with nafcillin induction of CYP3A4 being the most well documented.<sup>8,9,10</sup> As with other CYP induction interactions, the effects on warfarin dosing may persist long after nafcillin is discontinued.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Qureshi GD, Reinders TP, Somori GJ, Evans HJ. Warfarin resistance with nafcillin therapy. <i>Ann Intern Med</i>. 1984;100(4):527-529. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6703546\">[PubMed 6703546]</a></p>\n<p>2. Fraser GL, Miller M, Kane K. Warfarin resistance associated with nafcillin therapy. <i>Am J Med</i>. 1989;87(2):237-238. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2757063\">[PubMed 2757063]</a></p>\n<p>3. Shovick VA, Rihn TL. Decreased hypoprothrombinemic response to warfarin secondary to the warfarin-nafcillin interaction. <i>DICP</i>. 1991;25(6):598-600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1877267\">[PubMed 1877267]</a></p>\n<p>4. Heilker GM, Fowler JW Jr, Self TH. Possible nafcillin-warfarin interaction. <i>Arch Intern Med</i>. 1994;154(7):822-824. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8147690\">[PubMed 8147690]</a></p>\n<p>5. Davis RL, Berman W Jr, Wernly JA, Kelly HW. Warfarin-nafcillin interaction. <i>J Pediatr</i>. 1991;118(2):300-303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1993965\">[PubMed 1993965]</a></p>\n<p>6. Taylor AT, Pritchard DC, Goldstein AO, Fletcher JL Jr. Continuation of warfarin-nafcillin interaction during dicloxacillin therapy. <i>J Fam Pract</i>. 1994;39(2):182-185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8057070\">[PubMed 8057070]</a></p>\n<p>7. Kim KY, Frey RJ, Epplen K, Foruhari F. Interaction between warfarin and nafcillin: case report and review of the literature. <i>Pharmacotherapy</i>. 2007;27(10):1467-1470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17896903\">[PubMed 17896903]</a></p>\n<p>8. Yasuda K, Ranade A, Venkataramanan R, et al. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. <i>Drug Metab Dispos</i>. 2008;36(8):1689-1697. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18505790\">[PubMed 18505790]</a></p>\n<p>9. Veremis SA, Maddux MS, Pollak R, Mozes MF. Subtherapeutic cyclosporine concentrations during nafcillin therapy. <i>Transplantation</i>. 1987;43(6):913-915. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3296360\">[PubMed 3296360]</a></p>\n<p>10. Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, Lee TC. Evidence of an interaction between nifedipine and nafcillin in humans. <i>Br J Clin Pharmacol</i>. 2003;55(6):588-590. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814453\">[PubMed 12814453]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3198":"<p><b>Title</b> Serotonin Reuptake Inhibitor/Antagonists / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin Reuptake Inhibitor/Antagonists. This may cause serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to the use of a selective serotonin reuptake inhibitor and serotonin reuptake inhibitor/antagonist in combination. Conservative initial dosing is warranted. Monitor for evidence of serotonin syndrome (eg, agitation, coma, confusion, fever, diaphoresis, hypertension, muscle rigidity, seizures, tremors) if an SSRI and a serotonin reuptake inhibitor/antagonist are used concomitantly, or one is used following the discontinuation of the other. Trazodone is commonly used as a hypnotic for the management of SSRI-associated sleep disturbances.</p>\n<div>\n <p><b>Serotonin Reuptake Inhibitor/Antagonists Interacting Members</b> Nefazodone*, TraZODone</p>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine*, Sertraline, Vilazodone, Vortioxetine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Evidence of serotonin syndrome developed in a patient who initiated paroxetine therapy (20 mg/day) one day following the discontinuation of a 6-month course of nefazodone therapy.<sup>1</sup> Her symptoms included muscle rigidity, tremors, diaphoresis, flailing arms, and twitching legs. She became unresponsive and received successful supportive treatment in an emergency room. Reinitiation of paroxetine 7 days following this episode was uneventful. This interaction is likely the result of combined serotonin-related effects of the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. John L, Perrault MM, Tao T, et al, “Serotonic Syndrome Associated With Nefazodone and Paroxetine,” <i>Ann Emerg Med</i>, 1997, 29:287-9. [PubMed 9018197]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}